var title_f19_12_19648="Contents: Pediatric nephrology";
var content_f19_12_19648=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric nephrology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric nephrology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute renal failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/30/27114\">",
"           Acute kidney injury (acute renal failure) in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/53/19290\">",
"           Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8472\">",
"           Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/7/23673\">",
"           Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/16/42249\">",
"           Prevention and management of acute kidney injury (acute renal failure) in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic kidney disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28042\">",
"           Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/9/11418\">",
"           Clinical presentation and evaluation of chronic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/18/26919\">",
"           Epidemiology, etiology, and course of chronic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/14/27881\">",
"           Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/17/32026\">",
"           Overview of the management of chronic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/24/37258\">",
"           Uremic toxins",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic Renal Failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/31/28153\">",
"           Chronic peritoneal dialysis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/1/9242\">",
"           Hemodialysis for children with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/30/12774\">",
"           Overview on renal replacement therapy (RRT) for children with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/54/36713\">",
"           Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17240\">",
"           Prevention and management of growth failure in children with chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital and genetic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/59/33721\">",
"           Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28584\">",
"           Autosomal dominant polycystic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/13/29913\">",
"           Autosomal recessive polycystic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/33/36377\">",
"           Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/22/16744\">",
"           Clinical manifestations, diagnosis, and treatment of nephronophthisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/36/7753\">",
"           Congenital and infantile nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/18/12584\">",
"           Cystinosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/30/32231\">",
"           Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/56/10120\">",
"           Genetics and pathogenesis of nephronophthisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/5/24663\">",
"           Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/59/1973\">",
"           Nail-patella syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22472\">",
"           Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/55/12154\">",
"           Primary hyperoxaluria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/41/2712\">",
"           Renal cystic diseases in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28487\">",
"           Renal ectopic and fusion anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/43/10935\">",
"           Renal hypoplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/26/4520\">",
"           Renal involvement in the mitochondrial cytopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/51/35641\">",
"           Uncommon causes of congenital adrenal hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/10/5287\">",
"           Williams-Beuren syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/51/35641\">",
"           Uncommon causes of congenital adrenal hyperplasia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fluid and electrolyte disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/11/6330\">",
"           Approach to the child with metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25848\">",
"           Causes, diagnosis, and evaluation of hyperkalemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/33/3607\">",
"           Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41480\">",
"           Clinical features and diagnosis of diabetic ketoacidosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21048\">",
"           Clinical manifestations and causes of central diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/2/21545\">",
"           Clinical manifestations and causes of nephrogenic diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/16/44295\">",
"           Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/22/17768\">",
"           Etiology and clinical manifestations of renal tubular acidosis in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/48/11018\">",
"           General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5337\">",
"           Hypernatremia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/20/6470\">",
"           Maintenance fluid therapy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4279\">",
"           Management of hyperkalemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/15/18681\">",
"           Oral rehydration therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/46/7913\">",
"           Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27288\">",
"           Simple and mixed acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21526\">",
"           The ������anion gap/������HCO3 ratio in patients with a high anion gap metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7626\">",
"           Treatment and complications of diabetic ketoacidosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/31/505\">",
"           Treatment of central diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/17/17688\">",
"           Treatment of hypovolemia (dehydration) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24071\">",
"           Treatment of nephrogenic diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11558\">",
"           Urine anion and osmolal gaps in metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6691\">",
"           Urine output in diabetes insipidus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Glomerular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25974\">",
"           Complications of idiopathic nephrotic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/6/41066\">",
"           Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/35/37432\">",
"           Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7288\">",
"           Evaluation and management of edema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/62/11238\">",
"           Evaluation of a child with glomerular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30584\">",
"           Evaluation of microscopic hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26262\">",
"           Evaluation of proteinuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/1/12311\">",
"           Overview of the pathogenesis and causes of glomerulonephritis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/39/1657\">",
"           Pathophysiology and etiology of edema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/30/35304\">",
"           Poststreptococcal glomerulonephritis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/54/21354\">",
"           Steroid-resistant idiopathic nephrotic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/33/6679\">",
"           Symptomatic management of nephrotic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/15/28922\">",
"           Treatment of idiopathic nephrotic syndrome in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemolytic-uremic syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/52/43849\">",
"           Atypical hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35704\">",
"           Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30649\">",
"           Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/21/25943\">",
"           Ambulatory blood pressure monitoring in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17241\">",
"           Approach to hypertensive emergencies and urgencies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15878\">",
"           Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/45/17113\">",
"           Definition and diagnosis of hypertension in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/7/42105\">",
"           Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/60/37833\">",
"           Etiology, clinical features, and diagnosis of neonatal hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/42/2729\">",
"           Evaluation of hypertension in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9159\">",
"           Genetic factors in the pathogenesis of essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/37/44630\">",
"           Hypertension in infants between one month and one year of age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/59/42936\">",
"           Management of hypertension in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32954\">",
"           The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/62/27626\">",
"           Treatment of hypertension in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nephrolithiasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/41/38552\">",
"           Acute management of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/19/13623\">",
"           Clinical features and diagnosis of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/60/6090\">",
"           Epidemiology of and risk factors for nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26356\">",
"           Nephrocalcinosis in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/62/19432\">",
"           Prevention of recurrent nephrolithiasis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7288\">",
"           Evaluation and management of edema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/39/1657\">",
"           Pathophysiology and etiology of edema in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22154\">",
"           Complications of renal transplantation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/63/23543\">",
"           General principles of kidney transplantation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38394\">",
"           Immunosuppression in renal transplantation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/46/40680\">",
"           Outcomes of renal transplantation in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary abnormalities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1127\">",
"           Evaluation of gross hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30584\">",
"           Evaluation of microscopic hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26262\">",
"           Evaluation of proteinuria in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary tract infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/1/27674\">",
"           Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26360\">",
"           Epidemiology and risk factors for urinary tract infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/62/41961\">",
"           Management of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/10/3242\">",
"           Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/59/14264\">",
"           Urinary tract infections in newborns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24966\">",
"           Clinical manifestations and initial management of infants with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/7/28793\">",
"           Etiology and clinical features of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/50/25384\">",
"           Evaluation and diagnosis of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/51/41785\">",
"           Management of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/52/42824\">",
"           Overview of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/20/34119\">",
"           Postnatal management of antenatal hydronephrosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-AE5093AE81-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f19_12_19648=[""].join("\n");
var outline_f19_12_19648=null;
var title_f19_12_19649="RTT pseudostationary";
var content_f19_12_19649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rett syndrome, pseudostationary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Between ages two and 10 years in RTT, there is a period of behavioral improvement that follows rapid deterioration. Note the change from an irritable to pleasant appearance, but continued repetitious finger rubbing movement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright &copy; 1997 Medscape.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19649=[""].join("\n");
var outline_f19_12_19649=null;
var title_f19_12_19650="Patient information: Brain metastases (The Basics)";
var content_f19_12_19650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/27/34229\">",
"         Patient information: Seizures in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Brain metastases (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H549935443\">",
"      <span class=\"h1\">",
"       What are brain metastases?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Brain metastases are cancerous tumors in the brain that have spread to the brain from another part of the body. Cancers that commonly spread to the brain include lung, breast, kidney, colorectal, and skin (melanoma) cancers.",
"     </p>",
"     <p>",
"      Brain metastases are different from brain cancer. Brain cancer happens when normal cells in the brain change into abnormal cells and grow out of control. Brain metastases are made up of cancer cells from another part of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H549935458\">",
"      <span class=\"h1\">",
"       What are the symptoms of brain metastases?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Brain metastases can cause different symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Headache &ndash; The headache is often worse when you bend over, cough, or sneeze. Some people have nausea and vomiting with their headache.",
"       </li>",
"       <li>",
"        Trouble moving your arm or leg on 1 side of your body",
"       </li>",
"       <li>",
"        Memory or thinking problems",
"       </li>",
"       <li>",
"        Changes in mood, behavior, or personality",
"       </li>",
"       <li>",
"        Seizures &ndash; Seizures are waves of abnormal electrical activity in the brain. They can make people pass out, or move or behave strangely.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not brain metastases. But if you have cancer and get any of these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H549935473\">",
"      <span class=\"h1\">",
"       Is there a test for brain metastases?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The test most commonly done to check for brain metastases is an imaging test called an MRI. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      Another test that is sometimes done is a brain biopsy. For a brain biopsy, a doctor takes a small sample of tissue from the tumor. Then another doctor looks at the sample under a microscope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H549935488\">",
"      <span class=\"h1\">",
"       How are brain metastases treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on many factors, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your symptoms",
"       </li>",
"       <li>",
"        How far the cancer has spread in your body",
"       </li>",
"       <li>",
"        Your overall health",
"       </li>",
"       <li>",
"        Your prognosis &ndash; This is the term doctors use to describe how long they expect you to live.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatment for brain metastases can include 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery to remove all or part of a tumor",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells. Doctors use radiation in different ways to treat brain metastases. With &ldquo;whole brain radiation therapy,&rdquo; the whole brain is treated with radiation. With &ldquo;stereotactic radiosurgery,&rdquo; the radiation is aimed only at the area with cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People also usually have other treatments to help with symptoms or problems caused by the brain metastases. These might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines called steroids that can reduce swelling in the brain &ndash; These are different from the steroids athletes take to build muscle.",
"       </li>",
"       <li>",
"        Medicines to manage and prevent seizures",
"       </li>",
"       <li>",
"        Medicines to help prevent strokes",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H549935503\">",
"      <span class=\"h1\">",
"       What happens if my brain metastases come back or spread?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your individual situation. Your doctor might recommend that you have more treatment for the brain metastases. This can include surgery or radiation therapy. It sometimes also includes chemotherapy, which is the term doctors use to describe a group of medicines that kill cancer cells. Or your doctor might recommend treating your symptoms only and helping you feel more comfortable.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H549935518\">",
"      <span class=\"h1\">",
"       Will I need to stop driving?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your symptoms. Talk with your doctor about whether it is safe for you to continue to drive, given your symptoms.",
"     </p>",
"     <p>",
"      If you have a seizure, you will need to be seizure-free for a certain amount of time before you can drive again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H549935533\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for brain metastases involves making many choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H549935548\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       Patient information: Seizures in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/12/19650?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86632 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-18C17D12B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19650=[""].join("\n");
var outline_f19_12_19650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549935443\">",
"      What are brain metastases?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549935458\">",
"      What are the symptoms of brain metastases?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549935473\">",
"      Is there a test for brain metastases?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549935488\">",
"      How are brain metastases treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549935503\">",
"      What happens if my brain metastases come back or spread?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549935518\">",
"      Will I need to stop driving?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549935533\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549935548\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_12_19651="Anatomic classification biliary cancers";
var content_f19_12_19651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Anatomic classification of cancers of the human biliary tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 473px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19651=[""].join("\n");
var outline_f19_12_19651=null;
var title_f19_12_19652="Uchida tubal ligation B";
var content_f19_12_19652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uchida tubal ligation B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AZ4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKq6XqNnqtkl5ptzFdWrsyrLE25SVYqwB9mUj8KALVFFYZ1Wa48XLpdmFNvaW/n3shGcM/EUY9CQGY+wX+9QBuUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzvxB1q50Hwne3emokuqPtt7GJxkSXEjBIwQOo3MCfYGtrToHtrC3hl8oyogDmJNiFsfMQvYE5OK5bUtuu/ESwsMB7TQov7Qn7j7TIGSEfgnmt+K12NAHM/EPW4tC8MzTSlwZ2Fuvl/e+brj32hse+Kn8FaXPpujeZfhRqd9Iby8C9FkcD5B7IoVB7IK4i9LeOvjHFYoxbQPCSrPc4+7NfvzGnvsUbj6Hg9a9WoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK5a48UzXetDTPDNh/abQyhL28aXy7a1A+8u/B3yf7Cg4/iK9+poAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACorq4itLWa5uZFjghQySOxwFUDJJ+gFS1x3xGzqcel+GY8k6zcBbjBI22kWHmOf9oBY/8AtrQBP8OIJn0OTWL5St7rczai6kcojACGM/7sSxg++am+IniiHwd4P1HWZVMksSbLeEDJmnY7Y0A75Yj8MmujACgBQABwAO1eH/EnxTYXfxRsbO9YSaX4WhbUDDni91NgBb26+rgMGA9W56UAdN8HbRfDljd6DOpm1O3Rb/W9RZgFa9n+do/cquCT2XZ613uh6nBrOk2uo2iyC2uU8yIyLtLIfutj0IwR7EVwA0m4g0rTPCL3AbVtZkk1DXJ4zg+UWDT4I6BmKwr/ALOf7telxosaKkahUUAKqjAAHYUAOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKQkKCWIAHJJ7VwV54wvPED3Nv4KNumnwbhdeIrsZtIcZ3eSMjzmGDzkIO7H7tAHSeI/EunaAsKXbyS3lwdtvZWyeZcTn0RBzj1Y4UdyK5rU5bvUMf8Jbe/wBlWTAONF06RpbmVC4XMrx/MVywBWMbRnliKyPDdrPetOfBQlzccXni3VEMk11zyLdSBvX0PyxLj5Q1dx4a8J6X4eeae0jkn1GcYuNQun825n/3pDzj/ZGFHYCgCxpdpeWGoSWsEGnW/h+G3jS0igRllV8tvBH3QuNuMDPXNa1YXibxXpHhwRJqFyWvJ+Leyt1MtzcH0jjX5m+vQdyBWTYS+L9fu4p54ofDWkKwfyGK3F9OAc4YjMcQI7De3utAHZ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcf4ZX+2fF+teIGw1vb/8SmwPbahzO4+svyf9sRWn431iTQ/DF7eWqh74hYLRD/HPIwSJf++2X8M1Z8L6RFoHh7T9LhbetrCsbPjmRv4nPuzZJ9zQBkfFHxfB4F8Ealrs6ebJCmy3ix/rJm4Rfpnk+wNeS/CjRB9pWbXb+G+stJf/AISPVrmeLa8WqyxkNEx/6ZICx6EFl9qzvjJ4rt/EPxIfToJLS+0vwlB9qutNnbC6jdtIqC3X1I3DHB+bIIrudL8PSW1no3gaRzNd3Z/trxJPuL71L58sk8kSOBGOf9XE1AHY+Abaa5jvfEmoRvHe6yyypE/3oLVRiGP2O0l2H96Rq6yiigAooooAKKKKACiiigAooooAKKKKACiio7m4htbeSe6ljhgjUs8kjBVUepJ4AoAkrn/Fni7SfDC26ahLJLfXTbLWwtk825uW9I4xyfc8AdyK5i88Y6l4lhmbwa1vp+hxAmfxLqSYgCgcm3jYjzMf32IQYP3ulY/hTTH1KSabwZ9oSO5GLvxhqS+bd3YzyLZXH3fRsCMfwq3WgCHX7vUfEF/HY+LInkaZd8Hg/S5g8ki9nvphgLHnquQn++eK63TvBc2om3n8YPbXEMIX7Nolou3T7Xb935SB5rD1YADsorofDXh3TfDlm8GmQFWlbzJ55GLzXEh6vI55Zj6n6DA4rlfFvxEaDVZvDvgrTm8Q+KEA8yGNttvZ5/inl6L/ALudx6cUAdd4i17SvDWlSajrt9b2FjFw0szYGewA6k+w5rzdtb8afEf934Thl8K+GXxnWb2L/S7lf+mEJ+4COjt25GDxV7w58MPtGrQ+IviHfDxH4iX5okdcWdlznbDEeOP7zcnGeDXptAHM+DPBGi+EYpDpsDS383NzqF03m3Vye5eQ8n6cD2rpqKKACiiigAooooAKKKKACiuWm8aWVr4i1zTb9DbwaVbwXElySWDeaSAAoGc5AHfOasaZ408O6m1stlqsDvcSyQRqdyMZEXc6EMAQQpzg44oA+d9fu/Gq+D/F9zaajdjRBqc9w12LgiSBo52j8hec7W3RNxwNjDvXeeKviZqOgP4osDcxRX1qNNbS0kgJMscgjEzE9GALMMk8HivRLr4g+FLW1s7ifW7VYbuPzYX+Ygx7tu84Hyru43HA96vweKtCn106LDqtq+rAkG1V/wB5wu/p6bTnNAzyWP4jeJR4v12yiePUWto72S1s7GFJI8RIxRZeRLG2QByMMeF65E1t8Rrqxt9GvZ/FFpqllNeW0eqFLDyxYCSOUlCR0+ZVGD8y45+8K9Q1Xxh4f0nV4tM1DVLeC+kKARtk7Sxwu4gYTPbcRntRH4v0CSYQpqlu0xeaPyxnerRDMgK4yNo65oEeQQ+Mr3V/EXhrWJ5HkFu/iARC3hJZo4o08v8Ad5G5sDocZPpVGx+K3iRtC8RXEOoWd41va2V1azNGjGPzbhY2RwmFzgnI5IPevZrDx34Xvxcm11q0dba2+1ysWKgQ/wDPQEgAqDwSM4PB5pqePfDD6XJqK6xb/Zo5lt2yGD+YwyqbCNxJHIAHI5FAzb0eG+t9Oij1W8ivb0Fi88UHkq2WJACbmxgEDqc4z3q5XLXXxA8LWllaXdzrEEcF0rNESr52q21mZcZUBgQSwABql4x+JGieHGECTJfagXgBtoWOVWVwqsWAKjg7gDyR0oEdtRRRQAUUUUAFFFFABRRRQAUUVFeXMVnaT3Vy4jghRpJHPRVAyT+QoA43Vsa/8StL00Za00CL+07noVM8gaOBD7hfNf8A74NWPi14tj8EfD/WNbZl+0QxbLZT/FM3yoPfk5PsDUPwogmn8PTeIL5GS+8QTtqTq/3o4mAEEf8AwGJYx9c14b8evGkHiH4jDQbe7t/7P8LQtqLwTQ+cl9fqQI7fZxuyXVCP9p/SgCH4M6OsM5v/ABWka2nhppPEWpXc9vtmF5NHlYi3O4Ki+bkHkunANe+/DSwu/wCy7nXtZiaLWdckF5PG3WCPGIYP+AJjP+0WPevPPC/hh0bQvArRwfuWHiDxOYhmNpWbdDbemCwHB/ggHrXudABRRRQAUUUUAFFFFABRRRQAUUUUAFFZ+va1pugaZNqOtXsFlZRDLSzNtH0HqT2A5PavO9U8Q654lsp71bhvBngyIFpdVvQIr25T1iR+IVPZnG48YUUAdT4q8bWWi30ek2ME2seIpl3RaXZkGQD+/Ix4iT/abHtmuD1+LztQgXx/M/iHXZsTWXhHSiTbR4PytKDjeAeskuEGDheKseGdPu9TsWs/h/YzeGvD8533Ov3kRa/vzwd0ayfN8wJ/ey+vyr0r0Pwt4X0rwtZyxaXCwkmbzLm6ncyz3D93kkblj9eB2wKAOesfB9/r00N749ngniiZXt9CtCfsNvjBXzMgGdxgcsAoPRe9dfrGq6doWmyX2rXdvZWUI+aWZgqj0A9T6AcntXA678TmvtUm0L4caePEetodstwGK2Nmc4zNKOpHPyrknGOtanhzwGEvotZ8Y3p8Q+IV+ZJZkxb2Z/u28X3U/wB45Y9z2oAzPtOv/EdWXTnvfDXhJvla6eMxX+oL/wBMgeYIz/fPznsF6123hrw9pXhnS49O0Kyis7ROdqDJY92ZjyzHuxJJrVooAKKKKACiiigAooooAKKKKACiiigDgvEngCbV9R8RXltrk1hLq9vbQAxRHMXksSckMCytnBA28d643xH8Jb+38FX2n6POl3ql3q8V7DNbxLapZgqI3OC5JUJu4Bycjrivb6KAPMfEPwmtL+7s5tLvYrVINOj0x7e5tTcRPEmdpwHQhuT3IPpXT+D/AAoPDmo63dC7E41KSGTYIdnleXEseOpznbntjOK6eigDzbxP8L49Y8VX2sw6hDGuoeT9qt7q0+0KWiACsh3rtOAOoYZGcUjfDq8tvEOt+I4NWW41PU4LiG4h+yKiSRsgWKNDuyhXYuWJO7uB29KooA8b0D4TXWo+FreDxdqLLcjRF0qK2t4VT7GNyuSzhm81gyrzwMA8c5rV1H4XT6nb6nLqWs211quoXNvPNPJp+IgsEbIirGsgZW+ckurg9unFen0UAeS3HwdMkOmsNfkuby2smsJpNQt2uEmiMjOBt8xSNpcgZZuMA5xU+ofCieZ7uKy15LawvJLKa4gNgHJktggBVg42qQg+XBx2PavQ9fvLrTtHurywsX1C4gXeLVG2tKAfmC8H5sZwO5wOM5qXSdRtdX0y21DT5lntLmMSRyL0IP8AX27UAW6KKKACiiigAooooAKKK8+8VfEy0stVOheFLKXxN4mJ2tZWbgR2/wDtTy/djH159qAPQGYKpZiAoGSTwAK8g+IvjvQPFEmn+CNC1NL+41q9S0vHs1aVYrYMGm+dQV5ACHk43knGK1B8PtT8VsLj4mas17CSGXRNOdobGPHIDkYeY+7ED2qn8Nza6/8AE/xTq1nbxw6boCJ4e06OJQsa7SXnKgcD5tg47CgDqviV4mXwl4XkmtjFHdOrJBuwEiCqWaQj+6ignHc4HevkL4F6da3/AIs1v4g+JEd9G8Phr99wyZ7lifLT3Yt83+9t9a9R+Kran8V9Y1nQPCE8U728cokDN8scUD42A9A80wPX+GFT0rF/Z4W28RHSfBL6fJp8Wg3Mur61HOw3Xt0jhIV29dqcFgRjKKPegD6D+F2i3mm6BLqOtpt1/WpjqOoAjmN3A2wj2jQKg/3Se9djRRQAUUUUAFFFFABRRRQAUUVm+Idd0zw5pj6hrd7FZ2aEL5kh6seiqByzHsACTQBpVxfiPxt5Wrt4f8KWi614jx+8iV9sFiCOHuJBnaPRRlm7DvXOa7ruta7p019qd1N4G8HqcG4mwNSvQegRefJB5AGGkPYCk8M+GL/UdLXTtKs5vBvhA5JiiO3U9Qz1eR+TFnucmQ9ytAGaYwfEqrLIfHfjy3b/AFZPk6boxx1IGVjIz33Stjt27LS/ArXeoQ6v44v/AO3dUifzYINhSys27eVDkgsP777m9MVvWenab4Q8Ly2+i2UNpY2ULypDGOOAWJPck9yTk+tV/EF7cn4eajfrK1pd/wBlyTiSI8xP5RbK59DQBF458c6F4KsUn1u7xPL8tvZwjzLi4boFRByee/T1NcGug+MPig3m+MGufC3hQ5C6Lay4ursZ63Eg+6pH8A/HHWtn4XfDrTtJhtPEmrTXOteKby3jkl1LUG8ySPK52Rg8IoyRxz79q9KoAztA0TTPD2lxadoljBY2MX3YYV2j6n1PqTya0aKKACiiqmp6nYaVbG41S9tbK3HBluZVjX82IFAFuiuDPxU8OXLyR+HxqPiKaP7yaPZvcAH0MmAgP1YVUk8T+O9RQtp/hKz0K16m912/Q7F9TDFk59iw+tAHo9V76+tNPt2nv7qC1gXrJNIEUfieK8luLq+v2aPUPiHf3zLgtaeFNNUYOenmASsAfdhRYeB7Se6F9Y+B0ubuRc/b/Fd61xJnPXyiZCPp8v4UAep6JrOna7ZfbNGvYL203tH50LblLKcEA96v1geHdO121uHl1nV7W4hMYSOzs7IQRRYPUEszHjjqB7Vv0AFFFc34msvFVzeRP4b1rS7C1CYkju9Pa4ZmyeQwkXAxjjFAHSUV582lfE2FmeLxP4buj2im0mSJf++llJH61E+vfEfSFB1TwjpWsxj78mi6iUcD2jmUZ/76oA9Gory9/jX4e0+RY/E+meIfDrnqdS02RU/Bk3Aj3FdX4f8AHnhTxCVXRfEOl3kjYxFHcr5nP+wTu/SgDpaKKKACiiigAooooAK4iE/8Id4sW2Py+HtdnJhwPltL5uSnskvJHpJkfxiu3qhr2k2mu6Pd6ZqKF7W5TY+Dhh3DKezAgEHsQDQBforl/BOrXc32vRNdYHXNLKpLIBtF1Cc+XcKP9oAhgOjqw9K6igAoorJ8TeI9I8Macb7Xb+Gzt87V8xvmkb+6ijl2PZQCaANauX8beO9A8GW2/Wbz/SWUtFZwDzLiX/dQduPvHCjuRXlGr/FnXPF+ptpHgbTr2JDlX8lFa9I6Zbd+7tVyfvOWfphAa2fBXwXhW8bV/G851C+nIkksPNeWHcOnnSOS85HH3sID0WgDDtdX8efGqZl0kT+D/Axykl3kG6vl6ERt2GO68e7dK9L0uHwR8K9FTTYbnTtHi2eYVlmHn3BHG8j78jH2B9B6VqeK/Etj4a0aWSNoGnQ+RDbqwAD7cgEDooX5j7DjPAPmWq+M9W8Savq2j6ZZxaNqpga303Vr+FY1hlCqxjBYEmZwxOwE7AAfmORQBB8R/Hvi3xB5Xh7wDYy6ZfaiMQyXalLt4sgNMIutvEBn95JhjwFXPNeHab4k8bfC/S538MaiWsY3/wCJjaz+Xcp5zDb9ojOMmJyvDA8Mu1ucZ9t8K/D+/TxeNU8NXGt6FcrG7alJrMHny3Errt2ebnE6FlDEfw4yjKWIHJ61Bd+D9D1a41OGHW0W1mtb2O9h8qS2uHQr1UPjzAQUblZMDJVxuIBz37GOpXZ8fazaG7iSO7tftE0cikvOUYgbTkAYMhJOD0+prv8A9ovwtfeFdZsvin4LXyNTsZFXUkQfLNGflDsO4x8jexB4wTWJ4p0yD4a+MPCOoxqU1Cx8OwLasmUSeSAkXEUvYeakvysej7fWvo62m07xb4Vim2LcaXqtoG2OPvxSJ0I+hoAqfD/xVZeNPCOna9pxAiuowXj3ZMUg4ZD7g5H6966GvFPAejJ8H/HFv4Xjmml8L+IIg9nPNkmK/jUB4yQMASKNwz3XAr2ugAorB1zxj4b0Jgmr67ptpKeBFJcKJD9EzuP4CsC5+Jtg0Ly6No+tanbqARdrbC2tj/22nKKQO5GaAO9orxi++Ld20ojhu/CdiSSCiXsuqzD2KW6YB9i351z11468S61qlzoulX3iS81ZYxMLe00iLSoEjPR5JbhndE98AnsKAPoaWRIo2kldUjUZZmOAB9a5i++IHhWzl8k65aXFxnHk2bG5kz6bIwx/SvkXXfH6xrdG7s9Hu77T2WKS7vtSn1cXkwGf3cLuI9uRy23A7EkgHS8BeIfi38RJjaeHAdN0dg0bT2ECWNvCxBw3mKu5iP7qkn6daAPo3xV8UtP0e0tILSxvJtf1KZbbTNMuYzbSXDsQA534KR5OCxA6HGai8PeH5ZNVvtW8S6jBq/jOxhDRpKjx2OmmRSUWFcY7YaTlyB2zisXwj8MdL8L6xbXt3eXuv+J7NPtV9qt0xlkVQG2xRqxO3cc984U8jIrxjxX451X4m6/bWQjZtOu5GEcIbfFbqvGBH0kYllUyuCAxIUALkgH1x/ZcF9/Zl1rFrZ3Go2Y3xyqmVilKgM0eeR7Hrip9XvP7P0y5ugqu8aHYhbG9zwq59SxA/GuE+EAuEGp29tqN3qOg2fl2sF5dSmVrq5TInkjYniIHagAGMq2K6DxPY6lq15a29qix2Ub/ALyZmwyNj74HfaMhf9pgf4aAOd0+G5vbRbVria6k1Z/s0j+YSEt4iftEgPPDyM6j2dOwq78btXTRPhdrbLE0s1zD9hgt4gd8zy/IEUAZzgk8DoDWcfHPh+x1aTTfCWfFPiKYeWtrYSho7eJOFWSXlIo175ySSTgk1p6V4Q1a+8Q2XiDxjrBubuzcy2mmWQ2WdqxRkzyN0rAO3ztjrwooA4bS/wBoHSoVgttS8H+K9OCqF5st6oAOO4P6V0EXx6+Hpic3OtS2kyEBre4tJklBP+zt969QlkSGJ5JXVI0BZnY4CgdST2FfMHhjX5db+KcviPw/4Svdf1Jo7mSaVXSGKMStGtvHJK42jbBGGIGTmQ8cGgD0S++OujtbCXw94d8U66GOFe00yQRn/gTYP6GoLfxZ8WvEBL6Z4O0nw5ZN/wAvGt3TOyj12Jgg+xFdMlj8RNYXN/q2jeHIWH+r063N5OM9jJLhAR7IRVqP4b6JOwk1+TUPEM+c7tVummj/AAhGIwP+A0AcBNKbm58rxP8AFPUtSvMk/wBm+FYAm3/ZPkq8n/fRFaWkeFbR7n7Tofw8X7QE+TUfE90XctxztYyyfovPpXrGn2FnptuLfTrS3tIByI4IxGo/ADFWScDJ6UAcjBoXiS7g2ap4jSzj6eTo1osIUdgHk3n8QF/CrMHgjQUuRc3Vo2oXQGDNfzPck++HJUfgBTtT8ceGdMkaK71ux89esMUnmy/98Jlv0qlH40uL1nXRvC3iC7AOFlnt1tIm98zMrY9wpoA66KNIo1jiRUjUYVVGAB9KdXKJdeNbsgppeh6ahyD595JcOPfaqKPw3fjTn0jxRcg+f4ohttw6WWnKu0+xkZ/5UAdTRVXS7aazsIoLm9mvpkGGuJlRXc+pCAL+Qq1QAUUUUAFFFFADZY0ljaOVFeNhhlYZBH0rzvxv8JPBWuWN1PJ4VtnvwpkjNgRaSyOBwNwIXJx1bIr0aigD5TktPjD4A1Ap4M0/Xr3w8i/JZaq8F4Y+fugxuWx9Mdeneuv0D9oOTTlFv8TfCureH7kYBuUtZDCfqrfMvXoN1e+0yeGKeJo540ljbgq6gg/gaAOd8K+O/C3isD/hHtdsb2QjPlJJtkH1RsMPyrpa8/8AEfwd8Ca8C0/h+0s7jOVuNPX7NIp9cpgE/UGuem8EfEfwwFPgrxv/AGrZx9LDxFGJSQOwmUbv5UAew0V4gfjVrHhif7L8SvA+qaZIOl5p2Lm3f3BzwPbcxrodO+O/w5vYS/8AwkcVuQcFLmCSNvyK0AenUV5mvxn8NX4lHhiPUNfMXEslpB5UMJI48yWYoig49a48/FDxV4ou5IPDMMccUbbZF0izOpywt2Dzu0duCeehfHrQB6l420m7ZrXX9CiD67pYYpFnb9rgODJbk/7WAVJ6Oqnpmq118TvCFppFnqFxrVuqXab4oEzJOfUeUgL5B4IxwQc15zceCfiB4mJfUbi4gUtuI1fVWKlT1X7NZ7E/76kNYy/CHQvBGu2l34xvFutA1VjDcPCTY29tcn7gdVbJiYAryxw2M/eJABd1j43674qvJtK+FmgXNxcDCm7nh8wjJxnaCEj+sjD/AHaueFfgvrOp30mr/EPX7ia+myHitJT5pU/wNcYBVePuRKg9zXrPg2+8OXGhbvCX2QaRbsYVNpFsiyoGduAAw9xkVLLql/du0ej6c23bkXV7mKLnphfvt+QHvQA/TNP0Lwho0NnYQ2Ok6bEdqICsaZPqT1J9Tya5TXPGd5Jb6nd6Psj02zhJe6ZN+B3lA6dsKp653NhQN3MeJrjTLnV3tdZurjxX4gicfZNI0vDFCDxI4/1cI68ueB1LHps6J8N59RvY9Y8W3BtbuOEQ2WnaPPJBDYJ1++pDSyZ6sePQYoA5jS7e5bUdPn1O6/s6W3mZ9KmCC/06/D9WlmUfeYnknY24ZG4bQO98NaFLZ2VyNXik03TIiWl064uIruz2gZLxMw3onU7WwB2AFTxJ4X+HdubjULy2trm5OwylFWa5+YkARxqN784yq5Peo7PxBquoaomo6hBFoHhKOJ1K6rtjuLxzgBtpP7pBzw3zHPKigDo7a8murjTZNJSyn0Ga3aQ3Uc3P8Pl+WoGGUgnnPpXjPjDQtS1+8v8ARrKK5ttQuWK/Zru7CyxRGUMXjk5E9qcZMfLRsRjGcV2vjH4x+CPCEfkTarFe3i4SOx03E0hPZfl+VfxIrzvUtV+J/wATbrTp9A8IWfhmztpTNa6pqx3XERIwWRSMjKk8bCD60AaXxv1WztPHOnnVxaJaQWUkQN7G6wzJNhZI5CD80bfJ86AtEyqSCprnfhp8WtN8HeF7rTIrfUr3TLecDTBdCO38iJuTHJO7BWCsTtYZJHYdBv6b+zwupX8eqfEDxbrOu6kGLYjlMSIT2BOWA6fd29OlenaB8OPCGg3AudN0CyW7HP2mZPOlz3O98sPwNAHhvizWfE3xSihtIPN/s9J1kFroFhJM5ZTuXfeTiOJcEA7l4z61v2nwz8b6xDFHrV/KIVOHGr6zcXhYevkw+XHn2LNX0ABgYHSigDyTQfgraaeJGm1/UIZZMbho0MWmpn22Ayfm5rpbL4WeDreUTT6NHqNxkMZtSle8ZmHc+aWGfoK7auG8e/Ezw94U0S/uBqdheapCrLBp8VwryzTY+VNq5I5xk44oAl8Wa0ug/ZtB8LWtkuvXyM8MewLDaQr965m24xGvbpubCjuR89+MLi813RD4c+H9xJqMmpXGbiRG/wBM1p+fMup2H+qtlOFUMQGyMfKOe88MeBPE3jjw+0/ie5bRLTW9l1qbQtuv79cZWIt92CBQcLGNxwOcEtXonh208IeCIn0jwlpsX2rGZLbT082ZyP8Ano5PB5/jYdaAPKfhR+zRpukiHUfHTx6nfDDLYR5+zxn0c9ZD7cD617VPqMVvc/8ACPeGIbYXsEYLoqYgsYznaXC4GT2QYJ68DmiS31/WDsuZY9GsSQSltJ5ly4/ul8bU99u4+jDrWxpWm2elWgttPgSCHcWIXksx6sxPLE9yck0AZGpeFYL3whq2hm5mVtSglinuzzIzuu0ucY9uBgYGBgV5f4c/Z+tbPU55ta1pbuxlbJs7KyFoDGCCIS4dm8rKg7ARkjOeTXeeOvif4a8HLNFfXT3eoxgf6BYoZpsnoGA4TPbcR7Zrx7xb4z8d+N9Guk0OLVdOWWPEVhpOnT+exPTzbuVUVAOM+WD6Z70AeueLPiJ4U8BwJphkSS8gixFpWnoGkRFHcDCxoAOrFQAK80udX8Y/FM/2bNC+iWN7EJItMgc+YsDfdnvZRgqh52wptaTuQoLVzvhr4WeJ9NhEel+FBkweYbvV72EPcXhwRJKilyYYzkrF3YBnzwB6t4T8O+PNI0sWls/hrT3lPmXd3K09/c3EpA3Sux8sFjj6AYAAAAoA6n4c+BtH8A6AmmaLAoY/PcXJUCSd+7MR+g6AcCuqrhl8MeMJ2YX3j2VImHK2OlQRMPoz7/5Uq/Dm0mKNqniDxTqLL183VpYlb6rDsX9KAMT9oHWr618JvpGmWs0smoLtuJACEWIsqeXu6b5XdIwOuGY9q7XwN4cg8J+FdO0e3Kt9nj/eyAY82Unc7/ixJ9ulcj4k+D+jX8dlc6Jc3mla3YXKXVrfyTSXhR0zgMkrEMvfHHQc1eHw1h1ABvFviHXdec8vFJdG2tjxyBDDtXHs2760Aa+u+PvC+hz/AGe/1m1+2HgWluTPOx9BFGC36VnDxb4i1QH/AIR7wbeiE8Lc6xOtkn18v5pfzUZrpdE0DSNCgEOjaZZ2MXpbwqmfc4HJ9zWnQBwY0DxxqTE6v4vttNhdcGDRtPUMp9pZi5/8dFSxfDLQJWR9bfU9elQ5VtWvpLhR9I8hP/Ha7eigCnpel6fpMAg0uxtbKEDAS3iWNfyAq5RRQAUUUUAFFFFABWYPEGjnVbjS/wC1LEalb4821M6iVAVDAlc5xgg/jWnWB4s8HeH/ABbYy2viHSbW9SRPL8x0AkQZz8rj5l59CKAN8HIyOlcdrQ8R6BqVzqmlCXXdJmIefS2YC4gIHLWzHAYEf8smI5HysM4PnHhj4W+F9H8UT+FNbsZ53eJr3SdRS8mhkngDAPE5RwDJGWXkAZVlOAQay/jZ8Nbjwv4XGt+CfEXiHTmtplW4hbU5pIyjkIGGWzw5XPJ4JPagD3Dwx4q0fxNFMdIvFkntzsuLWRTHPbt/dkjbDKfqO3FblfHHwu8Far8WrG81t/HGrWXijSpvs26Vd7rGQGTMgZWPRhz3U11WqeNfix8MddOla01h4qsobZJ0lK+XJLG0oiBDDB3B2UHIbG5SeuaAPp2ivIdP+O+hQXK2fjTStY8J35ONuo2zGJj/ALLqOR7kAV3Fx458PxWFlqMV/Fc6TdTCA39s6yQQM3C+awPyAn5dx4BIyRmgC14p1HWtPghbQNCGsSuWDobxLfy+mDlgcg89PSvJ/G/xe8VeFriK31bw9pOlyOgldnupr3yYiSPMdYowMfKf4hXugORkdKR1V0ZHUMjDBBGQRQB8pap8cFuraSe68Xa7NDtw8Ph/RYrVEOcZ86dnYfl1rz7xl4zfS3judN8DQadd3Q3pqXiDN/fTdvMAl+VfwQj0r6L8b/C2/sl+3/D2S1ilgLyQaddxiRLV3IMklmW4ikODgEFMnjb1q58O/DvgG+12TVdO06YeK7OJY7qLWGZ72B8n95Irk5Yn/louQR904oA8M0Wa50nRF13VvhvZM07DbeeJb9pGu5iOkNttG5jjgInTvxXrHhDV/i/rOmW8emeFPDHhTTtn7v7YsgKj/ZiQ5H0IFel+FNWh8R+Yur6dDbeINHmMVxbuA5gcg4kiYjOx15VhjIyDyCK6igDxrUPDXxjvYX87x3oWnRBSWa0sOn4sMj65rwXx3Ne2GoPpmmeKrT4ia1ehonifTHu3hVlwTE5LKORxs5Fet/HLxVJor3beMWieF5mh0TQYpsQ3QAH+l3hBy0YY8R8D5cYPUVfAWq+HW0mHQorO81TxFrNiJ9VvY7mOxmV8eYsEbbl24UFljQgBACQMmgDzqx8dfHgwjTba21NJba1SQQvpcazeUMoHCsm5hkYJAPNVtW1nWNcvpLLxJ8T9a0nTlgSS4fULGa3Z5iDuiSGMYIHu3OeBXs3ivwKlpoq6r4Yu/GOk65ZrJLa77mS8BDKu+HOZMBgowckBsE5xitPSdJl8V6NbXXh74peIoC/EkNwbdpY3H3o3XYpV1OQR60AeAeFYfDkazaV4O8WeJpCX3yXEuqQ6JaliOG+bc79BxjNdt4f8LavbQhdW+PdrZxZ3mG11bz2Ge25pFz+VdJ8QtC0bR7mz8Palc+JvGPiXVgTb6SL8RRuoJ/eSFFURpkHnnofQkZOjfA/wVot42s/EbV9IszuEg0m2u/KtYRx8rPIxkk/MZ96AOQ1LSdBsPEUo8GeJvGfjTxdKnzz6VMFVR/tz7WYDP90/iK6PRv2etf8AF+oR6j49u4dHtwgC2dnK9zO3+/JIzYPvlvoK9P0z4pfDbw9YXFl4UR7m1skMk0ei6bJKkajPzMyrtxwfmJ/GoPDvxyt/Gd5c2fgLwvq2s3NvH5kpnlhtI1BOBlmY9fpQB2Hgb4ZeEvBKKdA0eCO5AwbuX95Of+BtyPoMD2rsq84Sb4qaoDttPC2gRN0Msst7Mv4KFQ/nXkVq/j/xZ430/QNY8S62LO8m81b7THhtrWW1jz5+wxjeTny1Uk5UsQwyOQD6U1jWtL0WDz9Y1KzsIf79zOsYP4sRXCX3xs8Fx3f2PSby716+Ks4t9HtXuXIHU8DHT3q7F8KvCWmwy3Om+HNOvNVVSYptUL3JZ+2533H8e1eb+OZ/C9jLKILK/wBA8YQt9qXRLOJpGuW6B4TDnYWxxIpX/bUjigDY034xeJPFt1PbeBPAslw8IR3k1O/ityiN91jHncQfUHsR14rhviZ8SPihpN9Dptvq/hlNauH2JpOhxPd3SH0fcrAH9fatK68Hanrl9DrGv3Fv4FFydoktlDa3qAYbSJDEAoyCMqi5zywrvvh34MPh1Yx4S8P2+iW7N/pOoax+/v7tc5+6rDZnn7zD/cFAHmfh34ZfEXxdatqHxV8ZajpGjBN8lot0Ecr33AYjjGPXJ9QK9Q8GaZ4Z8M2Mcfwx8LrqE0kYH9o8JGwz1e5fLMO+EDewr0nUtOstUtxb6law3UAdZPLmQMu5TkHB44PNPvLq2sLWS4vJ4ba2iG55ZXCIg9STwBQBzJ8M6hrLJJ4r1V5IwOdO05mgtjxyHbO+T8SF/wBmuhtbaw0bT/KtYbaxsoQTtRVjjQdz2A+teW6p8arTU9XfQ/htpc/irWO8kbCK0i/2mlbqB7cH1p0Pwz1zxdJHdfFXXmvoQQ40TTC0Fkp64c/ek/HH1NAHW6x4/wBJtL1tO0hLnX9XHWy0tRM0foZHyEjGe7MPoaoDQ/Fnigh/E2qf2DpxOf7L0aU+cw9Jbrg/URhf949a6vSbDSPD9rb6ZpdvZafDjEVvCqx5x6AdT71p0AZnh7QNK8OWAstDsILK2B3FYl5Zv7zHqx9ySa06KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKiummSB2to0lmH3Ud9gP44OPyqWqGraPp+rrENRtY5zCS0bHIaMnqVYcj8KAOU1O90u78b+G5dWku9J1Oye5W2huIsR3W+PawEoyvYHGckjpW54/t4rvwL4hguSoifT7gMW6D923P4daz9Y0HULKxuG0aaTVImxv0nVJfNimXIyqyMCyNjOCSy5xkdxxms32mWu4zjxz4U8tNrMltLdWgbjgqBLGw7YAwRxQBwP7Pon0L4o3pc7bPxBF9wDAE/2eK6HH+7LN+Qr1/4reBp/GbacIZooore3vYZdxO4+dAVQgDg7ZBG3P8AdryqVtV03VdJ8R2Gv+G/E8174jil+zWJ+zynfC1sihi5C5TBZSOCMZxXs0HjN7qaewj0LWLTVxBK8MV7askEkiLnb565jxnHINAEng24t/Gnw60S71qzguheWcb3ENxGJF8zbh8gjH3t1cN4m/Z/8NXrXU/he7v/AAxd3KFJRYyEwSqQQVeInBXnoCB7VvfArUoW+GPhe0vGjtdTktWkNpKwWVhvbLhDzg4z06GvRqAPmvQZPix8HI0tdTsP+Ew8JQj79oxea3QY+7kbgAP4SCvHBFeu+BPil4R8bIi6Jq0QvGHNlcfup1PptPX/AIDkV29fN/xz+Eelz60+o6ZaR29xrriKOVDs8i/UFo8Y4CTYZG9H2N3NAH0hXO+LPCVj4i8m4aSew1e1/wCPTU7RtlxAeuAejIe6MCp7ivAfhTqvxHjN5B4Z1q112zt4obm30zWyRPJbSA4KyjoyurxkE4DJ0wRXolv8bbDS5/s3xC0HV/CVySAr3MLT28h77ZUGD+VAGbrur67oHiKxn1u3gXxRaIyW15bqUtdftPvSW+M/u7gAFkQ5G4fKSGIr2LR9StNZ0q01LTplms7qJZopF/iUjI//AFVzVxd+D/iZ4en02HUtP1W1uE3AW86mSIjpIo+8rKeQccGvLPgrrup+A/Hup/DPxlcbvNla60e6cgLMrEkgdhuwWx2beOpoA5f42ajdaT488Xx6hPYSwR21rq8L3NuZDJs/dwWm3psEjNIexIOeprz3QL3Qrto7Oa30S2tLiaHT3urtXtXFtCnmyuWwxV7hmKluSBhRxjHp/wC2VoV3u0TV7JpFt70DTLwIuQ5VjJCD+JkrjtOVvE2myavp1w0i3l7q9vElxbRSlJ20+ORFGVB3t5ZUHtt4HqAfQdvbaxpOqlIPCdzaaPb2ZMJ07VWkZphjEflEhQmOAccEDtXPrenwxq+m6pqJNhpniGVP7TsdVt94sL1kAWRXAVdrFdjt0ztbua5Hw74rtdH1LT9K1WXQUtZ4dNNiUgmtZZRcxDLmRJCAFZSGYg+vFeqrHc+IdDnFj5mpaNeI8DeRqMV3DMvzI4zKgJGcj71ABqnw/wBD8V6jBP4g8P6TdeVlUvbG8lhlVMEgHZtJBz03Ec14jr3wr8EH4i27QG8udJuriaC3srNgDc3URw9oueVVcbmmZsHJGRjNerSTReCPCcMnimzSaxskitXuTbeVdzZZY0+ZGKseVz8wOFJ615F8Zde1XS/D+j+JbPas+pXGYXlBEmlywM6fZ0Q9AUch933ipJ6gUAWfAgtfGnxPsdEktd2mx6TNZ6paWo+yWVvIpbEUar/rdhY/MzEsXLDAGK6z4Kapa33xv1+CytfszWmhwWd4qxqim5hdUc4HHfH4Vxfwi0vxD4S03WNXg1OO507woftH2B2EUE8kseLlt+MsqKDtOcMyED39E+FvjDRfD/hdrqXfqni7xHcy6xNpmkx/aJx5pyiNt4QBNvLlQOaAPdq8ot7bQfh14x17WtY1RbvVtYYLY2FtBvuRF95kWJOXLOclsc4XJ71rLZ+OvFBVtRu4PCOltybWxK3N86+jTH93Gf8AcVj/ALXeuh8KeDtD8LJJ/Y9iqXM3M93KxluJz1y8rEs3JJ5OOeMUAcRr+u6/qOxdZu28HaXctst7S1xc6ve+yqoYRf8AAd5HqtXfC3hnUYI510PTofC1lcENJdzn7XqlyepaRmyqk9tzSY9B0F/WvE3gfwJqF9d6pqdpBq14S8wLme6kA6KEGXCgdFAAH515J4q/an06G4+z+GNFluMuFFzfuY0A9fLUFj+hoA970HwxpmiyvcW8ck+oSLtlvrpzNcSD0Mjc4/2RgDsKzfHHxE8LeCbcyeIdXt4Jf4bZG3zP9EHP49K8R0V/jJ8SGaaW5k0bRZGUo4U2CMMZOAMzsOw5UEd64tfhBZ+LPicmhaDfTX1ppv8AyHtXCBYVcniGIZJLgAjLMxySTwuKAO7k+P2teNfGNr4a+Gum2Nq13uEV7rLFd2ASSEU8cA4HzE+nauwh+CQ8QXUeofE7xHqXia8GG+yq5t7SM+iouDj3BGfSuZ/aK8OvoWs/DvX/AAtZBbjSZzbRwxL/AKxY1EkcQx3OyRQO5evYJ/iB4XsrKxuNY1my0mS7jWRba/mWGZNwzh0JypGec9KANbw/4e0fw7aC10LTLSwgAxst4gmfrjr+NZPjPxY2jXFrpOj2n9p+Jb8E2tkG2qiA4M0zc7Ih64yTwMnpxo8eeK/GsuqS/C6z0eTRtPZ4f7R1NnIvZ1AJSFVIwvIG9uDniuR+GPiWx1jSdY/tG7uJPE94WufEV5HG0ckES7QtrEOGBG4RBR/F5hGTg0AedePgNV8Va5qHiPxPJd63pV3FHZX+nusCQRxW73Eywx56q42A5yT6mvb/AIH/ABOn8Szy+GvEkltJ4gs4FlS8tWzBfxcZdDx8ykgMB3z6EDy34q+GoNQ8YRG7jtIX1bTpNPuR5YaLSZIoxPDDGw4MpWPa3+9xgECuG8N6lrFj4ds/EK26WereBJ44DBsZGeFpCGhdc5VmLTsxI6DtQB910VX028i1DTrW9tzmC5iWaM+qsAR+hqxQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUhYbguRuIyBnn/ADyKWgDzH43+F9HvPC41B7C3iv49RsW+3QoIrhA11ErFZQNynax5BrutI0mTS7a2t49SvrmGIvuN5IJpJNxyAXIz8vb9c1znxhfd4Rgs0wbi+1Swt4VJwWb7VGxx9FVm+imu3oA821fRLvVGmfxt4N0nWW/1UV5pTgXCxjkf6wo68k8I56ms3TtRsYNVXTfCXjC407UixVNC1+N5FLAfdXzMSj/gLsPQGvW6iuLaC48v7RDFL5biRN6BtrDowz0I9aAMF9fudF0GG98W20NtM10lq/2F2njBkkCRtkqrYJZcjHGe9Gr2lh428ORxQXciQNcxTpKilXV4J1fGGAIO6MqcjI5p3iLSFOh62bTUr/TprkfaGuoZPMaFkC8or5VRhBlQADk9zmuY1W5PjLRNN1a20Rdb8PzQrc20sEzWuowuQcyRhtoB9MOufcYyAZb+G/8AhBPFXh/WIpg0N7rF5ZXAjTaFgvHaWJD7JMqgf75r1e5t4LqFormGOaJuqSKGU/ga+ffH+qanH4P1S1tdae7axEOojT/EcP2bUIfJkSTdE6gLMPkPY4z97tXrGifEDR7+e3tNQS70TUp1UpZ6rEYGcnoEY/I59lYmgDzTxN8K/DviT4qPZaFAPDj6XpwvJ7zSP3EpuJmZYhx8oAEbscAE5HNeK+NrTx5rmhaRez6tFrUmlad/bi3nlCO7tkEzRsgfq+xk3HPp7V9V+BM3Hjj4g3jD/mIW9oh/2Y7WI4/76kc/jXm/gCKK7vJoASyTeHdUQj1U6lMB/M0AXo7wfHL9nO6Jijk1tYWVkUY23kPIxjpvGPwfFfLvhjwzNc+HbDWbLW7m2ji1H7NeQxRSM9lKUYxTbUOSjBWUsPmBUgA8V7n8Edaj8G/EnQ/DVlHGul+KdEs9QdWOPJuhbsWK9sOUOR6kemKveMfD8Xg34k6jLA32XStRC3csqAAW8Msqq0n/AGwuvJl9llf3oA+f/EV74u8ISLpeqSxXFpPZRQ2UoAmgmtllE0Twv/EA2cE5IDMMDJFdj4I+Len6P4ogvr7TJdNI1aSWWC3J8oW0/wDrVIGCDHIA6cdGZT619BXPwvtPFOh6hCbiGC1lf7VZQ+UH/sy/yy3ATsYXYfNGeDlsYyMeUav8N7SSygOt6bHpka3RsFuplZk0+6GAsUrdZLOXK7JCd0ZYDNAHVfG3xUnjqXRNB8OXlldaBdI+otqNtJukjktywZSvoN0bcjsa8c+IFt4p8RfEa4l1bR9Sew06aSS6S15jY26ot1PHuGwFtobpj5lHOeZNQ+Guq6HrF1qfhxdQtjpjtHq1jEFnutODKfnC8efA6klXA5XIYcE0zS9d8Y2mlahqOheLtF1FZxmVZLhVuQNnlkeTKBuZ1Cg4Dk7V7igD2KLQLrx74ksvCt3c3EthpkJj1S/gcIt1pxZZbOFgv/LRsAnoQFY969IbxB8NvhTpzaal9pGjrCMtbQnfOxH95Vy7Hnvk18v+HtS8R6XY3HhTW/EVl4N0XTYxPqbWjD7bcu68JwS8kpGFIBAUAA4wBVfRrzwn4ZYt4T0e/wDFevTvuknli85bCJs4WPC4afpmQqVU525xyAe3+If2jrQSJF4U8PX1+smBHd3ga3icnIXYoVnck9AACa85+Lvjjx6ujOfFHiSw0OWX/U6FpQZblwQcNN826NP95sn+7XHXM/i3WPFFrff2Tqfh+xtW2QWdtBdx+WCMM3mLE7b2/icjcfbjHpPg0aVb6hBZ2nhPwjZ3lzKES41qG/uXklY93lgUAkn1HJoA5X4UaDpN7d6bdvf2sF/KUjE0VlJqdyXbALEKDFFyT80hcj0XpX0T4E8CeGvDemv4i1zRorLW2Z5bu81WeKeRCGI371xGgIAPyBcZxXZ+EoNZttNaHX49IjmR8RLpausXl4GMq3IOc9OMYq3cadFc3lw95M9xazQLC1jKEaD7zHdtIySc4OSRhRx1oA47xoviDxgt94a0a2vtDsSypc668gjYpkFltlUlmLDjc20DJ6nikvdV8EfBXwdbWcs0Wn2USkxW6fPcXL45bA5Zjjljge4FJ4u+IFvDf3+i6DfafBd2Me/UdSu5B9n01DnqucyS8cRjj+8R0Pl/hHSNL+Jt9ca3qBuP+EH0uYyz32pn/SNbnQfelOAFgjHSMYXnGM5AAGat468R+ONHXX9XtNQ8N/D1GLRrYL5mo6iw6KhAzGp5y42jtuOayLPwDceKXtLS78N2XhTQ71la301U8/UrwBgTNPKfnVFBzgsvPHOefXbTTbu+v9N1rWNNsJ9e2yQ6PaRRukNnbbsiaYE9QAhxgYJCjBOa07iOGWw1Bf7TmhswGGp64jCOWRhx5UJH3QDx8v3egyxJAByH7NWtWttD4k8CxzCVvDmozx20pABntjKwDHHUhgwJ9xVbxj4eh8FfF+08UW8cUWl+I3S0uJWA2Wd9n93M3qrDdxwN4BPasP7BL4W8Z2nibQbb7BoPhSwttOvrWeUNczW0zuzySqOUZQ6y4PJ68dK948XaBY+LvC+oaLqI32V9CYyy4JXurr7g4I+lAHmPxCtxYaBF4mkgtF0Pw5c/a4bO9QM2pO26OSR3IO0sHOw45bBbgjHlmlW/hWw8Q694ystXtv8AhH9S0q5kl0m6usXAuHVF2Sp2O+ZgODxyCRzTIPixf+GbG98B+PbfUJ9d0ifyNP1C2hSZjgfu/MicgSAggZ6lW7HmmfCf4Nw+KfGmqyfEKH+ytRtfKuxotsixiSNzuDn7w8vIKbV6YwcdwD339nu5muvgx4VkuTl1tTED/so7Iv8A46or0OmQRRwQxwwRpHFGoRERQFVQMAADoBT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKCcDJ6UU2WNJonjlVXjcFWVhkEHqDQBzfjXw1NrkdpeaVfPpuvaezSWV2BuXkfNHIv8AHG2BkdeARyKyvC3j0z6ynhzxfZDQ/FBXMcLPut70Dq9vJ/GO+0/MO4OCasaNd3HhXU4NA1iVpdMuG8vSb+RiSTyRbSk/xgfcb+MDH3hzreMfCmkeL9IbT9ctRNGDvilU7ZYHHR43HKsPUfjkcUAXddtby6s4102a3gu0nikWWeHzQqhxvwM8EpvUHtmtCvCtZ1zxZ8NrO503xxDd+KPBU0TQf23ZjbeWsbDbiYA84B+/we+c8V6r4G1/QNf0C1l8L6lFf2MMaxKVkLugAwA+fmDYH8XNAHQUUUUAUtchNzouoQBQ5lt5E2nvlSMVm/D8xnwH4b8jHlf2bbbccceUuKXxZqVzpraI1s6rHcalFbT7lzlHDDHt823mqXwxlH/CIQWf8emzT6ewxjHkytGP/HVU/jQAz4peELXxt4RuNIvPKRHdHMzQCWSNVYF/Kz91yoIB7Z6HpXN6RoAu/DNreeFrz/hIPCd/aCT+xtbczBwQCvlyuCyHjBV9wz/dxmvUq474XaNf6BoupadqEflwx6rePZDIP+jvKXQ8dPvHigDivA0f9kSeII/AF2sl55zXN34W1g+XPaylBgLJksAcLgnchBGCOtYngmKLS59fdTcxXHh7wktrfC5iMZW5keeeTjuMjIIJBB4Jr1jUfAPh2+1C/wBRexMWq3kiTPfwSMlwjogRSjg5XCqOBwe4Oa848Q6Nrui+FPG9r4g26je+JJoraHUYHHzpI0dtHC0eBtdVYt8oKnLcjuAeNePotX0W80K9sIS+oaDbaYdy8bPs1kJZc+37wZr6I8dx2Pimx8HapEXm0zU2ewlMZPzW15bsvP0YRHnuKxJ/B6R+OE03V7iKc6taaxe3bquEjjcW0EYAP92IKM+xpn7JviZdc+GQ0uWfzrrRZ2tST3iJ3Rt9MZUf7lAGv+z5ri6j4avtKvZG/wCEg0W5On6irE/O0eUSXB/vKoBPcofqfStU0+01XT7iw1K3jubO4QxywyDKup7GvFbXQL7w/wDGrxRrWgPEsrS21zqFrPOI457CZCHkyeFeOWKRh6gkHrXuFtPDdW8U9tLHNBKoeOSNgyupGQQRwQaAGR2dtHdPdJBEty6LE0oUb2RSSqk9SBk8e5rg9W+C/wAP9U+1G58N2qy3MxneWFmjfecE4KkYHHQccnjmug1Aw6t4rsbWC4tJG0hvtV3AXcSxmRHWFgFIUg/vM7sjjjnmtDxFr2neHtPN7q1ysMW4IigFnlc9ERBy7HsoBNAHCxfAr4cpJO7eG4JBI2QrSSYQYAwuG6cZ55yTXO6n4M+HGm6hNpfhfw5f3uuKMSQ6HeTRtCc8edN5gSP6Mc+gNdstjr3jKPfq7XPh/QpF40+B9t5Op/57Sqf3QIx8iHd6sOldXouk6fomnRWGkWcNnZxDCxQrtA9/c+55NAHnNn4e+JsWg2trZ+JdLsHhf5Vuonv5vLLE7ZJ2272AIHCDp1712MfhbNjq9vda3rVwdSm85na52m35BCQ7QNicdOTyck10E0scMLyzOscUalndzgKByST2FJbzRXNvFPbypLBKoeOSNgyupGQQRwQR3oAe7BRliB25OOe1ePeM4ptVuftyzGbT78m0jLMbd4jkbrSVh/q3Ei74pf4ZBtJwwJ7zx3cqmmi3I88yK8jWY4e4RBlhEx6SLwy89V/EeZ6N4n1C68EWk8qWT65q8Fuk1pMV2X6TlUjuU4wZEU4kXp8hBwApoA8PuraHxvqeleDNMjhubl5jDYXP2dYpUh3Ez3V2QzM8p2tjnBG5sZYV9Srp9hpljaaHp9sB4b0REjMC/M11cAgxwj1wcM2erFc9Gr5g8PeDtcT4np4j8D61bnTYr64htNT1GRQZVgh/et5a4Lx4yuVHTsK9D8M/GrQ9V1620bTUvI54dtnpbmJpluLqaTbJdMOvAZmAYfxN0zigD2dZZd94810kTrg6reqx2wgDK28XuA3Jx3J+83Elys3+ibLSMSZC6Zp7LhIsAfv5h/s9cDpwPvEY5aTx58PrK8t7efxdpf2PSid1u0hLvdbv9YxH38fMeMjcc9QKq/Ff4tWHha7TS/ClsNb8Y6iVt7eGL50iJ+6GI75YHYPXJx1oAy/i14vsPhh4PudAt5JfEHirXfMBW4Cu8nmfKXkVQPlAO1E7gAdATXT/ALPuuanqPgWLSfElnLY67oeyyuIJlKyGPy1MUhB6blOPcqad8KPhlH4aMmveJpE1bxpfnzbvUJRvMRI/1cWfuqOmRjPsMAaHi8Dw5420TxQnyWd3jR9UI6BXbNvK3+7KdmT2moA8p/bA+Hrajo8HjPSoj9s08CK+CDl4c/K/1Qnn2Of4as+APFV94x8BaR4t09GufGfhUeRfwAjfqFmwBdfcsqh1/wCmkZHevoO8tob20ntbqJZbedGjljcZDqwwQR6EGvj/AEy01L4GfFi+m8uWXw3bSRpLJyWexnY7WI77HB5/vKR/GKAPrrR9StNZ0mz1LTplms7uJZoZF6MrDINXK878NPB4R8ULpVswbwx4gZrzSZEIMUFwQXlgB7K4/eoOn+sA7V6JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBR1zSbLXNKudN1OBZ7S4TY6H9CD1BBwQRyCARXLaHrN54c1S28OeK7hphO3l6Vq8hGLzjIhlPRZwB9JAMjnIHb1n6/ouneIdJn0zWbWO7spxh43/QgjkEHkEcg9KAL7KGUqwBUjBB5BFeJ+OPgcg1I6/wDDHUn8La+uSY4GK28/sVH3PwBX/Z71tWXiDUfhxqtpofjK5mvvDl1IINM1+U7njY/dguj/AHvSToe/OSPU6APlqT43fEbwFrFvoXjzw1Z6nevzGbWUJLMvTI2blP8A3yK9K0z4y3F9axSf8K58dB3HRNN3Jn0DkgY9zivQNB8KaFoEs82kaXbW1xO7SSzhd0sjMcktI2WP4nitugDyTXfiHLqWlyWmofDjx4IZCCDDZIXRlYFXXa+QwIBHuO9Ymk/FnQPDviS8n1eDxBpGnajGst1/aelSx7LtQqGQbARh1A3ADgoD/Ea92pskaSoUkRXQ8FWGQaAMHw1408NeJ0B0DXNPvmP/ACzimUuPqn3h+IroK838afBjwb4oY3P9nDStUHzJf6YfIkVuzED5WPuRn3Fcdbz/ABS+FrEakjeOvCsQ5miOL6BB3IPzPgf731FAHvNcd4sH9q+MfC+jJho7eZtXuh/dSIbYgfrK6kf9c29KTwL8TPCnjeMDQtVia7xl7Of91Oh9Ch69O2R7116xRrK0oRRI4Cs4HJAzgE+2T+ZoA8k+KF3LHrHiuW2cCSHw9Bp0ef4Zby4dF/H5VP5V5X8KNUPgT41sk1vBaeGvFjzW9h5ZAUeVM0cTYHAyVIx/00BrtviPqK22keI9ewdlx4ltbZMj7yWirx9PNjkrzHWvDGpXv7Odleu0seu+D9RkkcBsskUpSXIPUYEkb/gaAPpDxdaXNj470DWYbOe90+8ik0XUooo/M2RyENFKy/3VcMrHsJCarfFHV7PwB8NVi0u5i0Vd8NjZSKBtgywycHPCoHOPatH4TeLf+Ex8E6df3MbwamIUW8t5QFdJNoO4r2Vxh19VYVxOveGrf4v/ABAu49YaSbwZ4dzbRxxOUF3fH/WncOSIxheP4sjPWgC9oOty6RBd+Jbqwku/E3jCdW0zSYmUObaNMQKzdECoxkdzwvmEdcA2fDl3oVj44jg8YeItP1Hx9JCXWLO2GxRiB5MAPCk5AyT5jgZPHA87uNFufA3xSvdK8DanDZ6VDo8R1DUdVZrn+xIC7HZCWbAL4BCHOSAeldP4Q8Brcv5/h3S/7FsZG82TXtWhW51e+c8mRBICIQTzuYZ77B1oA9S13xXomgX9taa3qENg1zG8kclw3lxEJjILn5QeehPNZdr8RNA1HU7Wx0OS61mSaQI0unW7zQQg/wAbygbAv4k+1WNJ8BeHdOmNy2nrf35O5r3UWN1Ox9d8mSPoMD2rpo40iQJGiog4CqMAUAc9H4cmudV1e417Un1SwvYjbRaY8QW2hhPUMmT5jnu7duAAM56GKNIYkjiRUjQBVRRgKB0AHYUSSJFGzyuqIoyzMcAD3Nefa98Z/h/osTvceJbK4dRkRWZNwx9vkyB+JFADvGumz2OtXOry2lzqvh++tkt9RsoAXltmjJMdzEo5ONxDBfm4UjOCK+a08ZaR4Wu7TwxYaot1pumi+liuJQskQcwSm2kiP3opCZQkicDcvbJr6T0z4jz69ptjqHhnw1e3tnelhBLPeW1v5mM5wpkLZ4JxjOOTivP/AIn+GdP+KFo1nc+GLrw/4gjMkkWsMsE1tlP9Yk00LN2zgNggj6ggFj4C6m03hvwJHpFtAuiRWtzDcG7tQtwLhVDSTQuGI8su5Q8A8fl2+j2ehm+8N62PDelJrepSymG4ht1jkihKO28sBkts2g+7GvmfQf8AhLfg9Zrq9rpv9raJNBLEt/aTtcWVxFLg+YO8TDYvOBuAwR3r3Xw98SPC+tW/h670fVYTLbaReKlk/wAsqzRpEdpX12q+PUZwTQBk+KPhD8Lrvw9/wkklo+jaTZzy3N3JHI4NwisylPmY7VZgCAoBOQBjNeV+HZL20/aa8KQ6jaQ6bCu02mmRDC2UMkLGOM+smGBc92J5r2bxfax6hrnw/wDB0r3BtZ7dLmSNHISZYmjdxJ/eGEIx6vXlfxanbRv2m28RlS9rpUmnzXI9I2CoTntjP5mgD6+rM8T6La+I/D2o6Pfg/Zr2BoXI6rkcMPcHBHuBWkCGAKkEHkEd6WgDl/hxrFzq/hiJdU41iwkaw1AYx+/j4Zvow2uPZxWJ8ZPDMer6GNTW0N3JYRyLdWyfeu7Jx+/hH+1gB09HjX1q3Nnw78T45uRpviaIQueyXsKkqf8AtpECPrCvrXcUAfPfwtZtU0DUPhlrOoZvbCGPUfDurRjmW1JD29xF7o23j0O3sa9k8Ea7Jrmjk30S2+r2chtNQth/yynXrj1VgQ6nurKa8L+KWj3/AIM1aC78Own7bo0r6xowjH+ssyf9Msj6qhbzAP7kjAdK9GXXLJv7I+JGhyA6HqVukGrqTjbHnEczf7ULllb/AGWb+4KAPTqKAcjI6UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZXirQbHxP4dv9F1aIS2d5EYnHcZ6MPQg4IPqBXm/wQ8as2nDwf4mut3ifSb2XStrcvOkaM6Sn22KRk9wPWvXa8MsdEg079rq8u2QA6hoBu48f89AyRN/46h/OgD3OiiigAooooAKCcDJ6UV5z8WdWOxtILOLCKwuNW1RY2KvLbQ4AgVh93zXOCeDtVwOuQAc98UfhponxOg0678NRaZbXb3O641uHKyLEu4Eqq4EpZhgEnAxkGpdM+E/ivRLeFdF+KWuo0QwqXkCXUf02ueBXf8AgPRG0XQYftTJJqV0Fmu5EGF3lRhEH8MaDCKvZVHfOejoA+Y/iR4Q+KFp4Q03QPsWl+JdKt7rzlmsFaG6ZysoJkViV5MhYkd/rWh8PfHWgp4mXSNfEtlPrOn22m6ppepQsjpexIIgdpGDHLGcZ7bBnG6voyuT+I+k+F7nw9e6j4ut4Ra2cDs12PlmiQjkI6/MCemAec4oA8haw1fSvFtr4X0Wa5s/FsYeCC+BDxXWmMeLiZFIAaBT5ceSTkAfT2Wd9I+HXgN3VWj0vSbb5VJy8h7DP8Tux/Fm96wvhL4d1K0gvfEPiiWWfXtVICmZQHt7RSfJhIAwCAdzD+83OSM15V+0n8Vm8P8AjvQdDtYLO/tNPkj1G8glZgGmG7ylcjsuVkxzk7c0Adx8K/htdie48VePJXu9c1S5Gpf2c/MFjIR8ny/xSIuFBP3cYHqfX6+dNB+LfizxTHPcw3ujaPYpM0UbwaNfag02043oyhVIJyB0PHOK2NS8EeK/iDpAz8Qdbt7TdMkqPYx2glOBswkZDBQc5DnJHYdaAO78afFXwd4OZ4tY1qA3i8fY7b99NnsCi5x+OK848UfEfx/rkul2fhrRovCkV8Xn+2au6NPHaxrmSd4iCI4xkctkk4A9awPCHwb17Tbq31dPDej20+kPGyaZcXPnrqdygKm4ExG6JcEMqHI3DJA4rodS1O30nRdXu/iDpsd54t1OaNZdLu2aOKeFHzDb2jKGWRQxU4J5ZiXxxQBxuo+H7rX/AA9JL4x8Q6lrk2qO82lm5ka2jtdOh5mvniBCrlfuBv7yepxgT/CXNlb38fhvTYj4ouRFo1hNqE5ubKN0JEjKoCtsUGRsnjofSuwtvEdlqmt6jP8AEBm0u2WUtq7yKXhbyHzDpkEi5RkH35MHLscYxnHr3g7SrzX/ALT4t1h1t9R1C2aHS4kw39m2jcqBg4MrfKzn1AUcLyAeJTeEvDSa5ZQaXaPb2mlSCysJ9FVk1bWruFNszIwfbHErfekwOQfmFUoNI8f+DvElvB4e+x6iulpd340qaQzrpPmoxD3EyhFeYjdgEseTjgg16VryaZ8MrCx0rw2jSeJZdPt9Pl1BYTI8cQZgpSPODNLIXKxjq2Wb5UJrY8N+AYofD7XnjZJDYxI92dFEhnjRsbmluGXm6nOMljlQeFXgGgDmvhx8TJY9f0zRfGGl3Omare6PbhGu5jIdSlL7UKAfu1BDOTkA9j92tDxv8DPB/jeGTWfClyukalNvKXmnMGt5WyVbcgOOTkEqR3zmvL/iD4b0nR/h4kU+lm11S/DX1r9pkYz6XaowjtIATkhmaQFh6mT+6Mdt+zJ47udT0eG11OdBbxlLASTSrGglUYhgtolHP7tS7seST3A4APLNR0v4jeE/HOgJrHiHUzriStZ25WGW5T7LgFniYKwdcYBXAcYGR3rt/E9jc+Ifih8RYpYz9h1XT5tNheO2Nw5e0W2dtqAjL5fI54K5xxivpDxDodlr+nm01CNiFcSxSxttlgkXlZI2HKuD0I/kSK8W+HtreaR4y0TRddW6/t2HWNVuZJ50A+1wyxsVuF2/LhioGB0I6DigDo/2aPGX/CVfDi3trq483VNHP2G4yCGKr/q2OeeVGM+qmvWa+cfDf2zwH+0e9veDUTp3iRGtjdXlrFEk0yDcjK8WFcnoSQGy3I719HUAYHjrRZde8M3drZsseox7bmxlY48u5jIeJs+m5Rn2JFT+ENbj8R+GtO1aNDGbmIGSIjBikHyuh91YMp+lbFcTobDw74+1PRGGyx1gNqtj6CUYW5jH4lJMf7b+lAGl4+0GbXNCP9nNHHrNk4u9PlcZVZlBwrf7DgsjD+65rxT4R6tB4a8WzeGLy0aLwf4s82fTYLhfltLrlbixbPAwwZMd8L/fr6Prw74v+Co59Slghdra31udbqxuI2Cmz1mJSY2BOABOi7D/ALaKerUAegeCLiXSb668I37SNJp8Ym0+Zzn7RZE4Xnu8Z/dt/wAAb+Kuxry3wlqM/wARfC2k6oHXT/F+hXWy4V1wFlAAljYDny5UOfY4PVa9SoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8a8ZyS2n7TXgOSAOTd6ZdW0ozwUUM36HB/CvZa8h+KOLD40fCzU2OEee8sWPvJGAo/MmgD16iiqesanZ6Pptxf6lcJb2kC7nkc9PYDuSeABySQBQBcqvezywCEw2stwXlWNhGVGxSeXOSOB7ZPoK5MeOjNBDb2Gi3tz4gkjEraWrKGtQc7PtEmdsWRg4OW9AcVp+D9GvtMjv7vWrxbvVtRmFxceVkQREIqLHEp5CgKOTyTknrgAHQ1xc1va3nxL1Wx1CKOaG80KJPLdch4xNKJF+nzrke4rtK4/4iJLpsFp4rsxun0PfLcRgf66zYDz0+oCq494wO9AHXRIsUaRxgKigKoHYCnU2KRJYkkjYNG4DKw6EHoadQAV53c/8V544+yg7/DHh2dWn4+W9vxyI/dIeGP8AtkD+GtP4h6zewx2Xh/w9IqeIdZZooJDz9khUZluSPRARgd2ZRW94a0Sy8OaFZ6Tpkey0tYwi55Zj1LMe7MSST3JJoAg8Z+Ibbwr4Y1DWr1WeO1j3LEnLSueERfdmIA+tfJF1osWn6P408Z+LJzeapqu7R7Z9m5RcuD9rljA5KQqGUEddjdOK9l+KuqXPiLxTFo2kHzP7PnS1txjKPqcqFg59RbQ75j6OydxSafoVtfaZ4iuLDT57/QdD0yfw9pFmg3NcttxdTDkbmZwEyOTsbu1AHmHwz8GXlzq1rYaQujappt/ayXMZ1CK5jSCzjkMUUzRJIqs85BbB7IT3r6j8IaKPD+gW2nf6FuiB3GytBaxEk/wxgnH5k+prxT9kjVRqNl4hj1G5ik1qzNrYGNV2lbWCLZFgYHfzM8devWvcNN1/TtS1C+s7K4EstnL5EpA+XzAMsinozLkbgM7cgHnigDUrkPipp1tqfg68t9T1C003ScE311PAJWSDB3CPPCueAGwSM8AnFdJq+pWej6bc6hqdxHbWVuhkllc8KB/P6DkngVx+j6beeMNSttf8TWsltptu4l0rSJh8yN2ubgd5cfdTogP97kAHF6b8OtR8QafpN1p10/hrQ9Oljk0fRLm0WdFQBgZ7iNiMyvuLAE/LkE5YnGjp/hnxHZ38kUFtD4bvI43mXVdIlU6bdEEcXFm+CpIzyvI5+fgV69WBoeNXuk1549ZsWaB7T+z70+WgAkJ8wxZI3HHDZ+6RQBxXh3UoNT+IFjP4va3h1cW2dFWB91jeKwJe4gc8tIVIUq3Kr0yGJr1KSRIo3kldUjQFmZjgKB1JNYGvC70fdqum2lxqKqU8+yR8ssSqwJt0JA38glf4gMdcVwupeMdOs9Llbxjdx6v4F1uJpLHUfK5B2lmtJlUDLHa23gE4ZGGRyAc7rE1pcxzfEW6nkXVtQmkt/DsMj/uYoFRkjuXTHRVM05PQB/XFeI+HZbvwH8S7OPRrZnudYto5LSNE3XcUbt8qAH5UlmRFyx+6spr6JvNTk8PQP4r13T1bxBqELWmg6Ht2/YrYLuKuOi8APM/RQFUdBnwD4t6fBb6/4P1zWZ3ittTmaS7uSrR391EXUyXDIOURgzJEmMhEGeSQAD7W0m5e80u1uJfI82SNWcQS+ZGGxyFb+IA5Gaq3mjR3fiPTdWklO6whnijiC8EylMsT7BMY96g8FXVndeGbH+z7GPTYYoxF9gVkJtMAYjYKSFYAjK9s1uUAeBftIQXscsF/bXN/ZyWLxalZ+ZMGs7uaDczRgHmGYJuKkcSDI617jo2oQ6vo9jqVrn7PeQR3Eeeu11DD9DXn/wAadBE+gajqrRzXunizaHVNOB3CaAZIljB4WaI/OCOoBB7EUv2X9dfWvhDpkU7lrjTXexfIIOFO5Ov+wyUAes1yPxL0+6n0KLVdKRn1bRJ11G2ResuwESRf8DjLr9SPSuuooAqaTqFtq2lWeo2MnmWl3Ck8T/3kYAg/kaqeK9CtvEnh+80q8LIk6fLKn3oZAQySL6MrBWHuK5/wHH/YGs614Ubi3t5P7Q04cAC1mYkxgekcodfZWSu2oA8A0jU7rwx4nPiS8QJIZjp3iWGIELG6jJnA/u8idf8AYklH8Ir35WDKGUgqRkEcgivOPibpi6bfL4jiVBbTollqO9QUT5/3Fyw7iNmZW9Y5G7LVz4Z6g9qJvDV1vH2NPMsDIxZmtQ2wxse7QuDGfYIf4qAO8ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryH9qLTbif4arrOn8X+gX0GpQsOo2ttP4Ddn/gNevVX1Gyt9SsLmyvYlmtbmNoZY25DowwQfqDQBm+DPENp4r8LaZrmnsDb3sCygA52N/Ep9wcg/SuV8U6bqXinxXdWtjdR2qaPDC1u00e9EuZS264C9HeOIfIDwGfJ6CvGvBfiuX4Fa/4u8GeIpHbTEhl1HRZpAcSNtJVP+B4A9Ayn1zX0V4AlvrjwPoFxq1ybnUJ7GGaeYgDe7IGJwOOpoAueHdDsfD+mpZabEVTJeSRzukmkP3pJG6s5PJJrToooAKw/G+mnWPCWq6d9uewjubdopriOLzGWIj94FX1K7gD2zkA1uVFdwJdWs1vIXEcqNGxjcowBGDhhyD7jkUAJZCIWcAtgRAI1EeQR8uOOvPSq+uarZ6Ho93qepzCGztYzLK57Aeg7k9AO5OKsWVrDZWcFrbKUggRY41LFsKBgcnk/U81w92P+E38Zi1GH8NaBOGuc8reX68rH7rFwx/2yo/gNAFv4faTeM954n1+Ix63rAU+S/WytRzFbj0IyWbHV2PoK1PHPiAeGfDV1qEcP2m8JWCztQebi4chYox9WI+gye1b9eMeNtTufFHjiOx0iV1/s6dtNsnXkC+kTM9x9LeAnB/56SY64oAwtDtLzTdKkvNPlS41y7mk0XRrk8+beSsWvr8j0Dq4B/uW4HRsV7n4c0e18P6DYaTp6lbWzhWFM8k4HUnuScknuSa4fwJpdtqXieTVbWJV0LQIW0XREyCCVIW4nB9SyiMH0Rj/FXpNAHknxU8EX9heyeOvhzHDa+LbWNzcwhMpqMJHzK6/xOMAg9SQO+MZP7PZsNWt7vxIJSbHS7WLS7aScFNj+Ws15Md3RnlkO5u4Qdq9xrw3U75/B3jjX5LWF9M0fVXWLU4XjWWO2mmzHBqMY+60bkbJFOMMBnORkA7LQkm8eanFr9+pXwzbSB9ItGGPtTDpdyA9v+eant855Ix2+p39rpen3F9qNxHbWduhklmkbCoo5JJqON10vRkfU7xGW1gBuLqQLGp2r8zkDhRwTgcCvN/Cmrx/F2+TVvsssfg3TbhhawzjB1G5RhtmZf+eadQp6scnlMUAXby08R/EPTbh4NRv/AAnok0RFmYF2X05I+WWQnmNO4jGHP8RXpXd6LZzafo1jZ3V5LfT28CRSXUv35mVQC7e5Iz+NXaKACvBPjLpXh/QvE1tLqFl/allroeAaKtzsWK+kGxb0Rn5VzkI0mPlYqwySa9V8e3+oadpInsdV0fR7YZ+06hqWWEC44KJkBm68MwHTg9K8H1bxBZ6/DqvhvwHYatrOraig/tDXrmEyXEm0gptBKiNdwG3cY0XqqmgDpvh7rk+lxS21/wDaPEXxW3Pps8ErfLaxxN8rM2MRwEbJC+N0hboTgDzz9pQWnhnT/D/n6nZ6t41bUf7Qv5mUMw2r8ibOdkIJAVD1wTycmum+HnhzWZrrRNR1bVbnSrDxErWWox6fdv8Aabi9h8w5nnbLBm2zAiPbjaqg1X/ar8KWGm+DvC+i+FdIhiludTbZFbx5klfyyCS3VicjJJJ4FAHvvgDSIdE8H6XaQfMxhWaaU/emmcbpJGPcsxJP1roK85+B/iK78XeF212QSxafMIre0gkA+URRhJH4/vSb/wAFFejUAR3EMdxbyQzKHikUo6noQRgivEf2amltm1O1nn80XWnafqEYH3VGx4D9SfIBJr13xZevpvhrU7uG2vbqWKBykNkMzucYATr83pXnuj6fB4T+Mui6ZaMYdOvPC4soInYFjJaygjnudkrE/iaAPV6KKKAOM+I6Npaad4rgDeZokha5C/x2cmFnB9doCyfWMV2SMrorowZGGQQcgimXEMVzbywXEayQyqUdGGQykYII9MVyPw1kk0+0vvC95I0lzoUogid2y0tow3QP/wB8/IfeNqAOrvrSC/sp7S8iSa2njaKWNxlXVhgg+xBryXTNF1Cym1KwtJTJ4k8PyRXdiJDg31uVKZZj1Mka+U/GBJEH7ivYa5XxzZz2/wBj8R6ZC0uoaTuZ4k+9cWrY86L3OAHUf3kUdzQB0tnP9ptIJ/Klh81Ffy5V2umRnDDsR3FS1BYXcF/ZW95ZyrNbXEayxSL0dWGQR+BqegAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwf9sHwvb6t8Nl1wJ/pujzKysByYpGCMp9s7T+HvXqXwxuhe/DjwvcjGJdMtm4/wCuS034oeH5fFPw91/Rbbb9ou7R0h3HAMg5TPtuArn/ANnrXo9d+FGiqEMVzpsf9m3MZ6pJCAvP1G0/jQB6RRRRQAUUVW1S/ttL066v7+VYbS2jaaWQ9FVRkn8qAOe8d6xd20dnouhuo17V2aG3cjIt4x/rbhh6Ip4B6sUHetrw9o9noGi2ml6ajJa2ybV3HLMc5LMe7EkknuSTWD4I0+5uZ7rxRrMDQ6pqahYoJPvWdoCTHF7Mc73/ANpsdFFddQBz3jzW5tC8PSS2CrJqt1Itnp8TdHuJDtTPsOWP+yrV5folrJovh4SaJPNLqGoOdB0KZ+WYMxa4vmHqziWUnuscfrWl4puJvFXjT7NZyOI4nl0nT5YuschQG9ugf+mcZEKn++7Cul8HWltqniGfVbaMLpWjxnRtJQcqAmBPKv1ZVjB9Ij/eoA6rQNJtdB0Sx0rT02WlpEsMY74Axk+pPUnuTWhRRQAVwnj/AEi21XxLoNreR77XVLe90q5X+9G8PmfmDFkehru65rWdM07XfE9lDdXLtLplvJM9mB8rrcK0QZj9FlAAPf6UAfP3i/xfqM3w507wTqEnn6va31xpF6A2GuTAFW33f7EjSQEnvtYdyK+j/COhW3hnwzpujWQAhsoFiBH8bfxMfdmJJ9zXzZrPw8uPhr8VtFuImW88K63qtmrXl5+8mtHSTcsTOf4SQuCeoUA8jJ9z+JeqXx/svwxoNw1vrGuyNF9oT71paoMzzj/aCkKv+06+lAHRz2WoyeIra8j1VotLihZJLBYFPnSE8OZDyAB/CMe57U/xBren+H9Ne+1a4WC3UhF4LNI56IijlmPZQCTWddzaZ4B8FPIqXLafp0WEjDNPNIS2FUFiSzMzADJ6mqPhnw3dXF9F4h8XFLnXSpNvbjmHTUb/AJZxDu+OGkPLdsLxQByUngE+P9YbXPEun3Gk2Mo/d2cs7SXbrgY3EsVtgR1SLDHuwORXpuhaJpmgaeljotjb2VqnSOFAoJ9T3J9zzWhRQBxng6wsrptcgeESxWWvTTwhhxHKQshK/wDApH/M15/+0ZBPeeNPhTZwOB5mtbiCcZ2tEc5HPTd09a9R1PVfDngq0mkvbiCxF1O8/lgl5biVzltiDLOxPZQfyFeP+K9avvEnx2+GKTaU2n2kL3c8CXEqtcMvlgl3jXPlj5RgEk9cgdKAO1+CF02m6dqfg/ULY2GpaPe3DR27LtEtrJM7xyoejL8xXI6EYODXptc3Nojj4i22vm6jEX9lyaf9nYnczmVJAwHTorZ79K6SgDH8U3OsW9jbjw9aRXN5NdRRMZmwkMRYeZIwyCcKDgDnJFeNfHjV5dF+Mvwuv4lUxw3EkUzN0VJmSPk9uC35V77Xz9+0Pave23jS7T5ZNI0rTZoHXqsn2uVj+gFAH0DRVXSrpb7TLO7jYMlxCkqsOhDKDn9atUAFcZ40xoOv6R4qX5YVZdM1Hjj7PK42Of8Acl2/8Bd67OqesadbavpN5p18m+1u4XglXOCVYEHHoeetAFyiua8AXGpNoZsNcjn/ALR0yU2UtzJGVW7CgbJ0J6hlKk+jbh2rpaAMHwvosmgyahZwMDpLzG4tEzzBvJMkY/2Q2WX0DY6AVvUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeV6Ja/wDCD/GPUbMLs0TxeDeWxHCxX0a/vU9i6/OPUqR2r1Suf8d+GofFfhyfTnla3uVZZ7O7QfPa3CHMcq+4b8xkd6AOgorkvh54pl1+yubLWIFs/EuluLfUrQHhXxxInrG4+ZT9R2rraACuM1EHxZ4pXTVw2haPKst6cZW5uh80cPoVTh2/2tg7MK2vE2pS2VvDa2G1tUvn8i1UjIU4y0jD+6g+Y/gOpFXNG02HSdNhs7fcypks78tI5OWdj3ZmJJPqaALtYHjTUrmx0kW+lFP7Y1B/sliG6CRgSXI9EUM59l96364Y2EnjC91i9E7Q2SxvpVjIvJ2lsXMy+hYjYrDpsz3oA5nQYfsWim80HzBNfY0PQGcbisO4mS7PrvYPMT3VE9a9S0TS7XRdIs9NsEKWtrEsUYJycAdSe5PUnua57w3aQXuvS3ttEI9M0iM6Xp0YGFG3AldfbKrGP+ubetddQAUVlnXbM389nB59xc288dvcJDCzeS0i71LHGNu0gk9s81j3vjrT9N1Wa01mx1XTLaOTyxqN3bbbRz2PmgkKD2LbRQB1lcvfxT2/xI0m5t4maC70+4t7lwpwvlujxknoOXkHPrXToyuiujBkYZBByCKhS1iS9kux5nnSIsbZkYrtUkjC52g/MeQMmgDO8X+HrHxX4bv9F1RC1rdxlCR95G6q6+6kAj3FeWfBC41rWPG3iWbxiY31zw7bw6GroDh03M7Tc9TJtjP/AAEV7XXm2r/8Ux8Z9K1BWKaf4otm0+5A+79rhG+Fz7snmJ+AoA3vFmkWPjNo9HbVlWHT7yC51CzgKmR9uJI43OcxgkK3qQOMZzXV1GsUUckkqxojyYMjhQC2BgZPfArg5dUu/HXnrot9LpfhS3crcatG2yS+2n5lt2/gjGCGm6nkJ0LUAa+ueNbDT7+TTNOguNY1mNdz2ViAxiHrLISEiH++wPoDXjfiHx18RPG+qDRfh3Np0DiQpeXNkjTw2QGPle7cBGb2jQ+xNaGiadH8T5X0rwzE+i/C/T7hknkty0cutyD7w3dfLz1Yklvr933HSNMsdG06Gw0q0gs7OFdscMKBVUfQUAeG6L+znDNqMmqeNPFus6xqMy/vGhkMIJPUFiWYjtjiuf8Ahl4B0vw/+1Bqdt4cubiTT9GsDNMJ23lJZVCiMN/EMPnJ54I7V9G+I9YtPD2g6hq+ovstLKB55COuFGcD3PQe5rxH9mGw1STXvGXiLXoVivNc+zX6LuyyxSmV1Htxjj0xQB7J4h0FdYvtEuhOLebTLwXSyLEGdl2MrRhj90NuGSOoBHfI26KKACvJvFll/bGl/F3aS6NZLZphc5eO1MmB6kGWvWa8x+Nk/wDwjPgG/vtLsNgSSS7e5hBJhnYH53QcsrklGOeA+cYzgA2fgpf/ANp/CXwnc7tx/s+KIn3QbD+qmu1ryj9ludp/gf4e3sWMZuE57ATyYH5V6vQAUUUUAZd5G9vrNreqdQmEq/ZGgicGCMHLec6nHI27cjP3unpqUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxPxA8I3mqXFtr/he7XT/FenqVgmb/AFV1FnJt5x3jY9+qnke+n4Z8URapoct3qkP9k39nHv1GxnkUvZkAn5yP4SAWDd1wa6OuY1Syt9b1p7GOKMWkTRy6k6qMzsvMULHuP4mHptHRjQA3wjb3GoXlz4l1JWjmvUEdlA2Qbe0ByoI7O5+dv+Ar/DXU0UUAYPi68nSzh03T3ZNR1N/s0Lr1iXGZJf8AgC5I/wBraO9TX+n3Vp4Vk07w0Ybe6jtxb2jzZKRHG0Mcdcdcd8VX0FP7R1O612TJR1NtZA/wwg/M4/32Gf8AdVK6CgCppFhDpel2tjbA+VbxrGpPVsDqfc9SfU1zHxG1S9WPTvDugzPBrWtyGJJ062tuuDPP6Aqpwv8AtMtdlXGxWok+L95dNIrPFoUMUS5GY99xKWOP9rYn/fFAHRXd9ZaHpge/vUjhgiGZLmZQzAYGSzEZJOOT3NVfD/iDSfFWktcWMqTQsPLnt5lxJExHMcqHlTzjB69sg15/8H7n/hKZtcuPEkMV9qMCQ2okniViIGiXdH06GRJCR615l8RtLn0P4naFb/D37HBAmpQwD7RJsiF0F3/Zt2SWjAIOCp8t5FCkZwAD6A1e8j8HW1tchDH4bt40tWtra2BFmM8TEg5EajAIAOBz0BrpY3WRFeNgyMAVZTkEHuK5L4d+KX8baRqN9Np62lol3JZxwySLI52ALJvAyo+feBzyoB71H8LohY6ZrGjxbvsmk6pPaWqtzshwsiID6KJNo9gB2oA7OvMf2iCbb4eJq0R23WkalZ38Bzg71mVcD6h2H416dXmPxzvbXUPB2p+HEY/2hcTafEqkYx590qIw9eUbp0xQB3OsXj/arXTrK609L6ZhI8F1lme3UgSFUBBJ5AyeASM56V5l4qM3xF8TXHgHQ2Nj4V0jyxrtzB8hl7rZxY6AgfMR0HHsey+JXihfDGkxGxgW68Rai/2HSrYAbpZm6Z9EXhmPQAe4p/wx8Gx+CvDYs3n+2ancyNd6jesPmubh+Wb6dh7D60AdLp1ja6ZYW9lp8EdtaW6CKKGNdqooGAAKsUV5J+0D8To/BOhppWlSF/E2qjybVIwWaBWO0ykDnPOFA5J+hoAxPiB4k0zxt47j8N3V9EnhLQ7hJNU2gu2pXmf3dnGq8vgjLAZ6YOMA17jBFEg3RRLHuUA4XacAcA/SvKfgJ4DsvCmmSzf2Bc219IATqWoupurkn7x8sZ8lfRSdx/i5r1ugAooooAK8v8eeIRY+NI9M1ZJY9FvLX7NdRyvmG4tpTsaZP7rRSMiuD1SYN/Dx6hXlX7R9sYvh/JrcUQkl0xmEi8ZeCdDBKgz6iRW+qCgCH9l23+x/CiG1DFlgv7uJWJzkCUjIr1uvJ/2Wbdrf4IaAXUqZWuJOfQzvg/kK9YoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmpGibtiKu47jgYyfX606igAqlrVnLqGlXNpBObdp18syqOVUnDY99ucHsau0UANjRYo0jjUKiAKqgYAA6CnUUEgdeKACsr7Mi+KjdC3gEr2XlGbzz5hCvkL5fTaNxO7rk4rVrnPGGkXt2LPU9DdE1rTWaSBZG2x3CMMPA57KwA5/hZVPbBAPEvF2q6h4F8V6+ugXEdqszyRXmpSQPJbWKTsJoHfaDmUSSToFAPDoT6VyGg6Nb6pZPJb6hHo97qETQ+ILGeEt/ZdnHtMlxNI+GW4d0Vw2BuLDj5d1fR2n614b8VXdpFqltBDrmnS+cNP1FFW4tZcY3Kp4brw6ZU9jVqfwH4bnYmXTEYPff2lMpdiJ7js0oz8+OoVsgYGBxQBynwXvLO8vNZ/s6yubGzhWGG2tPLMcVvAASm/OMzuD5j8EhXQE5FdpoEE1nreu2y6WtrYNMl1FdCbebuSRSZCQfu7SoGPTGK17q6trNUe6nhgWSRY1aRwoZ2OFUZ6knAA71BZWMttf39zJfXNwlyyskEu3ZbhVxhMAHBPJzk5oAvV4X+0Lc2+g+Nfhz4j1C48jTLbUGW7YgsMKA6cDqR8+Pc17pXzd8ZJl+MHxI0n4e6CJWs9IuGudYv0AKQ8bSq+4yV/wB5sdjQB2PwiS+8ea9N8SfEFsbaJka00GzP/LC2yd0rerueM+gOOCK9gqvptlb6bp9rY2MSw2ttEsMUa9ERRgAfQCqPivX7HwvoF3q+qM4trdR8sa7nkYkBUUd2ZiAB6mgDL+IfjWx8FaOtzcRyXeoXD+TY6fBzNdynoqj09T2H4A8h8LPhrcWmtXPjbx0yX3jLUD5m0/NHp6kcRx9eQMLnsBgdydnwD4Vu5dRk8YeMokfxReDEMLEOml2/O2CP0bB+dh1JPbr6BQAUUUUAFFFFABXlH7SV6H+Hd3oUG57zUlLFUXOy3hxLNIT0UBVxk92Ar1evJfG9rcw/Da/0xdVGp3fijVvssE8bZRUuJvuLkkbUhVun900AdT8HNOOlfCvwraFNjLp8Lsv+0y7j+rGuxpsUaRRJHGoWNAFVR0AHQU6gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqtqVjbanYXFlfwrPa3CGOSNujKeo/8Ar1ZooA4IL4n8GkiJLjxT4fUfKgZf7RtVHYFiBcL9SH/3zW/4X8XaJ4oSX+xr5JZoTie2dTHPCfR42AZfxGPSt6vK/H9zpev641j4d0VtW8UWGVfU7e4NmmmcHiS6UZB55iXcSM5A60AdB46v/C0d7b2XjXSYnsZFBi1C+tFktVck/IZDny24zltoOeCTWxLoWnXum6fFYXFza2lqh+zHT7lo1ClCo+6cMADkZzyAa8R0Wb4g6ppxtPD/AIyOswIzC91m9sIU02OMfeWNmUvORzlhheOTXJw+C9fv9QZ/hT4p1O4u5ZP9N1CxgGm6OuOCECnDtnH3Aw60AfRGmeA9OttTttR1O+1XW761bfbyancmVYHxjckYARWwfvBc+9aXiTxd4e8MwGXX9ZsbBR2mmAY/Rep/AV49H8HfiHqVp5Wv/FjU0UgBo7NHwfUFt6k/iKvaL+zT4Is7n7Rqsuq6zMW3N9rudqsffYAT+dAGTr/xf1n4h3U3hr4O6dcSyyApc6zcKY47eM8blzyDycE88cKT09P+E3w8074d+GxYWbfaL+c+be3rDD3Enr7KMnA/qSa6Xw/oWl+HdNSw0LT7aws05EVvGEGfU46n3PNaNADZHWNGeRgqKCWZjgADua8/0OE+PfENt4lvEceHNOcnRreRcC5l6G9YHtjIjz2y/wDEMWfFjt4s1z/hEbNm/s6ELNrkyHjyzylqD13SdW9EB/viofG2rXl5qkfhDwxcmwn+z/adS1CFQTp1pyAEHQSvghf7oDNjgUAdtb39nc3VxbW93by3NvgTRJIGePPTcAcj8awfHXixPDFvYRW9m2o6xqVwLSwsUkEZmkIJyzH7qAAktg49DXnvwW0PRtA0HVviHPCmnW2o25liQsSYLJMlWkYnLyvjzGY5OSB2rQ8C6bZaL4TuPiP4vtmk8Rz202pT3FyS8lrC25kgjB+4BHtXAxySPagDZ8H+J/Ec3jq/8M+KbTSTPFYJqKT6W8jJErSFBFLv53nGQRgEA8V0/ivxJp3hbSTqGqySBC6xRRQoZJZ5W4WONByzk9AP5Vx3gOS18I+BLnxZ4vuI7XUdZf8AtPUJXySGcfuoFHU7E2IqjnIOBk1l3lrq2oaXrvxB8Q2lxBdWOnXL6DpJ/wBZZJ5bfvXA/wCW74HT7o465oA7vwD4us/G3h8avptte20BmkgMd5F5bhkOG4BIxnI69QR2qDxf4vXRry20jSbNtW8SXiF7fT43CbUHBllc8Rxg8bjyTwATXDeDPGmlad4B8PeG/ARg1/xCLCJVt7dsxQOVBea5kHEahiWIPzEnAGTXe+B/Ccfhu3uZ7q5bUddv2EuoalKoDzv2AH8Ma9FQcKPckkA4HSbXxVL8ZtKt9U8U3F4bTT5b3VLK0URWMayZSGJU5LNne25yThAeM1N8Qtc0Xw9488Jaa8YW30m1n1C20qxhBknnYCCCOKJepw8xHQDaSSBWX4A1XxbF/bLweDdRHi3WL2S4vbzVFFvY2qg7Io1fJaVEQDAUcknkZzWrFot14O1EatqM0Hib4ia9ObKznkTyYoIgGbCqMlIkUMzYyW4GckUAaVh4s8X23jLw7p/iLS9Jt7bXvPMVpBK73NmsSbyZH+4/UAhcYLDGetel1zfhzwsmm3z6rql7Nq2vSp5b3kw2iNCQTHDGOI0yBwMk/wARY10YYEkAgkdRnpQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHNa+dQ1631LR9GubzSJV8kNqnkAq0b5LiBs/fCgjcRhSwPJqG/8EaEfBf8AwjarJY6Gu1p0gl8szIp3Osjnkh8fOc5IJ55rpWa3srV3YxW9tCpdjwqoo5JPYDvXCadDJ8SIE1HUxLB4Rdt9nYHKNqCdpp+/lnqsXQjBbOQoAMIWJ+IXi6zgtYI5fhfplsEEO0xQX1yD8uxRjzYUAX0QkcbsV63DFHBCkUEaRxIAqIgwqgdAAOgpY0WNFSNQqKAFVRgADsKdQAUUUUARXdzDZ2s1zdypDbwoZJJJG2qigZJJ7ACuBg8TeL/FMRuvBukafZaQ4zb6hrjSK1wP76W6DcEPYuykjnFdJ488Mw+MfCWo6Bc3U9rDeoEeWHG4AMG4z64xXLx/DvS9E0IHVfFnihrOzhzLcXGtSRIiKOSdpUKuP5UAZXh74fePdEtrg23xBt/tFzPJdTRvo0bo8rnJJYtvPYdeAAB0FdF4E8GahpNv4km8S6rHqWqa9P5tzJBD5Uca+WI1RASTgKO5/wATmfBoeJZ/7Tu9Q1K8uvCkjY0RdSjH2x4uvmu3Uqc/Lu+YjBOOhxvjXofjDxBr9vbaNpV1eaSljItu0GqfZES9ZhiWXDBiqKCVAzkmgDBsLHW7C78OfD/4jS6ZYeErWLFvcxSEJrDQkeXA7EgJxtcofvbcDIzXp/jjXtFS6tfDXiWNI9F160ng+2yShIS+FHk7uzMrMQcj7vGTXz74v+GPxFvNFtpviBrE+r2zS+TKlrFJePZRqpKzoilQzMQFJ2lsNknrXGx/CL4kXvg6zsV8F2qRs3mLO8+y6HJPzq0uB1xymcUAfUVr4O8LeC7aLX/EGs3+oQacqm1utbvfPSzXovlLgKD0AbBb3rV074meEdUv9Os9J1q2vp79pRGsDZ2LGCXZ842rxgE9c8Zr5k8O/s7ePbzTMa9Pbx2lv88OlS37fvDzwGQMsZx0ODz1GM1u6V+z1E9xotlqWl3cUF0fPa9EmZLfadz210qtsIYZCSx7TnGRQB63rfxN8M6dOdI8E3eg3GsT7meTz44rS1VThpZ5AQMAn7oyzH061hwfHrQdOtxpVrPqni/WYSY5bqysljhkbP3sjhU7AgNwO/U85q3wX0a81qx8MadrMNprGlh7q3uYNNWSQWbFQqXTDCmQHeEY8kDOOK1NY/Z98HeH7SPULTxTq/hxowkcl416qK7E4yxIGCSexA54FAHceAvEOqa5rvn6h/akySIyhINPe1sLXjOC8wWSZzwNwG30A61FL4a8dHxaviY6h4euLpYZLWDTp4ZhDaRMwOY5Qcl22ruYp2wMAVqeCtC8KaYsl/4fujrF/bQmOW5GovezNxkj5nYAnHTisPR/iHq/izw+97aeAr+50acSwShNRgE4wSrKY9wIbqMEgigCr4j1u9N4dK8V+JlS8ccaH4Shke8lHBG+Q5dB7gRjn71UH8N2E0YbQ/hhr9jekcXa6nHYzZPJLyrMXY/XdVfR9eg8PajJDoXiGzsbqYqJNL8YWjWly+35VUXeAX9AW83sATXeP421XSN0vizwtdWWnrjOoafOL6FB3Z1UCRV99hA74oA0Phvp3iLS/D7weLNQW9uzO7wnf5rQwnG2N5Nq+Yw5+baOvtXVVX06+tdSsYb3T7iK6tJl3xzQuGRx6gjrVigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqmr29zd6bPb2V2bO4kG1bgIHMYzyQDxnGcehweelAHI+J1bxpqUnhm0b/iS27qdanHSX+IWin1bgueykDq/HcKoVQqgBQMADgAVT0bS7TRtOisdPi8uCPPU5ZmJyWYnlmJySTySau0AFFFFABRRRQAjMFUsxAUDJJ4AFeY3l9YeM3k1rXbiK28AaZIWhFw4WLU5lb/XSZ+9CpHyL0dvmOQFr0yeKOeGSGZFkikUo6MMhgeCCPSuWtvA1g2tLqeryyam9u/+gW0yqttYIBhRFCBt3AD75y3oQOKAMCL4oS3firRLDT/DV/No+rTPBb6jK3kvIVXc0qwMN5hUYy529eAeM7/inxedO1OPRNB099a8RSx+aLOOQRpBH/z0nkORGp6Dglj0BrgY/Gdpa/EXxfc3Vnc3/iu2kXSdJ0mCMtKYAiyb89ESR23NIxACovpiu98BeHz4V8PXFxrNxHPrN47X2rXuOHlPJAJ52IMKo7KvQZNAHO+A7rxV4r8R3994hvrfT7LQ7+SzTT9LLGK6kCDc0srcuF342gKNyknOBWZ4t8YeJNW8QWlh4duItJ8Pvra6HPqKoJLqWYIzSeUrAoqArs3HJ3ZwOKqeC/GUEHgMweG2iv8Axbrt1d31tZxESNEZ53ZJZ8ZEaKpDHdjhcDJ4rU8RaFa+GNP+GOgW0wdrfXY5GmmbaZmWCdpZGJ/iZmLY7k4oA2tQ1m+0gx+EPCIuda8RRQrJLd6lIXitY3Y4luJOCxODiNeTjsOaXwnqevaX40uPC/inUotWeay/tKyvo7Zbc7Q4SWJlXj5SyFT1weckUnwlEd9J4t14HzZNS1u4RZuu6GDEMYB7qNjY+pqvd31pYfGnUbzVpltktfDStbFzgSR+c7zsPUrsiz6A0AZXhHw/qOta34x1C28S3+lebrlxBcJZxQs0qxoiRje6MV2qOg9axta+1a78GPtviST+2bbR9bae7SZFEk1nb3TIwkAABYRgseBnHvXf/B21mj8DW+oXaGO61mebVpUJ5X7Q5kUH3CFB+Fc/4s0+48NTa1YLtk8N+LpJLcFhzYX9whTJ45ikbBJ/hcns3AB0Gt/DvQ9QSK80JB4f1eJf9G1HSkWF07gMoG2RD3VgQfbrXC3dvq+g+Ibe71XyvDmu3kqwHW7AGbS9UkOAq3UBwYnbgBsg5yA54Feu+FrS50/wzpFnflGvLezhhmKMWUuqANgnkjINTa3pVjrmk3ematbR3VjdRmKaJxwyn+R7gjkHkUAc/wCFdSXxdpWp2XiPSrMXmn3b2F7bkCaB3VVYOm4ZKMrKQCMjOO2Tnf8ACI6t4XmMvw+urWGxc5l0XUC7WwPrAwy0J6/KAU6cCrHw/wDAQ8H6rrN2uualqa6gIVVLxgxiWMELlhy7YIG484UA5xXbUAeSWHhPxZb+J313SrXTfDkUavJcaVZ3b3EWqynHLgqiRcbsOoLZOTnFepaZcyXunW1zNazWck0au1vPjfESOVbaSMj2JqzRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMWGJJXlWNFlfAZwoBbHTJ70ssaTRPHKivG4KsjDIYHqCO4p1FAGdoehaToNqbbQ9MstOt2O4x2kCxKT6kKBk1JrGk6frVi9lq9lbXto5BMNxGHXI6HB7j1q7RQBW02wtNLsILLTbaG1s4F2RQwoERB6ADgVneKfCuh+K7OK18Rabb38MT74xKDlD3wRgjI4IzyODmtqigBscaRRpHEipGgCqqjAUDoAKgv7K2v4UivYI540kSZVcZAdGDK31BAP4VZooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19652=[""].join("\n");
var outline_f19_12_19652=null;
var title_f19_12_19653="Epidemiology of asthma";
var content_f19_12_19653=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19653/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19653/contributors\">",
"     Augusto A Litonjua, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19653/contributors\">",
"     Scott T Weiss, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19653/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19653/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19653/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19653/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/12/19653/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate assessment of the prevalence of asthma has been hindered by varying definitions of asthma and methods of data collection, each combining to make data comparison across studies difficult. Following a brief discussion about the definition of asthma and the identification of affected individuals, studies of asthma prevalence are reviewed. The definition, diagnosis, and treatment of asthma are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DATA COLLECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential to any study of prevalence are the definition of the disease being studied and the methods available to identify affected individuals. Although many definitions and methods of data collection have been used and reported, herein we discuss the most common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definition of asthma that incorporates both a positive test of airway hyperresponsiveness and symptoms was proposed and tested for epidemiologic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/1\">",
"     1",
"    </a>",
"    ]. The study defined \"current asthma\" as bronchial hyperresponsiveness (BHR) in the presence of wheezing in the 12 months prior to the study. According to this definition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Current asthma\" identified a group of children with more severe BHR, greater peak flow variability, more symptoms, more atopy, and more medication use than children with BHR alone or wheeze alone",
"     </li>",
"     <li>",
"      Children who only had wheeze did not differ from the normal group except in reporting symptoms and in more associated use of asthma medications",
"     </li>",
"     <li>",
"      Children with BHR only were intermediate in severity, in terms of BHR and other study parameters, between the normal and current asthma groups",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It appears, therefore, that this definition identifies a group of children with clinically important asthma. Because therapy can return both symptoms and BHR to the normal range, the authors recommend extending the definition of current asthma to include subjects who have had their illness recognized by a clinician. This definition may not be as useful in adults because of the effects of smoking and because BHR has been unable to adequately distinguish asthma from chronic bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Questionnaires",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologists have relied primarily on historic or questionnaire sources to identify patients with asthma. Adding to the inherent limitations of questionnaires, different studies have used different symptom questionnaires, and cases have been identified either by physicians or by surveys of population groups in which the definition of who has asthma has been left to the patients themselves, the parents of patients, or to the report of the diagnosis by the patient's clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/3\">",
"     3",
"    </a>",
"    ]. Other studies have included objective tests of lung function and airway responsiveness in the identification of asthma.",
"   </p>",
"   <p>",
"    Each method of selecting asthma patients has its inherent problems. It is likely that some bias in reporting of cases is present in each group and that the biases in each approach are different. The table summarizes the potential problems of the various approaches to identifying persons with asthma (",
"    <a class=\"graphic graphic_table graphicRef73952 \" href=\"UTD.htm?17/41/18075\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As part of ongoing studies, a 1996 report validated questionnaire-defined asthma and BHR versus respiratory clinician assessment of current asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/4\">",
"     4",
"    </a>",
"    ]. Using the Tasmanian Asthma Survey (TAS) questionnaire for adults and the International Study of Asthma and Allergies in Children (ISAAC) questionnaire for children, subjects with symptoms in the past year were identified. BHR testing was conducted using hypertonic saline. Subjects were then interviewed by one of two respiratory physicians who were blinded to the results of the questionnaires and BHR testing. A clinician diagnosis of \"current asthma\" was defined as a history of wheeze suggestive of a clinical diagnosis of asthma within the past 12 months.",
"   </p>",
"   <p>",
"    Using the clinician's diagnosis as the \"gold standard,\" questionnaire responses alone were found to be sensitive (0.80 for adults, 0.85 for children) and specific (0.97 for adults, 0.81 for children). Questionnaire response plus BHR was found to have high specificity (0.99 for adults, 0.94 for children) but low sensitivity (0.37 for adults, 0.47 for children). This study, however, did not incorporate a previous asthma diagnosis to the definitions of asthma, particularly for the children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GLOBAL VARIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature is replete with studies reporting the prevalence of asthma and asthma like symptoms from different countries around the world [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. However, comparison of these prevalence estimates has been difficult given the different methods used between studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two multicenter studies, the International Study of Asthma and Allergies in Children (ISAAC) and the European Community Respiratory Health Survey (ECRHS) are addressing this issue. Reports from ISAAC have confirmed the wide variations in the prevalence of asthma symptoms in children worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. This study employed standardized simple surveys which were conducted among representative samples of school children in two age groups (6 to 7 and 13 to 14 years) in 61 countries. In a subset, a video asthma questionnaire was also administered.",
"   </p>",
"   <p>",
"    For the ISAAC surveys conducted from 2000 to 2002, there was marked variation in the prevalence of wheeze in the last 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, in the younger age group, the prevalence of wheeze ranged from 2.4 to 37.6 percent with lowest rates in India, Indonesia, the Isle of Man, and Malaysia and highest rates in Australia, Brazil, Costa Rica, New Zealand, and Panama. In the older age group, the difference in prevalence between countries ranged from 0.8 to 32.6 percent with lowest rates in China and India and the highest rates in Australia, Brazil, New Zealand, Republic of Ireland, and the United Kingdom.",
"   </p>",
"   <p>",
"    For asthma prevalence, the variations were just as large as for wheeze in the last 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/7\">",
"     7",
"    </a>",
"    ]. For example, among six to seven year olds, prevalence of ever having asthma ranged from 3.4 percent in Africa to 29.2 percent in Oceania; among the 13 to 14 year olds, prevalence ranged from 5.1 percent in Northern and Eastern Europe to 22 percent in Oceania. The authors point out that a striking feature of the data is the high rates of asthma symptoms (23 percent of 13 to 14 year olds) in countries whose predominant language is English.",
"   </p>",
"   <p>",
"    The ECRHS is a multicenter survey of the prevalence, determinants, and management of asthma in 20 to 44 year old adults from 48 centers, predominantly in Western Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/8\">",
"     8",
"    </a>",
"    ]. As in the ISAAC reports, the prevalence of all symptoms varied widely. Wheeze prevalence ranged from 4.1 to 9.7 percent from centers in India, Algeria, and Italy to 23.2 to 32 percent from centers in Sweden, Denmark, Estonia, United States, United Kingdom, Australia, New Zealand, and Ireland. Asthma prevalence ranged from 2 to 3.3 percent from centers in Estonia, Germany, Spain, Greece, Austria, Algeria, and Italy, to 8 to 11.9 percent from centers in the United Kingdom, New Zealand, and Australia.",
"   </p>",
"   <p>",
"    As with the ISAAC results, English speaking centers had a generally high prevalence of symptoms in the ECRHS survey. This remains unexplained and will require further study. One may speculate, however, that being in an English speaking center may be a marker for an exposure which increases the risk for asthma and asthma-like symptoms.",
"   </p>",
"   <p>",
"    The Global Initiative for Asthma (GINA) summarized data from both ECRHS and ISAAC in the Global Burden of Asthma report [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/11\">",
"     11",
"    </a>",
"    ]. Highlights of this report are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As of 2004, it was estimated that as many as 300 million people of all ages suffer from asthma. By 2025, it is expected that this number will rise to 400 million worldwide.",
"     </li>",
"     <li>",
"      The rate of asthma increases as communities adopt western lifestyles and become urbanized. Despite this knowledge, the international patterns of asthma prevalence cannot be explained by the current knowledge of potential causes for the development of asthma.",
"     </li>",
"     <li>",
"      The increase in the prevalence of asthma has been associated with an increase in atopic sensitization, and is paralleled by similar increases in other allergic disorders such as eczema and rhinitis.",
"     </li>",
"     <li>",
"      It is estimated that asthma accounts for about 1 in every 250 deaths worldwide. Many of these could be prevented with optimal access to medical care.",
"     </li>",
"     <li>",
"      The direct (eg, hospital admissions and pharmaceutical costs) and indirect (eg, time lost from work or school) economic cost of asthma is considerable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TRENDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Centers for Disease Control have shown that the prevalence of asthma increased in the United States from the early 1980s to the mid 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. During the period from 1982 to 1992, the overall annual age-adjusted prevalence rate of self-reported asthma increased by 42 percent, from 34.7 to 49.4 per 1000. For the younger age group 5 to 34 years, where the diagnosis of asthma is thought to be more accurate, the rate increased from 34.6 to 52.6 per 1000, an increase of 52 percent. Since that time, the prevalence of asthma has increased more gradually [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. During the years 2001 through 2009, the age-adjusted prevalence of asthma increased from 7.3 to 8.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The annual death rate from asthma in the United States also increased from 1982 to 1995, but has declined since then (",
"    <a class=\"graphic graphic_figure graphicRef59239 \" href=\"UTD.htm?39/12/40143\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/15\">",
"     15",
"    </a>",
"    ]. Consistently higher rates have been reported for blacks than for whites, but not for Hispanic or Latino ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/15\">",
"     15",
"    </a>",
"    ]. This difference in death rates is thought to be due both to socioeconomic factors and to differences in access to medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/14,17\">",
"     14,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These overall trends are not unique to the United States. Use of the same methods in other countries has also shown that the prevalence of asthma is on the rise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some areas have seen a moderation or even a decline in mortality. For example, in an analysis of data between 1969 and 1993 in New Zealand, mortality rates peaked in 1979 and began falling in early 1980s to a low of 0.5 deaths per 100,000 in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/19\">",
"     19",
"    </a>",
"    ]. According to an analysis of asthma mortality data from 20 countries, asthma death rates, which increased during the 1980s, have significantly decreased subsequently to a level of 0.23 deaths per 100,000 in 2004 to 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several explanations for the observed increase in prevalence have been suggested. Increased clinician and public awareness of the signs and symptoms of asthma could have led to a change in diagnostic recognition and accuracy. However, changes in disease classification and the effects of the 1979 ICD revision have probably had only a minor impact. It is likely that changes in the risk factors thought to cause and worsen asthma are responsible for much of the increase in asthma prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19653/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96276425\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accurate assessment of the prevalence of asthma has been hindered by varying definitions of asthma and methods of data collection. &nbsp;A definition of \"current asthma\" as bronchial hyperresponsiveness (BHR) in the presence of wheezing in the preceding 12 months identifies a group of children with clinically important asthma, ie, more severe BHR, greater peak flow variability, more symptoms, more atopy, and more medication use than children with BHR alone or wheeze alone. However, this definition may not be as useful in adults because of the effects of smoking and because BHR has been unable to adequately distinguish asthma from chronic bronchitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologists have relied primarily on historic or questionnaire sources to identify patients with asthma. However, it is likely that some bias in reporting of cases is associated with each of the various approaches and that the biases differ among the approaches. The table summarizes the potential problems in identifying persons with asthma (",
"      <a class=\"graphic graphic_table graphicRef73952 \" href=\"UTD.htm?17/41/18075\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Questionnaires'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many studies have evaluated the prevalence of asthma and asthma like symptoms in different countries around the world, although comparison of these prevalence estimates is difficult given the different methods used. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Global variation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two multinational studies, the International Study of Asthma and Allergies in Children (ISAAC) and the European Community Respiratory Health Survey (ECRHS) are monitoring the prevalence of asthma and asthma like symptoms. Reports from ISAAC have confirmed wide variations in the prevalence of asthma symptoms in children worldwide. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Global variation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data from the Centers for Disease Control have shown that the prevalence of asthma increased in the United States from the early 1980s to the mid 1990s. Since that time, the prevalence of asthma has increased more gradually; during the years 2001 through 2009, the age-adjusted prevalence of asthma increased from 7.3 to 8.2 percent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Trends'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/1\">",
"      Toelle BG, Peat JK, Salome CM, et al. Toward a definition of asthma for epidemiology. Am Rev Respir Dis 1992; 146:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/2\">",
"      Enarson DA, Vedal S, Schulzer M, et al. Asthma, asthmalike symptoms, chronic bronchitis, and the degree of bronchial hyperresponsiveness in epidemiologic surveys. Am Rev Respir Dis 1987; 136:613.",
"     </a>",
"    </li>",
"    <li>",
"     Weiss ST, Speizer FE. Epidemiology and natural history. In: Bronchial Asthma Mechanisms and Therapeutics, 3rd ed, Weiss EB, Stein M (Eds), Little, Brown, Boston 1993. p.15-25.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/4\">",
"      Jenkins MA, Clarke JR, Carlin JB, et al. Validation of questionnaire and bronchial hyperresponsiveness against respiratory physician assessment in the diagnosis of asthma. Int J Epidemiol 1996; 25:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/5\">",
"      Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/6\">",
"      Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998; 12:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/7\">",
"      Lai CK, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009; 64:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/8\">",
"      Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996; 9:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/9\">",
"      Sembajwe G, Cifuentes M, Tak SW, et al. National income, self-reported wheezing and asthma diagnosis from the World Health Survey. Eur Respir J 2010; 35:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/10\">",
"      Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006; 355:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/11\">",
"      Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/12\">",
"      Weiss KB, Wagener DK. Asthma surveillance in the United States. A review of current trends and knowledge gaps. Chest 1990; 98:179S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Asthma--United States, 1982-1992. MMWR Morb Mortal Wkly Rep 1995; 43:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/14\">",
"      Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma--United States, 1980-1999. MMWR Surveill Summ 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/15\">",
"      Moorman JE, Rudd RA, Johnson CA, et al. National surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001--2009. MMWR Morb Mortal Wkly Rep 2011; 60:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/17\">",
"      Weiss KB, Gergen PJ, Crain EF. Inner-city asthma. The epidemiology of an emerging US public health concern. Chest 1992; 101:362S.",
"     </a>",
"    </li>",
"    <li>",
"     Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma. file://www.ginasthma.org/local/uploads/files/GINABurdenSummary_1.pdf (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/19\">",
"      Kemp T, Pearce N. The decline in asthma hospitalisations in persons aged 0-34 years in New Zealand. Aust N Z J Med 1997; 27:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/20\">",
"      Wijesinghe M, Weatherall M, Perrin K, et al. International trends in asthma mortality rates in the 5- to 34-year age group: a call for closer surveillance. Chest 2009; 135:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Asthma mortality and hospitalization among children and young adults--United States, 1980-1993. MMWR Morb Mortal Wkly Rep 1996; 45:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Asthma mortality -- Illinois, 1979-1994. MMWR Morb Mortal Wkly Rep 1997; 46:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19653/abstract/23\">",
"      Weiss KB, Gergen PJ, Wagener DK. Breathing better or wheezing worse? The changing epidemiology of asthma morbidity and mortality. Annu Rev Public Health 1993; 14:491.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 573 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19653=[""].join("\n");
var outline_f19_12_19653=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H96276425\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DATA COLLECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Questionnaires",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GLOBAL VARIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TRENDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96276425\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/573\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/573|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/12/40143\" title=\"figure 1\">",
"      Asthma annual mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/573|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/41/18075\" title=\"table 1\">",
"      Identifying asthmatic patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_12_19654="Gefitinib: Drug information";
var content_f19_12_19654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gefitinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/20/34116?source=see_link\">",
"    see \"Gefitinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iressa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9748130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      IRESSA&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer (NSCLC):",
"     </b>",
"     Oral: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      NSCLC, first-line therapy in patients with EGFR mutations (unlabeled use):",
"     </b>",
"     Oral: 250 mg once daily (Maemondo, 2010; Mok, 2009; Sequist, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inducers (eg, phenytoin, rifampin):",
"     </b>",
"     Consider increasing gefitinib dose to 500 mg once daily with close monitoring",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F175655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F175656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F175657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Moderate-to-severe impairment due to metastases: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatotoxicity during treatment (elevations in transaminases): Discontinue if severe.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F175673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Worsening pulmonary symptoms (cough dyspnea, fever):",
"     </i>",
"     Interrupt treatment and evaluate promptly; discontinue if interstitial lung disease is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Diarrhea (poorly tolerated or associated with dehydration) or skin toxicity:",
"     </i>",
"     Interrupt treatment for up to 14 days; may reinitiate at 250 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Ocular symptoms (eye pain):",
"     </i>",
"     Evaluate and interrupt treatment based on symptoms; once symptoms or eye changes have resolved, may consider reinitiating at 250 mg once daily.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F175627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iressa&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     As of September 15, 2005, distribution of gefitinib (IRESSA&reg;) is limited to patients enrolled in the IRESSA&reg; Access Program. Under this program, access to gefitinib will be limited to the following groups:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Patients who are currently receiving and benefiting from gefitinib",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients who have previously received and benefited from gefitinib",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Previously-enrolled patients or new patients in non-Investigational New Drug (IND) clinical trials involving gefitinib if these protocols were approved by an IRB prior to June 17, 2005",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     New patients may also receive gefitinib if the manufacturer (AstraZeneca) decides to make it available under IND, and the patients meet the criteria for enrollment under the IND",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional information on the IRESSA&reg; Access Program, including enrollment forms, may be obtained by calling AstraZeneca at 1-800-601-8933 or via the web at www.Iressa-access.com",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F175629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     For patients unable to swallow tablets or for administration via NG tube: Tablets may be dispersed in noncarbonated drinking water. Drop whole tablet (do not crush) into",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     glass of water; stir until tablet is dispersed (~10 minutes). Drink immediately. Rinse glass with",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     glass of water and drink.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of platinum-based and docetaxel therapies. Treatment is limited to patients who are benefiting or have benefited from treatment with gefitinib.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to the lack of improved survival data from clinical trials of gefitinib, and in response to positive survival data with another EGFR inhibitor, according to the U.S. labeling, physicians are advised to use treatment options other than gefitinib in patients with advanced nonsmall cell lung cancer following one or two prior chemotherapy regimens when they are refractory/intolerant to their most recent regimen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canada labeling: First-line treatment of locally advanced or metastatic NSCLC with activating mutations of EGFR-TK",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F11569624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     First-line treatment of NSCLC with known EGFR mutation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2138082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Gefitinib may be confused with axitinib, crizotinib, erlotinib, imatinib, SORAfenib, SUNItinib, vandetanib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F175670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (43% to 54%), acne (25% to 33%), dry skin (13% to 26%), paronychia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (48% to 67%; grade 3: 1%), nausea (13% to 18%), vomiting (9% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (8% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (7% to 10%), weight loss (3% to 5%), mouth ulceration (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia (2%), conjunctivitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (2%), interstitial lung disease (1% to 2%; includes alveolitis, interstitial pneumonia, pneumonitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aberrant eyelash growth, angioedema, CNS hemorrhage (pediatrics), corneal erosion/ulcer, corneal membrane sloughing, epistaxis, erythema multiforme, eye pain, fever, hematuria, hemorrhage, ocular hemorrhage, ocular ischemia, pancreatitis, toxic epidermal necrolysis, urticaria, vesiculobullous rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F175632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gefitinib or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F175617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Interruption of therapy may be required in patients with poorly tolerated diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eye irritation: Promptly evaluate eye pain. Therapy may be interrupted based on appropriate medical evaluation; may be reinitiated following resolution of symptoms or eye changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Asymptomatic increases in transaminases have been reported; monitor liver function periodically and discontinue if elevations/changes are severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Rare, sometimes fatal, pulmonary toxicity, including interstitial lung disease (ILD) (eg, alveolitis, interstitial pneumonia, pneumonitis) has occurred. ILD has occurred in patients with prior radiation therapy, prior chemotherapy, and less commonly in treatment na&iuml;ve patients.  Therapy should be interrupted in patients with acute onset or worsening pulmonary symptoms (dyspnea, cough, fever); discontinue if interstitial pneumonitis is confirmed. An increase in mortality was observed in patients with concurrent idiopathic pulmonary fibrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: Interruption of therapy may be required in patients with adverse skin reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Gefitinib exposure may be increased in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NSCLC genomics: EGFR mutations, specifically exon 19 deletions and exon 21 mutation (L858R), are associated with better response to gefitinib in patients with NSCLC (Riely, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; CYP3A4: There is a high potential for CYP3A4 mediated interactions with gefitinib. Concurrent use with CYP3A4 inducers may decrease gefitinib levels; consider increased gefitinib doses (to 500 mg) with close monitoring if concurrent use with inducers cannot be avoided. CYP3A4 inhibitors may increase gefitinib levels, use caution with concurrent administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F175665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, CYP2C19 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F175621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Gefitinib. Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Gefitinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vinorelbine: Gefitinib may enhance the neutropenic effect of Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Gefitinib may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F175647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Grapefruit juice may increase serum gefitinib concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease serum gefitinib concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F175623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated fetal harm; there are no well-controlled studies in pregnant women. The risk of fetal harm should be carefully weighed. Women of childbearing potential should be advised to avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F175661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11569625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F175636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect gefitinib absorption.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F175625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests (ALT, AST, bilirubin and alkaline phosphatase), INR or prothrombin time (with concurrently warfarin treatment), pulmonary symptoms",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Geftilon (IN);",
"     </li>",
"     <li>",
"      Iressa (AR, AU, BE, CH, CL, CN, CR, CZ, DE, DK, DO, EE, FR, GB, GR, GT, HK, HN, ID, IE, IL, KP, MY, NI, NL, NO, NZ, PA, PE, PH, PL, RU, SE, SG, SV, TH, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F175616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gefitinib is a tyrosine kinase inhibitor (TKI) which inhibits numerous tyrosine kinases associated with transmembrane cell surface receptors found on both normal and cancer cells, including the tyrosine kinase associated with the epidermal growth factor receptor, EGFR. Tyrosine kinase activity appears to be vitally important to cell proliferation and survival.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F175631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 1400 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%, albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily via CYP3A4; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: 41 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 3-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (86%); urine (&lt;4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Azzoli CG, Baker S Jr, Temin S, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(36):6251-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/12/19654/abstract-text/19917871/pubmed\" id=\"19917871\" target=\"_blank\">",
"        19917871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fukuoka M, Yano S, Giaccone G, et al, &ldquo;Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(12):2237-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/12/19654/abstract-text/12748244/pubmed\" id=\"12748244\" target=\"_blank\">",
"        12748244",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Inoue A, Kobayashi K, Usui K, et al, &ldquo;First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(9):1394-400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/12/19654/abstract-text/19224850/pubmed\" id=\"19224850\" target=\"_blank\">",
"        19224850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maemondo M, Inoue A, Kobayashi K, et al, &ldquo;Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(25):2380-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/12/19654/abstract-text/20573926/pubmed\" id=\"20573926\" target=\"_blank\">",
"        20573926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mok TS, Wu YL, Thongprasert S, et al, &ldquo;Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(10):947-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/12/19654/abstract-text/19692680/pubmed\" id=\"19692680\" target=\"_blank\">",
"        19692680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Non-Small Cell Lung Cancer,&rdquo; Version 3.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riely GJ, Pao W, Pham D, et al, &ldquo;Clinical Course of Patients With Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated With Gefitinib or Erlotinib,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2006, 12(3 Pt 1):839-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/12/19654/abstract-text/16467097/pubmed\" id=\"16467097\" target=\"_blank\">",
"        16467097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sequist LV, Martins RG, Spigel D, et al, &ldquo;First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(15):2442-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/12/19654/abstract-text/18458038/pubmed\" id=\"18458038\" target=\"_blank\">",
"        18458038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8712 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-218.189.88.190-9543B823DE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19654=[""].join("\n");
var outline_f19_12_19654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175651\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9748130\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175672\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175654\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175655\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175656\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175657\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175673\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175627\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175614\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233825\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175629\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175628\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11569624\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138082\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175670\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175632\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175617\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175665\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175621\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175647\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175623\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175635\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175661\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11569625\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175636\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175625\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539869\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175616\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175631\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8712\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8712|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/20/34116?source=related_link\">",
"      Gefitinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_12_19655="Quinine: Pediatric drug information";
var content_f19_12_19655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"    see \"Quinine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/0/13317?source=see_link\">",
"    see \"Quinine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9776905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3343866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Qualaquin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Quinine&reg;;",
"     </li>",
"     <li>",
"      Novo-Quinine;",
"     </li>",
"     <li>",
"      Quinine-Odan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"      see \"Quinine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Actual duration of quinine treatment for malaria may be dependent upon the geographic region or pathogen. Dosage expressed in terms of the",
"     <b>",
"      salt",
"     </b>",
"     ; 1 capsule Qualaquin&reg;  = 324 mg of quinine sulfate  = 269 mg of base.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of uncomplicated chloroquine-resistant",
"     <i>",
"      P. falciparu",
"     </i>",
"     m malaria: CDC guidelines: 30 mg/kg/day in divided doses every 8 hours for 3-7 days depending on region (maximum dose: 1944 mg/day).Tetracycline, doxycycline, or clindamycin (consider risk versus benefit of using tetracycline or doxycycline in children &lt;8 years of age) should also be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of uncomplicated chloroquine-resistant",
"     <i>",
"      P. vivax",
"     </i>",
"     malaria: CDC guidelines: 30 mg/kg/day in divided doses every 8 hours for 3-7 days depending on region (maximum dose: 1944 mg/day). Tetracycline or doxycycline (consider risk versus benefit of using tetracycline or doxycycline in children &lt;8 years of age)",
"     <b>",
"      plus",
"     </b>",
"     primaquine should also be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Babesiosis: 30 mg/kg/day, divided every 8 hours for 7-10 days with clindamycin; maximum dose: 648 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of uncomplicated chloroquine-resistant",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria: CDC guidelines: 648 mg every 8 hours for 3-7 days. Tetracycline, doxycycline, or clindamycin should also be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of uncomplicated chloroquine-resistant",
"     <i>",
"      P. vivax",
"     </i>",
"     malaria: CDC guidelines: 648 mg every 8 hours for 3-7 days. Tetracycline or doxycycline",
"     <b>",
"      plus",
"     </b>",
"     primaquine should also be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Babesiosis: 648 mg every 8 hours for 7-10 days with clindamycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adult:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe chronic renal failure not on dialysis: Initial dose: 648 mg followed by 324 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sulfate: 324 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Qualaquin&reg;: 324 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9662364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM192698.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM192698.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Do not crush capsule to avoid bitter taste",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Do not refrigerate or freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chloroquine-resistant, uncomplicated",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria infection (inactive against sporozoites, pre-erythrocytic or exoerythrocytic forms of plasmodia) in conjunction with other antimalarial agents [FDA approved in pediatrics (age not specified) and adults]; has also been used for the treatment of uncomplicated chloroquine-resistant",
"     <i>",
"      P. vivax",
"     </i>",
"     malaria (in conjunction with other antimalarial agents); treatment of",
"     <i>",
"      Babesia microti",
"     </i>",
"     infection in conjunction with clindamycin",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       QuiNINE may be confused with quiNIDine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F216597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, chest pain, hypotension, irregular rhythm, nodal escape beats, orthostatic hypotension, palpitation, QT prolongation, syncope, tachycardia, torsade de pointes, unifocal premature ventricular contractions, U waves, vasodilation, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aphasia, ataxia, chills, coma, confusion, disorientation, dizziness, dystonic reaction, fever, flushing, headache, mental status altered, restlessness, seizure, suicide, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acral necrosis, allergic contact dermatitis, bullous dermatitis, bruising, cutaneous rash (urticaria, papular, scarlatinal), cutaneous vasculitis, exfoliative dermatitis, erythema multiforme, petechiae, photosensitivity, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, esophagitis, gastric irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, coagulopathy, disseminated intravascular coagulation, hemolytic anemia, hemolytic uremic syndrome, hemorrhage, hypoprothrombinemia, idiopathic thrombocytopenic purpura, leukopenia, neutropenia, pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Granulomatous hepatitis, hepatitis, jaundice, liver function test abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blindness, blurred vision (with or without scotomata), color vision disturbance, diminished visual fields, diplopia, night blindness, optic neuritis, photophobia, pupillary dilation, vision loss (sudden)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness, hearing impaired, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute interstitial nephritis, hemoglobinuria, renal failure, renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, dyspnea, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Black water fever, diaphoresis, hypersensitivity reaction, lupus anticoagulant, lupus-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quinine or any component or to mefloquine or quinidine (cross sensitivity reported); history of potential hypersensitivity reactions [including black water fever, thrombotic thrombocytopenia purpura (TTP), hemolytic uremic syndrome (HUS), or thrombocytopenia] associated with prior quinine use; prolonged QT interval; myasthenia gravis; optic neuritis, G6PD deficiency",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with clinical conditions or on medications which may prolong the QT interval or cause cardiac arrhythmias (quinine has quinidine-like activity), in patients with myasthenia gravis, and in patients with impaired liver function.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10053515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Quinine is not recommended for the prevention/treatment of nocturnal leg cramps due to the potential for severe and/or life-threatening side effects (eg, cardiac arrhythmias, thrombocytopenia, HUS/TTP, severe hypersensitivity reactions)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These risks, as well as the absence of clinical effectiveness, do not justify its use in the unapproved/unlabeled prevention and/or treatment of leg cramps. Use may cause significant hypoglycemia due to quinine-induced insulin release.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe hypersensitivity reactions (eg, Stevens-Johnson syndrome, anaphylactic shock) have occurred; discontinue following any signs of sensitivity. Other events, including acute interstitial nephritis, neutropenia, and granulomatous hepatitis, may also be attributed to hypersensitivity reactions. Immune-mediated thrombocytopenia, including life-threatening cases and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), has occurred with use. Chronic renal failure associated with TTP has also been reported. Thrombocytopenia generally resolves within a week upon discontinuation. Re-exposure may result in increased severity of thrombocytopenia and faster onset.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2C9 (moderate), CYP2D6 (moderate), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of QuiNINE.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Carbonate; Sodium Bicarbonate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Herbs (Hypotensive Properties) may enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: QuiNINE may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: QuiNINE may enhance the adverse/toxic effect of Halofantrine. QuiNINE may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the adverse/toxic effect of other Herbs (Hypotensive Properties). Excessive blood pressure lowering may manifest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: QuiNINE may increase the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pitavastatin; Pravastatin; Red Yeast Rice; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of QuiNINE.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: QuiNINE may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of QuiNINE.  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinine when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: QuiNINE may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: QuiNINE may increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: QuiNINE may increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): QuiNINE may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3343867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been reported in some animal studies. Quinine crosses the human placenta. Cord plasma to maternal plasma quinine ratios have been reported as 0.18-0.46 and should not be considered therapeutic to the infant. Teratogenic effects, optic nerve hypoplasia, and deafness have been reported in the infant following maternal use of very high doses; however, therapeutic doses used for malaria are generally considered safe. Quinine may also cause significant hypoglycemia when used during pregnancy. Malaria infection in pregnant women may be more severe than in nonpregnant women. Because",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria can cause maternal death and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites. Quinine may be used for the treatment of malaria in pregnant women; consult current CDC guidelines. Pregnant women should be advised not to travel to areas of",
"     <i>",
"      P. falciparum",
"     </i>",
"     resistance to chloroquine.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with platelet count, liver function tests, blood glucose, ophthalmologic examination",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses oxygen uptake and carbohydrate metabolism; intercalates into DNA, disrupting the parasite's replication and transcription; affects calcium distribution within muscle fibers and decreases the excitability of the motor end-plate region",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Readily absorbed, mainly from the upper small intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed to body tissues and fluids including small amounts into bile and CSF (2% to 7% of plasma concentration); crosses the placenta; excreted into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     (children): 0.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     (adults): 1.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 70% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily in the liver via hydroxylation pathways",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 8-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In bile and saliva with ~20% excreted unchanged in urine; renal excretion is twofold in the presence of acidic urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not effectively removed by peritoneal dialysis; removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/0/13317?source=see_link\">",
"      see \"Quinine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report to physician if bleeding, bruising, tinnitus, hearing loss, rash, or visual disturbances occur during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral form of quinine (dihydrochloride) is no longer available from the CDC; quinidine gluconate should be used instead; the FDA has banned over-the-counter (OTC) drug products containing quinine sold for treatment and/or prevention of malaria, as well as, products labeled for treatment or prevention of nocturnal leg cramps",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Berns JS, Brier ME, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults",
"      </i>",
"      , 4th ed. Philadelphia, PA: American College of Physicians; 1999, p 73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, May 18, 2009. Available at:",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at:",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Treatment Guidelines From the Medical Letter",
"      </i>",
"      , 2004, 50(Suppl):e1-14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulbe DE, &ldquo;Quinine Ban Signals Change for Pharmacists, APhA,&rdquo;",
"      <i>",
"       Pharmacy Today",
"      </i>",
"      , 1995, 1(12):6.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12756 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19655=[""].join("\n");
var outline_f19_12_19655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9776905\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343866\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216572\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049633\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049626\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216550\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216535\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662364\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049637\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049629\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049636\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216599\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216597\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049640\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049625\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10053515\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216586\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216544\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216547\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343867\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049632\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049624\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049639\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049631\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049641\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12756\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12756|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=related_link\">",
"      Quinine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/0/13317?source=related_link\">",
"      Quinine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_12_19656="Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn";
var content_f19_12_19656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19656/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19656/contributors\">",
"     Firas Saker, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19656/contributors\">",
"     Richard Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19656/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19656/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19656/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/12/19656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress syndrome (RDS), formerly known as hyaline membrane disease, is a common problem in preterm infants. This disorder is caused primarily by deficiency of pulmonary surfactant in an immature lung. RDS is a major cause of morbidity and mortality in preterm infants.",
"   </p>",
"   <p>",
"    The pathophysiology and clinical features of RDS will be presented here. The management of RDS and other disorders of perinatal transition are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=see_link\">",
"     \"Transient tachypnea of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20446149\">",
"    <span class=\"h1\">",
"     LUNG DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the normal fetal lung development is central to understanding the pathophysiology of neonatal RDS as it is due to inadequate surfactant activity resulting from lung immaturity.",
"   </p>",
"   <p>",
"    Normal fetal alveolar development occurs in the following stages [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Embryonic period &ndash; At about 26 days gestation, the embryonic stage begins with the first appearance of the fetal lung, which appears as a protrusion of the foregut. The initial branching of the lung occurs at 33 days gestation forming the prospective main bronchi, which begin to extend into the mesenchyme. Further branching forms the segmental bronchi as the lung enters the next stage of development.",
"     </li>",
"     <li>",
"      Pseudoglandular stage &ndash; In the pseudoglandular stage (7th to 16th weeks of gestation), 15 to 20 generations of airway branching occur starting from the main segmental bronchi and ending as terminal bronchioles. At the end of the pseudoglandular stage, the airways are surrounded by a loosely packed mesenchyme, which includes a few blood vessels, and is lined by glycogen-rich and morphologically undifferentiated epithelial cells with a columnar to cuboidal shape. In general, epithelial differentiation is centrifugal so the most distal tubules are lined with undifferentiated cells with progressive epithelial differentiation of the more proximal airways.",
"     </li>",
"     <li>",
"      Canalicular stage &ndash; During the canalicular stage (16",
"      <sup>",
"       th",
"      </sup>",
"      and 25 weeks gestation), the transition from previable to a potential viable lung occurs as the respiratory bronchioles and alveolar ducts of the gas exchange region of the lung are formed. The surrounding mesenchyme becomes more vascular and condenses around the airways. The closer vascular proximity ultimately results in fusion of the capillary and epithelial basement membranes. After 20 weeks gestation, cuboidal epithelial cells begin to differentiate into alveolar type II cells with formation of cytoplasmic lamellar bodies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/2\">",
"       2",
"      </a>",
"      ]. The glycogen in these cells is used for surfactant production, which is stored in the lamellar bodies.",
"     </li>",
"     <li>",
"      Saccular stage &ndash; At the beginning of the saccular stage (about 24 weeks gestation), there is potential for viability because gas exchange is possible due to the presence of large and primitive forms of the future alveoli. In this stage, formation of alveoli (ie, alveolarization) occurs by the outgrowth of septae that subdivide terminal saccules into anatomic alveoli, where air exchange occurs. The number of alveoli in each lung increases from zero at 32 week gestation to between 50 and 150 million alveoli in term infants and 300 million in adults. Alveolar growth continues for at least two years after birth at term.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Pulmonary surfactant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary cause of RDS is deficiency of pulmonary surfactant, which is developmentally regulated. The fetal lung is filled with fluid and provides no respiratory function until birth. In preparation for air breathing, surfactant is expressed in the lung during the third trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/3\">",
"     3",
"    </a>",
"    ]. Surfactant reduces the alveolar surface tension, thereby facilitating alveolar expansion and reducing the likelihood of alveolar collapse atelectasis.",
"   </p>",
"   <p>",
"    Because of the developmental regulation of surfactant production, the most common cause of surfactant deficiency is preterm delivery. In addition, mutations in the genes encoding surfactant proteins SP-B and SP-C [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] and the ATP-binding cassette (ABC) transporter A3 (ABCA3) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/6-8\">",
"     6-8",
"    </a>",
"    ] may cause surfactant deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysfunction, and hereditary respiratory failure in infants born at term.",
"   </p>",
"   <p>",
"    Pulmonary surfactant is a complex mixture that is mostly composed of lipids (90 percent), primarily phospholipids, and about 10 percent proteins.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipid &ndash; Approximately 70 percent of the lipid in surfactant is phosphatidylcholine species. Of this, approximately 60 percent is disaturated palmitoylphosphatidyl choline, the major surfactant tension lowering component [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Protein &ndash; Four surfactant-specific proteins have been identified, and their functions have been partly elucidated [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/1,10-12\">",
"       1,10-12",
"      </a>",
"      ]. They include the hydrophobic surfactant proteins SP-B and SP-C, and the hydrophilic proteins SP-A and SP-D.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      SP-A, a member of the collectin protein family, is an innate host defense protein and a regulator of inflammation in the lung. This protein facilitates phagocytosis of pathogens and their clearance from the airspace by macrophages. Patients with a deficiency of SP-A have not been identified. SP-A levels are low in surfactant from preterm lungs and increase with corticosteroid exposure. Mice that lack SP-A have normal lung function and surfactant metabolism indicating that SP-A is not critical to the regulation of surfactant metabolism. SP-A is not present in currently available surfactants used for treatment of RDS. &nbsp;",
"     </li>",
"     <li>",
"      SP-B facilitates surface absorption of lipids and, as a result, contributes to the surface tension lowering ability of surfactant. Animals with antibodies to SP-B develop respiratory failure. Homozygous SP-B deficiency is extremely rare and essentially lethal in term human infants [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/4\">",
"       4",
"      </a>",
"      ]. SP-B and SP-C are both components found in commercial preparations of surfactants.",
"     </li>",
"     <li>",
"      Humans with SP-C deficiency do not have respiratory distress at birth, but develop progressive interstitial pulmonary fibrosis as infants and into early childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/5\">",
"       5",
"      </a>",
"      ]. SP-C deficient mice have normal lung and surfactant function at birth. However, the mice develop progressive interstitial lung disease and emphysema as they age. In this animal model, the misprocessed SP-C results in SP-C deficiency in the airspaces and injury to the type II cell. SP-B and SP-C probably work cooperatively to optimize rapid adsorption and spreading of phospholipids on a surface and to facilitate surface tension lowering and alveolar stability on surface area compression at low lung volume.",
"     </li>",
"     <li>",
"      SP-D is a hydrophilic protein and, like SP-A, a member of the collectin protein family. It also functions as an innate host defense molecule by binding pathogens and facilitating their clearance. The absence of SP-D results in increased surfactant lipid pools in the airspaces and emphysema, but no major deficits in surfactant function in mice [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/13\">",
"       13",
"      </a>",
"      ]. Treatment of preterm lambs with recombinant surfactant protein D has been shown to inhibit lung inflammation, which reduces surfactant inactivation, and may hold promise for future human investigation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Synthesis, secretion, and adsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surfactant is synthesized within the alveolar type II cells starting with phospholipid synthesis in the endoplasmic reticulum, than is processed through the Golgi apparatus to the lamellar bodies. Phospholipids combine with the surfactant proteins SP-B and SP-C to form the surfactant lipoprotein complex within the lamellar bodies. Lamellar bodies localize to the apical surface of the type II cell and are released into the alveoli by exocytosis.",
"   </p>",
"   <p>",
"    As the lamellar bodies unravel within the alveoli, the surfactant complex forms a lipoprotein array (includes SP-A, SP-B, SP-C proteins, and phospholipids) called tubular myelin that contributes to the surface film within the alveoli and airways and reduces alveolar surface tension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/1\">",
"     1",
"    </a>",
"    ]. Secreted surfactant moves from the airspaces back to type II cells, where it is recycled back into the cell by an endocytotic process into multivesicular bodies and subsequently lamellar bodies. Both endogenous and exogenous surfactant recycling are important contributors to the surfactant pool [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/15\">",
"     15",
"    </a>",
"    ]. Mice who are SP-A deficient have no tubular myelin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86660867\">",
"    <span class=\"h3\">",
"     Prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the preterm infants, both a decrease in the quantity and quality of surfactant contributes to decreased surfactant activity resulting in RDS.",
"   </p>",
"   <p>",
"    In addition to low surfactant production seen with decreasing gestational age, the surfactant produced in preterm infants compared to surfactant from term infants has reduced activity because of differences in lipid and protein composition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surfactant from immature lungs compared to surfactant from mature lungs contains larger amounts of phosphatidylinositol (10 versus 2 percent of the surfactant composition) and smaller amounts of phosphatidylglycerol (less than 1 versus 10 percent). The more mature form of surfactant with the higher phosphatidylglycerol content has greater surface activity. The phosphatidylglycerol content begins to rise in amniotic fluid after 35 weeks gestation and is used as a marker for fetal lung maturity.",
"      <br/>",
"      <br/>",
"      Several other techniques are available to assess fetal lung maturation. These include",
"      <span class=\"nowrap\">",
"       lecithin/sphingomyelin",
"      </span>",
"      <span class=\"nowrap\">",
"       (L/S)",
"      </span>",
"      ratio and lamellar body counts. As discussed above, surfactant production is first noted around 20 weeks' gestation with the appearance of lamellar bodies within the epithelial cells of the airways. Clinically, lamellar body counts in the amniotic fluid may also be used to measure fetal lung maturity and surfactant production. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=see_link&amp;anchor=H8#H8\">",
"       \"Assessment of fetal lung maturity\", section on 'Phosphatidylglycerol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The protein content of surfactant from preterm lung is low relative to the amount of surfactant lipid. In general, type II cells with lamellar bodies appear in the human lung after 22 weeks with very little surfactant protein mRNA expression until later in gestation. The expression of the four surfactant proteins varies with gestational age: SP-A increases after 32 weeks gestation, SP-B increases after 34 weeks gestation, SP-C mRNA is highly expressed at the tip of branching airways during early lung development, and expression of SP-D mRNA is low until late gestation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of antenatal glucocorticoids reduces the risk of RDS in premature infants because it improves neonatal lung function by enhancing maturational changes in lung architecture and by inducing enzymes that stimulate phospholipid synthesis and release of surfactant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link&amp;anchor=H2#H2\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\", section on 'Mechanism of action'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link&amp;anchor=H4#H4\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\", section on 'Reduction of RDS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86661090\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary abnormality in RDS is surfactant deficiency. In the premature lung with inadequate surfactant activity, the resultant higher surface tension leads to instability of the lung at end-expiration, low lung volume, and decreased compliance. These changes in lung function cause hypoxemia primarily due to a mismatch between ventilation and perfusion due to collapse of large portions of the lung (atelectasis), and additional contributions of",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    mismatch from intrapulmonary and extrapulmonary right-to-left shunts.",
"   </p>",
"   <p>",
"    Surfactant deficiency also leads to lung inflammation and respiratory epithelial injury, which may result in pulmonary edema and increased airway resistance. These factors further exacerbate lung injury and worsen lung function. At the same time, abnormal fluid absorption results in inefficient clearing of lung liquid in the injured, edematous lung that also impedes gas exchange.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surfactant deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In premature infants, surfactant deficiency is the primary cause of RDS because the loss of surfactant leads to an increase in the amount of pressure needed to open alveoli and alveolar instability at low volume resulting in alveolar collapse and diffuse atelectasis. (See",
"    <a class=\"local\" href=\"#H86660867\">",
"     'Prematurity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The relationship of the inflating pressure, surface tension, and radius of curvature is illustrated by the model of a distal alveolus as a sphere connected to a distal airway described by LaPlace's law. According to LaPlace's law, the pressure (P) necessary to keep the sphere open is proportional to the surface tension (T) and inversely proportional to the radius (R) of the sphere, as shown by the formula:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;P =",
"    <span class=\"nowrap\">",
"     2T/R",
"    </span>",
"   </p>",
"   <p>",
"    If the surface tension is high and the alveolar volume is small (ie, the radius is low), as occurs at end expiration, the pressure necessary to maintain the alveolus open is high. If this increased pressure cannot be generated, the alveolus collapses. Diffuse atelectasis occurs when alveolar collapse occurs throughout the lung, which leads to hypoxemia. Pulmonary surfactant reduces the surface tension, even at low volumes, leading to a decrease in the required pressure, thus maintaining alveolar volume and stability (",
"    <a class=\"graphic graphic_figure graphicRef70666 \" href=\"UTD.htm?42/5/43102\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86661250\">",
"    <span class=\"h2\">",
"     Inflammation and lung injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of inflammation in the pathogenesis of RDS is suggested by animal experiments in which surfactant deficiency was associated with the rapid accumulation of neutrophils in the lung and evidence of pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/17\">",
"     17",
"    </a>",
"    ]. In this model, depletion of neutrophils prevented pulmonary edema. In addition, as noted above, surfactant deficiency causes atelectasis that may lead to injury of the respiratory epithelium and the alveolar capillary endothelium, which can trigger a cytokine-mediated inflammatory response. Further injury may be caused by positive pressure ventilatory support or excessive oxidant exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. The inflammation and lung injury may, in turn, lead to accumulation of protein-rich pulmonary fluid that can deactivate any surfactant which is present, thereby further exacerbating the underlying surfactant deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86661320\">",
"    <span class=\"h2\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants with RDS, pulmonary edema often occurs because of the following contributory factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation and lung injury (see",
"      <a class=\"local\" href=\"#H86661250\">",
"       'Inflammation and lung injury'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Reduced pulmonary fluid absorption &mdash; In the fetus, lung fluid is actively transported into the potential airspaces in a process mediated by chloride channels. In preparation for birth and air-breathing, the lung shifts from a secretory to an absorptive mode. Fluid absorption is mediated by sodium channels expressed on epithelial cells (ENaC). However, ENaC expression increases with gestational age in parallel with the surge in surfactant production. In premature infants, an inadequate number of ENaC may result in fluid retention, similar to what is seen in infants with transient tachypnea of the newborn [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low urine output &mdash; Infants with RDS typically have low urine output contributing to fluid retention in the first few days, which may exacerbate pulmonary edema. Some infants have hyponatremia due to increased free water. Infants recovering from RDS typically have a spontaneous diuresis on the second to fourth day, followed by improved pulmonary function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86661736\">",
"    <span class=\"h2\">",
"     Surfactant inactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to decreased surfactant production and synthesis of a less active surfactant,",
"    <strong>",
"    </strong>",
"    surfactant inactivation further reduces the effective surfactant pool size. Factors that contribute to surfactant inactivation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meconium and blood can inactive surfactant activity, which is more typically an issue in term infants with meconium aspiration than in preterm infants with surfactant deficiency.",
"     </li>",
"     <li>",
"      Proteinaceous edema and inflammatory products increase the conversion rate of surfactant into its inactive vesicular form. This conversion can be accelerated by oxidant and mechanical stress associated with mechanical ventilation that uses large tidal volumes in the absence of positive end expiratory pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/21,27\">",
"       21,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393256\">",
"    <span class=\"h2\">",
"     Pulmonary function and gas exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major negative effects of surfactant deficiency on pulmonary function are low compliance and low lung volume (functional residual capacity), and are primarily due to atelectasis, although both pulmonary edema and inflammation may be contributing factors. Total lung resistance is slightly increased, probably as a result of airway compression by interstitial edema and damage to the airways by the increased pressure needed to expand the poorly compliant alveoli [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/28-31\">",
"     28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exogenous surfactant therapy prevents or corrects these pulmonary functional abnormalities (ie, low lung compliance and volume, and increased lung resistance). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056094#H23056094\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Surfactant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393351\">",
"    <span class=\"h3\">",
"     Hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypoxemia that occurs in RDS is due primarily to mismatch of ventilation and perfusion with right-to-left shunting of blood past substantial regions of the lung that are poorly ventilated. Extrapulmonary shunting occurs typically across the foramen ovale and patent ductus arteriosus.",
"   </p>",
"   <p>",
"    The proportion of hypoxemia due to shunting versus poor alveolar ventilation depends upon the extent of hypoxic pulmonary vasoconstriction and the relative size of the underventilated region. Although minute ventilation may be increased, alveolar ventilation is decreased as most of the lung is collapsed and poorly ventilated. Poor ventilation is reflected in elevated values of arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    , and a resultant respiratory acidosis. Metabolic acidosis also may be present due to lactic acid production from anaerobic metabolism, in response to hypoxemia and compromised tissue perfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393411\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of RDS increases with decreasing gestational age. The risk is highest in extremely preterm infants as illustrated by a study from the National Institute of Child Health and Human Development Neonatal Research Network that found a 93 percent incidence of RDS in a cohort of 9575 extremely preterm infants (gestational age 28 weeks or below) born between 2003 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the incidence is lower, RDS still occurs in a significant number of late preterm infants (gestational age between 34 weeks, and 36 weeks and 6 days). In a report from the Safe Labor Consortium of 233,844 deliveries from 2002 and 2008, RDS was diagnosed in 10.5, 6, 2.8, 1, and 0.3 percent for infants born at 34, 35, 36, 37, and &ge;38 weeks gestation, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/33\">",
"     33",
"    </a>",
"    ]. In late preterm and term infants, male gender is associated with an increased risk of RDS (adjusted odds ratio [AOR] 1.7, 95% CI 1.45-1.93), and white versus Asian (AOR 0.57, 95% CI 0.47-0.7), black (AOR 0.66, 95% CI 0.5-0.87), and Hispanic ethnicity (AOR 0.76, 95% CI 0.64-0.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19656/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of RDS result primarily from abnormal pulmonary function and hypoxemia. Because RDS is primarily a developmental disorder of deficient surfactant production, it presents within the first minutes or hours after birth. If untreated, RDS progressively worsens over the first 48 hours of life. In some cases, infants may not appear ill immediately after delivery but develop respiratory distress and cyanosis within the first few hours of age. These infants may have a borderline amount of surfactant that is consumed or becomes inactivated.",
"   </p>",
"   <p>",
"    The affected infant is almost always premature and exhibits signs of respiratory distress that include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachypnea",
"     </li>",
"     <li>",
"      Nasal flaring, which reflects the use of accessory respiratory muscles and lowers total respiratory system resistance.",
"     </li>",
"     <li>",
"      Expiratory grunting, which results from exhalation through a partially closed glottis and slows the decrease in end-expiratory lung volume.",
"     </li>",
"     <li>",
"      Intercostal, subxiphoid, and subcostal retractions, which occur because the highly compliant rib cage is drawn in during inspiration by the high intrathoracic pressures required to expand the poorly compliant lungs.",
"     </li>",
"     <li>",
"      Cyanosis due to right-to-left intra- and extra-pulmonary shunting (See",
"      <a class=\"local\" href=\"#H393351\">",
"       'Hypoxemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On physical examination, auscultated breath sounds are decreased, and infants may be pale with diminished peripheral pulses. The urine output often is low in the first 24 to 48 hours and peripheral edema is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to surfactant use, uncomplicated RDS typically progressed for 48 to 72 hours. This was followed by an improvement in respiratory function associated with increased production of endogenous surfactant, and resolution of the respiratory disorder by one week of age. A marked diuresis typically preceded the improvement in lung function. The natural history of RDS is greatly modified by treatment with exogenous surfactant, which dramatically improves pulmonary function, leading to the resolution of symptoms, and shortens the clinical course. In addition, the use of continuous positive airway pressure (CPAP) has also improved the clinical course of RDS, even in infants who do not receive surfactant therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056129#H23056129\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Continuous positive airway pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056094#H23056094\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Surfactant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RDS is based on a clinical picture of a premature infant with the onset of progressive respiratory failure shortly after birth (manifested by an increase in the work of breathing and an increase in the oxygen requirement), in conjunction with a characteristic chest radiograph. The chest radiographic features of RDS include a low lung volume and the classic diffuse reticulogranular ground-glass appearance with air bronchograms (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52323 \" href=\"UTD.htm?36/11/37040\">",
"     image 1",
"    </a>",
"    ). This pattern on radiograph results from alveolar atelectasis contrasting with aerated airways. Pulmonary edema may contribute to the diffuse appearance. Pneumothorax and air leaks are uncommon findings in the initial chest radiography, and are more frequently observed when lung compliance improves. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4631?source=see_link\">",
"     \"Pulmonary air leak in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393454\">",
"    <span class=\"h2\">",
"     Other laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory findings associated but not diagnostic for RDS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial blood gas measurements typically show hypoxemia that responds to administration of supplemental oxygen. The PCO2 initially is normal or slightly elevated, but usually increases as the disease worsens.",
"     </li>",
"     <li>",
"      As the disease progresses, infants may develop hyponatremia. This results from water retention, and usually improves with fluid restriction. Attentive fluid management prevents hyponatremia, and as a result, this finding is less commonly observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for RDS includes other causes of respiratory distress, which are distinguished from RDS by their clinical features and course:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient tachypnea of the newborn (TTN) &ndash; TTN is generally seen in more mature infants (ie, term or late preterm infants) compared to RDS. Patients with TTN have milder respiratory distress and improve more quickly than those with RDS. Only extremely severe cases of TTN, which are rare, require mechanical ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=see_link\">",
"       \"Transient tachypnea of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial pneumonia &ndash; It is often difficult to differentiate between infants with RDS and those with bacterial pneumonia because of overlap of both clinical and radiographic findings. As a result, blood cultures and, if possible, tracheal cultures should be obtained, and empirical antibiotics are given to infants at risk for infection pending culture results and clinical course. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"       \"Neonatal pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Air leak &ndash; Air leak (eg, pneumothorax) may be a complication of RDS, an isolated problem, or associated with another underlying disorder. It is detected by chest radiography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4631?source=see_link\">",
"       \"Pulmonary air leak in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cyanotic congenital heart disease &ndash; Most patients with cyanotic congenital heart disease (CCHD) have milder respiratory distress than that seen in patients with RDS. In addition, CCHD is usually differentiated from RDS by the absence of the characteristic diffuse reticulogranular ground-glass appearance with air bronchograms on chest radiograph. If lung function and the chest radiograph do not improve with respiratory support and surfactant administration, an echocardiogram should be performed to rule out structural heart disease in infants with severe arterial hypoxemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link\">",
"       \"Cardiac causes of cyanosis in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-pulmonary systemic disorders, such as hypothermia, hypoglycemia, anemia, polycythemia, or metabolic acidosis, may present with respiratory distress. Differentiation from RDS requires an adequate history and appropriate laboratory evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/20/26945?source=see_link\">",
"       \"Patient information: Transient tachypnea of the newborn (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393565\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory distress syndrome (RDS), formerly also known as hyaline membrane disease, is a common problem in preterm newborn infants.",
"     </li>",
"     <li>",
"      RDS is caused primarily by deficiency of pulmonary surfactant in an immature lung. Other contributing factors to lung injury include inflammation and pulmonary edema. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pulmonary surfactant'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H86661090\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surfactant deficiency leads to low lung compliance and volume, which causes alveolar collapse, and ventilation and perfusion mismatch resulting in hypoxemia. (See",
"      <a class=\"local\" href=\"#H393256\">",
"       'Pulmonary function and gas exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of RDS increases with decreasing gestational age. Extremely preterm infants (gestational age 28 weeks or below) are at the greatest risk for RDS with an incidence of over 90 percent. (See",
"      <a class=\"local\" href=\"#H393411\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of RDS are primarily due to abnormal pulmonary function and hypoxemia in a premature infant. RDS presents within the first minutes or hours of birth with signs of respiratory distress, such as tachypnea, nasal flaring, expiratory grunting, intercostal, subcostal and subxiphoid retractions, and cyanosis. Additional findings may include decreased ausculatory breath sounds, pallor, and diminished perfusion. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typically RDS progresses over the first 48 to 72 hours of life with increased respiratory distress and begins to resolve after 72 hours. Subsequent improvement is coincident with increased production of endogenous surfactant with resolution of symptoms by one week of age. The use of exogenous surfactant",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      continuous positive airway pressure dramatically improves pulmonary function and shortens the clinical course. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of RDS is based on clinical findings of a premature infant with onset of progressive respiratory failure shortly after birth and a characteristic chest radiograph, which demonstrates low lung volume and diffuse reticulogranular ground-glass appearance with air bronchograms (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52323 \" href=\"UTD.htm?36/11/37040\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of RDS includes other causes of respiratory distress in the newborn including transient tachypnea of the newborn, bacterial pneumonia, air leak, cyanotic congenital heart disease, and non-pulmonary systemic disorders. These disorders are distinguished from RDS based on differences in clinical presentation, chest radiograph findings, and clinical course. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4293459\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Stephen Welty, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jobe, AH. Lung Development and maturation. In: Neonatal-Perinatal Medicine , 2, 9th, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St Louis 2011. p.1075.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/2\">",
"      Schmitz G, M&uuml;ller G. Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids. J Lipid Res 1991; 32:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/3\">",
"      Frank L, Sosenko IR. Development of lung antioxidant enzyme system in late gestation: possible implications for the prematurely born infant. J Pediatr 1987; 110:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/4\">",
"      Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994; 93:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/5\">",
"      Nogee LM, Dunbar AE 3rd, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/6\">",
"      Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004; 350:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/7\">",
"      Somaschini M, Nogee LM, Sassi I, et al. Unexplained neonatal respiratory distress due to congenital surfactant deficiency. J Pediatr 2007; 150:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/8\">",
"      Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol 2009; 12:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/9\">",
"      Jobe AH, Ikegami M. Biology of surfactant. Clin Perinatol 2001; 28:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/10\">",
"      Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med 2002; 347:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/11\">",
"      Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 2010; 61:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/12\">",
"      Nkadi PO, Merritt TA, Pillers DA. An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease. Mol Genet Metab 2009; 97:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/13\">",
"      Wu H, Kuzmenko A, Wan S, et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003; 111:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/14\">",
"      Sato A, Whitsett JA, Scheule RK, Ikegami M. Surfactant protein-d inhibits lung inflammation caused by ventilation in premature newborn lambs. Am J Respir Crit Care Med 2010; 181:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/15\">",
"      Verlato G, Cogo PE, Balzani M, et al. Surfactant status in preterm neonates recovering from respiratory distress syndrome. Pediatrics 2008; 122:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/16\">",
"      Hallman M, Kulovich M, Kirkpatrick E, et al. Phosphatidylinositol and phosphatidylglycerol in amniotic fluid: indices of lung maturity. Am J Obstet Gynecol 1976; 125:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/17\">",
"      Carlton DP, Albertine KH, Cho SC, et al. Role of neutrophils in lung vascular injury and edema after premature birth in lambs. J Appl Physiol 1997; 83:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/18\">",
"      Clark RH, Gerstmann DR, Jobe AH, et al. Lung injury in neonates: causes, strategies for prevention, and long-term consequences. J Pediatr 2001; 139:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/19\">",
"      Naik AS, Kallapur SG, Bachurski CJ, et al. Effects of ventilation with different positive end-expiratory pressures on cytokine expression in the preterm lamb lung. Am J Respir Crit Care Med 2001; 164:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/20\">",
"      Brus F, van Oeveren W, Okken A, Oetomo SB. Number and activation of circulating polymorphonuclear leukocytes and platelets are associated with neonatal respiratory distress syndrome severity. Pediatrics 1997; 99:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/21\">",
"      Turunen R, Nupponen I, Siitonen S, et al. Onset of mechanical ventilation is associated with rapid activation of circulating phagocytes in preterm infants. Pediatrics 2006; 117:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/22\">",
"      Buss IH, Senthilmohan R, Darlow BA, et al. 3-Chlorotyrosine as a marker of protein damage by myeloperoxidase in tracheal aspirates from preterm infants: association with adverse respiratory outcome. Pediatr Res 2003; 53:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/23\">",
"      Cheah FC, Winterbourn CC, Darlow BA, et al. Nuclear factor kappaB activation in pulmonary leukocytes from infants with hyaline membrane disease: associations with chorioamnionitis and Ureaplasma urealyticum colonization. Pediatr Res 2005; 57:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/24\">",
"      Nitta K, Kobayashi T. Impairment of surfactant activity and ventilation by proteins in lung edema fluid. Respir Physiol 1994; 95:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/25\">",
"      Smith DE, Otulakowski G, Yeger H, et al. Epithelial Na(+) channel (ENaC) expression in the developing normal and abnormal human perinatal lung. Am J Respir Crit Care Med 2000; 161:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/26\">",
"      Helve O, Pitk&auml;nen OM, Andersson S, et al. Low expression of human epithelial sodium channel in airway epithelium of preterm infants with respiratory distress. Pediatrics 2004; 113:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/27\">",
"      Jobe AH, Hillman N, Polglase G, et al. Injury and inflammation from resuscitation of the preterm infant. Neonatology 2008; 94:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/28\">",
"      Edberg KE, Sandberg K, Silberberg A, et al. Lung volume, gas mixing, and mechanics of breathing in mechanically ventilated very low birth weight infants with idiopathic respiratory distress syndrome. Pediatr Res 1991; 30:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/29\">",
"      Macklem PT, Proctor DF, Hogg JC. The stability of peripheral airways. Respir Physiol 1970; 8:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/30\">",
"      NELSON NM, PROD'HOM LS, CHERRY RB, et al. Pulmonary function in the newborn infant. II. Perfusion--estimation by analysis of the arterial-alveolar carbon dioxide difference. Pediatrics 1962; 30:975.",
"     </a>",
"    </li>",
"    <li>",
"     Goldsmith J and Karotkin, E. Assisted Ventilation of the Neonate, 4, WB Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/32\">",
"      Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/33\">",
"      Consortium on Safe Labor, Hibbard JU, Wilkins I, et al. Respiratory morbidity in late preterm births. JAMA 2010; 304:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19656/abstract/34\">",
"      Anadkat JS, Kuzniewicz MW, Chaudhari BP, et al. Increased risk for respiratory distress among white, male, late preterm and term infants. J Perinatol 2012; 32:780.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5055 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-110.170.48.130-F96105F60D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19656=[""].join("\n");
var outline_f19_12_19656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H393565\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20446149\">",
"      LUNG DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Pulmonary surfactant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Synthesis, secretion, and adsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86660867\">",
"      - Prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86661090\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surfactant deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86661250\">",
"      Inflammation and lung injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86661320\">",
"      Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86661736\">",
"      Surfactant inactivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H393256\">",
"      Pulmonary function and gas exchange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H393351\">",
"      - Hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H393411\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H393454\">",
"      Other laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H393565\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4293459\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5055\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5055|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/11/37040\" title=\"diagnostic image 1\">",
"      Chest radiograph RDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5055|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/5/43102\" title=\"figure 1\">",
"      Surfactant effect on lung pressure-volume",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=related_link\">",
"      Assessment of fetal lung maturity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=related_link\">",
"      Cardiac causes of cyanosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/20/26945?source=related_link\">",
"      Patient information: Transient tachypnea of the newborn (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=related_link\">",
"      Prevention and treatment of respiratory distress syndrome in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4631?source=related_link\">",
"      Pulmonary air leak in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=related_link\">",
"      Transient tachypnea of the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_12_19657="Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death";
var content_f19_12_19657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19657/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19657/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19657/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19657/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19657/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19657/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/12/19657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrhythmic death (SCD) is a common problem that usually results from ventricular fibrillation (VF), which is sometimes preceded by monomorphic or polymorphic ventricular tachycardia (VT). The implantable cardioverter-defibrillator (ICD) has become the primary therapeutic modality for the secondary prevention of SCD and, in some groups of patients, for primary prevention. Other nonpharmacologic therapies include ablative surgery, transcatheter ablation, and, in selected individuals, cardiac transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical trials supporting the efficacy of the ICD for the primary prevention of SCD will be reviewed here. The clinically important issue of recommendations for the use of an ICD for primary prevention in patients with prior myocardial infarction or nonischemic cardiomyopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H29#H29\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'ICD therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H13#H13\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention of SCD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the use of an ICD for secondary prevention are also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H4#H4\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Secondary prevention of SCD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for the ICD for primary prevention of sudden death is limited to specific risk groups. Randomized controlled trials demonstrating benefit have been performed in patients with ischemic and nonischemic cardiomyopathy. An observational series of patients with ischemic cardiomyopathy has validated this benefit in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/1\">",
"     1",
"    </a>",
"    ]. An ICD may also be inserted for primary prevention in patients with selected genetic disorders who are at increased risk of SCD, such as Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with NYHA class IV heart failure have a very high mortality from progressive pump failure unless they are candidates for either cardiac transplantation or cardiac resynchronization therapy. Therefore, such patients are not usually considered appropriate candidates for ICD therapy. Primary prevention ICD trials have excluded patients with NYHA class IV heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results of recent ICD trials have been used by physician organizations and third party payers to shape new guidelines regarding ICD therapy for primary prevention. The national coverage determination by the Center for Medicare and Medicaid Services (CMS) for reimbursement of ICD therapy, which was updated in January 2005, has had a significant impact on patient selection in the United States.",
"   </p>",
"   <p>",
"    Most clinical trials have involved the use of modern transvenous ICD systems. However, a recent small, nonrandomized study demonstrated the efficacy of a novel, totally subcutaneous defibrillator for the prevention of cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/2\">",
"     2",
"    </a>",
"    ]. Seventy eight percent of the patients enrolled in this study underwent defibrillator implantation for primary prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ISCHEMIC CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have had an acute MI are at increased risk SCD, most often due to a ventricular tachyarrhythmia. The best approach to selecting patients with ischemic cardiomyopathy for ICD therapy for primary prevention has been explored in several major randomized trials, described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     MADIT I trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Multicenter Automatic Defibrillator Implantation Trial (MADIT, now called MADIT-I) was the first trial to demonstrate that the ICD has a role in primary prevention of SCD in certain high risk, asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/3\">",
"     3",
"    </a>",
"    ]. This trial enrolled 196 patients with a prior myocardial infarction (MI), nonsustained VT (NSVT) on monitoring, left ventricular (LV) dysfunction (LVEF &lt;35 percent), and inducible sustained monomorphic VT that was also inducible after administration of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ; these patients were randomly assigned to pharmacologic therapy, which could include an antiarrhythmic drug at the discretion of the clinician, or an ICD. Most patients assigned to pharmacologic therapy were tried on an antiarrhythmic drug, most often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The major findings at 27-month follow-up were significant reductions in the incidence of overall mortality, cardiac mortality, and arrhythmic deaths in the patients treated with an ICD (",
"    <a class=\"graphic graphic_figure graphicRef76854 \" href=\"UTD.htm?38/48/39693\">",
"     figure 1",
"    </a>",
"    ). The average survival for the ICD group over a four year period was 3.7 years compared with 2.8 years for the conventionally treated patients; the incremental cost effectiveness ratio was $27,000 per life-year saved [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link\">",
"     \"Management of nonsustained ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subset analysis found survival benefit from the ICD only in high-risk patients with more severe heart disease, ie, left ventricular ejection fraction (LVEF) &lt;26 percent, heart failure (HF) requiring therapy, or a QRS duration &ge;0.12 sec [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/5\">",
"     5",
"    </a>",
"    ]. Benefit increased progressively as a function of the number of risk factors; the greatest reduction in mortality with the ICD was seen in those with two (hazard ratio 0.30) or three risk factors (hazard ratio 0.20).",
"   </p>",
"   <p>",
"    There are, however, a number of important limitations to this study, in addition to its small size, that limit its applicability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of patients with reproducible NSVT identified on sequential Holter monitoring is low, reported by one study to be 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/6\">",
"       6",
"      </a>",
"      ]. Reproducibility is especially low in those with infrequent NSVT episodes per 24 hours. Reproducibility was not associated with the induction of VT on electrophysiology study (EPS), suggesting that NSVT is of limited clinical value as a selection criterion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"       \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      By enrolling only patients in whom inducible sustained VT was not suppressed or slowed by the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , the study selected patients who were less likely to respond to antiarrhythmic drugs.",
"     </li>",
"     <li>",
"      Two factors other than true benefit may have contributed to the better outcome in the ICD group. First, 23 percent of patients receiving conventional therapy were not taking any antiarrhythmic drugs at the last follow-up. Second, more patients given the ICD were taking a beta blocker at one month (8 versus 26 percent) and at the last follow-up visit (5 versus 27 percent). It is possible that beta blockade itself confers a survival benefit.",
"     </li>",
"     <li>",
"      By comparing the ICD to antiarrhythmic drugs that may increase mortality via their proarrhythmic effect, it was not demonstrated that the ICD was better than no therapy. However, the mortality rate in the \"conventional therapy\" group was 32 percent at two years, a figure that is in accord with previously reported results in high-risk patients. Thus,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      did not appear to confer an increased mortality in this trial, and the results probably reflected a survival benefit of the ICD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MADIT I was not intended to be interpreted as the screening procedure of choice for high-risk patients. Nevertheless, based upon the results of MADIT I, the FDA approved the prophylactic use of the ICD in patients who have the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sustained VT induced by EPS and not prevented with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"     </li>",
"     <li>",
"      Ischemic heart disease",
"     </li>",
"     <li>",
"      Prior MI",
"     </li>",
"     <li>",
"      Non-sustained VT",
"     </li>",
"     <li>",
"      Reduced LVEF (&lt;35 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It remains unclear how many patients with a recent MI would be candidates for a prophylactic ICD based upon MADIT I criteria. Using data collected from the Cardiac Arrhythmia Suppression Trial (CAST) registry, it was estimated that between 0.3 and 1.1 percent of patients were at high enough risk to benefit from a prophylactic ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     MADIT II trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to address some of the criticisms of MADIT I and to expand the population that may benefit from the ICD, the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) enrolled 1232 patients with a myocardial infarction more than 30 days prior to enrollment (and more than three months if bypass surgery was performed) and an LVEF &le;30 percent; electrophysiology study (EPS) was not performed and the presence of NSVT was not an entry criterion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/8\">",
"     8",
"    </a>",
"    ]. The patients were randomly assigned to a prophylactic ICD or conventional medical therapy.",
"   </p>",
"   <p>",
"    The study was prematurely terminated after an average follow-up of 20 months because the ICD significantly reduced all-cause mortality (14.2 versus 19.8 percent for conventional therapy, hazard ratio 0.65, 95 percent confidence interval 0.51 to 0.93) (",
"    <a class=\"graphic graphic_figure graphicRef63529 \" href=\"UTD.htm?19/35/20029\">",
"     figure 2",
"    </a>",
"    ). The survival benefit was entirely due to a reduction in sudden death (3.8 versus 10.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/9\">",
"     9",
"    </a>",
"    ] and was seen in all subgroups analyzed. There was no significant effect of the QRS interval, but the benefit appeared to be greatest at a QRS interval &gt;150 msec.",
"   </p>",
"   <p>",
"    An unexpected finding was a higher rate of hospitalization for HF in the ICD group (20 versus 15 percent). The reason for this is uncertain, but possible explanations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher incidence of progression to HF as a result of preventing sudden death",
"     </li>",
"     <li>",
"      The development of myocardial injury and depressed left ventricular function as a result of multiple ICD shocks",
"     </li>",
"     <li>",
"      The negative impact of unintended right ventricular pacing on ventricular synchrony and function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CABG Patch trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Coronary Artery Bypass Graft (CABG) Patch trial evaluated the efficacy of an epicardial ICD implanted at the time of coronary artery bypass for reducing overall mortality in 900 patients undergoing surgical revascularization for severe CHD who had significant LV dysfunction (LVEF &lt;36 percent) and a positive signal-averaged electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/10\">",
"     10",
"    </a>",
"    ]. Enrolled patients did not have a history of a sustained ventricular tachyarrhythmia or syncope. After an average follow-up of 32 months, there were 101 deaths in the ICD group (71 of which were cardiac) and 95 in the control group (72 of which were cardiac). The hazard ratio that compared the risk of death per unit of time in the ICD group with that of the control group was 1.07, a difference that was not significant (",
"    <a class=\"graphic graphic_figure graphicRef78888 \" href=\"UTD.htm?23/1/23581\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Prophylactic therapy with the ICD did reduce arrhythmic death at 42 months by 45 percent (4 versus 6.9 percent in the control group) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/11\">",
"     11",
"    </a>",
"    ]. However, since 71 percent of the deaths in this trial were nonarrhythmic, the reduction in arrhythmic death did not impact upon total mortality. It is possible that ICD therapy was unable to improve mortality in this primary prevention trial because coronary revascularization itself has such a beneficial effect in the prevention of sudden death.",
"   </p>",
"   <p>",
"    This negative trial is a primary reason why current guidelines recommend against ICD implantation for patients who have recently undergone coronary revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     MUSTT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Multicenter Unsustained Tachycardia Trial (MUSTT trial) involved 704 patients with a prior MI (less than one month to more than three years previously), asymptomatic NSVT, an LVEF &le;40 percent, and inducible sustained VT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients were randomly assigned to no therapy or to guided antiarrhythmic therapy (based on electrophysiology study [EPS] results), which included either an antiarrhythmic agent (class IA with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ), or an ICD if at least one antiarrhythmic agent was ineffective. The primary endpoint was arrhythmic death or resuscitated SCD. This trial was designed to study the concept of guiding the management of high-risk patients with the results of EPS. It was not primarily designed as a randomized ICD clinical trial. However, the data from this trial regarding the outcome of patients who received ICD therapy is useful.",
"   </p>",
"   <p>",
"    There were 353 patients discharged with no therapy and 351 who received EPS guided therapy, including an antiarrhythmic drug in 154 and an ICD in 161. The median follow-up was 39 months and the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two-year (12 versus 18 percent) and five-year (25 versus 32 percent) rates for the primary endpoint were significantly lower for EPS guided therapy compared to no therapy.",
"     </li>",
"     <li>",
"      There was a nearly significant reduction in the secondary endpoint of total mortality at five years in the group receiving EPS guided therapy (42 versus 48 percent, p = 0.06).",
"     </li>",
"     <li>",
"      The reduction in the primary and secondary endpoints in the EPS guided group was largely attributable to ICD therapy; at five years the primary endpoint occurred in 9 percent of those receiving an ICD, compared with 37 percent of those receiving an antiarrhythmic drug, and the secondary endpoint occurred in 24 and 55 percent, respectively. There was no difference in outcome between patients receiving no therapy and those treated with an antiarrhythmic drug (",
"      <a class=\"graphic graphic_figure graphicRef68247 \" href=\"UTD.htm?1/34/1582\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The MADIT II trial mentioned above found that the risk of death from any cause was significantly improved by prophylactic implantation of an ICD in patients with a prior MI who had an LVEF &le;30 percent, independent of the presence of ventricular arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/8\">",
"     8",
"    </a>",
"    ]. Whether inducible arrhythmia might be prognostically important in patients with an LVEF of 30 to 40 percent was addressed in another analysis from MUSTT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/13\">",
"     13",
"    </a>",
"    ]. The rate of arrhythmic death at five years was not significantly increased if VT was inducible when the LVEF was below 30 percent (40 versus 31 percent) but was significantly increased at higher LVEF (30 versus 17 percent). It was suggested by the authors that, for patients with LVEF &ge;30 percent only, EP testing may have useful predictive value. However, the magnitude of the difference in risk for the two groups was similar (9 percent for LVEF &lt;30 percent, 13 percent for LVEF &ge;30 percent), suggesting that the perceived difference in the utility of EP testing may have resulted from a beta error (ie, the study was underpowered).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     SCD-HeFT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) examined the role of an ICD or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in patients with heart failure (HF) due to either an ischemic or nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/14\">",
"     14",
"    </a>",
"    ]. A total of 2521 patients with an LVEF &le;35 percent and NYHA class II or III HF were randomly assigned to ICD implantation, amiodarone, or placebo. The etiology of cardiomyopathy was ischemic in 52 percent and nonischemic in 48 percent. In preliminary analysis, all-cause mortality was 7.2 percent per year and was not reduced by amiodarone therapy.",
"   </p>",
"   <p>",
"    Overall mortality at five years was significantly reduced with ICD therapy (29 versus 36 percent with placebo, HR 0.77, 95% CI 0.62-0.96). The benefit of an ICD was comparable among patients with either an ischemic or nonischemic cardiomyopathy. However, patients with NYHA class III HF did not appear to benefit from ICD therapy as there was a nonsignificant trend toward increased mortality in this group (HR 1.16 compared to 0.54 in NYHA class II HF). In a post hoc analysis, the benefit of an ICD was seen in patients with an LVEF &le;30 percent, but not in those with an LVEF &gt;30 percent (HR 0.73 versus 1.08).",
"   </p>",
"   <p>",
"    These results suggest that an ICD is beneficial in patients with HF and a diminished LVEF (&le;35 percent, or perhaps &le;30 percent). In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    was not beneficial in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H15#H15\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Ischemic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Early post MI trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the patients in the MADIT trials, and most of those in MUSTT, were enrolled at least three weeks post-MI. The DINAMIT and IRIS trials evaluated the role of prophylactic ICD implantation in the first weeks following MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     DINAMIT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT) evaluated the role of prophylactic ICD implantation compared to no ICD in 674 patients with MI in the preceding 6 to 40 days (mean 18 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/15\">",
"     15",
"    </a>",
"    ]. Entry requirements also included an LVEF &le;35 percent and reduced heart rate variability or elevated resting heart rate (&ge;80",
"    <span class=\"nowrap\">",
"     beats/min).",
"    </span>",
"    Patients with sustained VT &gt;48 hours post-MI, NYHA class IV HF, or coronary artery bypass grafting (CABG) or three-vessel percutaneous coronary intervention post-MI were excluded. Mean follow-up was 30 months.",
"   </p>",
"   <p>",
"    There was no difference in annual all-cause mortality between the ICD patients and controls (7.5 versus 6.9 percent). Arrhythmic deaths were more frequent in the control arm, while nonarrhythmic deaths were more frequent in the ICD arm.",
"   </p>",
"   <p>",
"    This negative trial is the primary reason that current guidelines recommend that ICD implantation should be deferred until at least 40 days after an MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H16#H16\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'Evolving indications for an ICD following myocardial infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     IRIS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic ICD implantation early after MI was also evaluated in the Immediate Risk Stratification Improves Survival (IRIS) trial, which enrolled 898 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/16\">",
"     16",
"    </a>",
"    ]. Inclusion criteria included an MI within the preceding 5 to 31 days, and one or both of the following two criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LVEF &le;40 percent and a resting heart rate &ge;90",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"     </li>",
"     <li>",
"      Nonsustained VT at a rate of &ge;150",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mean follow-up was 37 months. Similar to the DINAMIT trial, there was no difference in all-cause mortality between patients randomly assigned to ICD therapy and those assigned to medical therapy. The rate of SCD was higher in the control group, but the number of nonsudden cardiac deaths was higher in the ICD arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Possible explanations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible reasons why DINAMIT and IRIS did not show the benefit from an ICD seen in the MADIT and MUSTT trials include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant recovery of ventricular function may have occurred in some of the patients, which would dilute the long-term benefit of the ICD in such patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H7#H7\">",
"       \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'LV dysfunction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some SCD events in the early postinfarction period may have been due to recurrent ischemia, which would not be definitively treated by ICD discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ICD implantation might impose additional risk in these patients immediately post-MI.",
"     </li>",
"     <li>",
"      The enrollment requirements of reduced heart rate variability in DINAMIT and resting heart rate &ge;90",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      in IRIS could have selected a group of patients with a high mortality from nonarrhythmic causes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H15#H15\">",
"       \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'Reduced HRV'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more extensive discussion on the temporal pattern of SCD risk after an MI is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H3#H3\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'Time after MI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NONISCHEMIC CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias are common in patients with heart failure (HF) and a nonischemic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     CAT and AMIOVIRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although patients with severe HF and a nonischemic cardiomyopathy are at increased risk for arrhythmic death, two small randomized trials of prophylactic ICD insertion in such patients showed no survival benefit compared to placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Cardiomyopathy Trial (CAT) randomly assigned 104 patients with recent onset (&le;9 months) dilated cardiomyopathy and an LVEF &le;30 percent to an ICD or control [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/19\">",
"       19",
"      </a>",
"      ]. The trial was terminated prematurely because there was no significant difference in the primary endpoint of all-cause mortality. The cumulative survival was similar at two and four years (92 versus 93 percent and 86 versus 80 percent in the control group); there were no sudden deaths during the first two years of follow-up. There was no benefit from the ICD in any subgroup, including those with or without NSVT.",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      Versus Implantable Cardioverter-Defibrillator (AMIOVIRT) trial compared an ICD, often with amiodarone, to amiodarone alone in 103 patients with moderate to severe nonischemic dilated cardiomyopathy as manifested by class I to III heart failure, an LVEF &le;35 percent, and asymptomatic NSVT [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/18\">",
"       18",
"      </a>",
"      ]. There was no significant difference in overall survival between the amiodarone and ICD groups at one year (90 versus 96 percent) or three years (88 versus 87 percent). There were nonsignificant trends toward better arrhythmia-free survival and lower costs during the first year with amiodarone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The statistical power of both the CAT and AMIOVIRT trials were limited by small numbers of patients and an unexpectedly low mortality rate. In addition, there was no placebo control group in the AMIOVIRT trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     DEFINITE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the above observations, the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial found a trend toward a reduction in mortality with an ICD in patients with a nonischemic dilated cardiomyopathy, an LVEF &le;35 percent, and ventricular premature beats or NSVT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/20\">",
"     20",
"    </a>",
"    ]. A total of 458 patients were enrolled; all received standard medical therapy including, in most cases, an ACE inhibitor (86 percent) and a beta blocker (85 percent). Patients were randomly assigned to an ICD or medical therapy alone. At two years, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a trend toward reduction in the primary endpoint of all-cause mortality in patients treated with an ICD (7.9 versus 14.1 percent with medical therapy alone, hazard ratio (HR) 0.65, 95% CI 0.40 to 1.06). Among the subset of patients with NYHA class III HF, the difference was significant (HR 0.37, 95% CI 0.15 to 0.90).",
"     </li>",
"     <li>",
"      Fewer sudden deaths occurred in the ICD arm, although the number was very small (three deaths versus 14 deaths in the medical therapy arm, HR 0.20, 95% CI 0.06 to 0.71).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The all-cause mortality rate in the \"medical therapy only\" arm of DEFINITE (14.1 percent at two years) was lower than had been anticipated when the study was designed. As a result, the trial was underpowered and might have demonstrated a significant difference in the primary endpoint with a larger number of study subjects.",
"   </p>",
"   <p>",
"    Despite the trend toward benefit suggested by DEFINITE, the lower than anticipated mortality rate in the control arm, the lack of statistical significance of the primary endpoint, and observational data showing that NSVT was not an independent predictor of mortality have led to a cautious approach to the interpretation of this trial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     SCD-HeFT and nonischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) trial examined the role of an ICD or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in 2521 patients with HF due to either an ischemic (52 percent) or nonischemic (48 percent) cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/14\">",
"     14",
"    </a>",
"    ]. ICD therapy significantly reduced overall mortality (HR 0.77 versus placebo, 95% CI 0.62-0.96). The benefit of ICD therapy was comparable among patients with either an ischemic or nonischemic cardiomyopathy. However, patients with NYHA class III HF did",
"    <strong>",
"     not",
"    </strong>",
"    appear to benefit from ICD therapy as there was a nonsignificant trend toward increased mortality (HR 1.16). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'SCD-HeFT trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHER CATEGORIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     NYHA class III HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been conflicting data on the benefit of an ICD for primary prevention of SCD in patients with NYHA class III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SCD-HeFT trial of patients with ischemic and nonischemic cardiomyopathy, subgroup analysis suggested that the benefit of ICD therapy was limited to patients with class II HF [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the DEFINITE trial of patients with nonischemic cardiomyopathy, subgroup analysis showed greater benefit from ICD therapy among patients with NYHA class III compared to class II HF [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a post-hoc analysis from the MADIT II trial of patients with ischemic cardiomyopathy, the degree of benefit was similar among patients with NYHA class I, II, and III HF [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons for these discrepant findings from subgroup analyses are unclear. Until more definitive data are available, the indications for ICD therapy are similar in patients with class II and class III HF despite optimal medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H26#H26\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     ICD combined with CRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simultaneous pacing of both ventricles (biventricular or BiV pacing), or of one ventricle in the presence of bundle branch block, to optimize cardiac pump function through synchronization of ventricular contraction is referred to as cardiac resynchronization therapy (CRT). CRT can be achieved with a device designed for pacing only or can be incorporated into a combination device with an ICD (",
"    <a class=\"graphic graphic_figure graphicRef79450 \" href=\"UTD.htm?15/35/15925\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     COMPANION trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Comparison Of Medical Therapy, Pacing, And Defibrillation In Heart Failure (COMPANION) trial demonstrated the benefit of combination therapy with CRT and an ICD in 1520 patients with NYHA class III-IV HF and an LVEF &le;35 percent who had had a hospitalization for HF within the year prior to enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/26\">",
"     26",
"    </a>",
"    ]. Nearly half of all patients enrolled had a nonischemic etiology of HF. Patients were randomly assigned to optimal medical therapy, CRT alone, or CRT with an ICD. Medical therapy for HF included angiotensin converting enzyme inhibitors or angiotensin receptor blockers in 89 percent, beta blockers in 66 percent, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    in 55 percent.",
"   </p>",
"   <p>",
"    During the course of the study, a significant number of patients in the medical therapy only arm of the trial withdrew to receive a device because of arrhythmia or HF (26 percent versus 6 and 7 percent in the CRT and CRT plus ICD arms, respectively). Patients who withdrew from the trial were asked in a second consent to agree to the collection of follow-up data.",
"   </p>",
"   <p>",
"    At 12 months, there was a significant reduction in the incidence of the combined endpoint of all-cause mortality and all-cause hospitalization in the two arms receiving CRT compared to the medical therapy only arm (56 versus 68 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/26\">",
"     26",
"    </a>",
"    ]. The CRT plus ICD arm, but not the CRT only arm, experienced a significant improvement in the secondary endpoint of all-cause mortality alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost-effectiveness of ICD implantation for primary prevention in high-risk populations is difficult to determine, and estimates vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Most published estimates put the cost-effectiveness well within a range that is generally considered acceptable in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], but some analyses have reported much higher costs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/29\">",
"     29",
"    </a>",
"    ]. The cost range of $50,000 to $100,000 per QALY gained has generally been considered to be acceptable in the United States and several other countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variables to be considered include the cost of initial device implantation, the cost and frequency of generator change, the projected life expectancy and mortality rate of the population receiving the ICD, and the efficacy of ICD therapy. In addition, cost-effectiveness analysis often incorporates quality of life adjustments, which can be challenging due to the impact of device implantation and concurrent diseases such as heart failure.",
"   </p>",
"   <p>",
"    One study estimated cost-effectiveness of prophylactic ICD implantation with a statistical model derived from cost and outcome data from the primary prevention trials cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/27\">",
"     27",
"    </a>",
"    ]. Among the six trials in which ICD therapy showed a mortality benefit (MADIT I, MADIT II, MUSTT, DEFINITE, COMPANION, and SCD-HeFT), use of an ICD was projected to add one to three quality adjusted life-years (QALYs), with an estimated cost per quality-adjusted year of life saved ranged from $34,900 in MADIT to $70,200 in SCD-HeFT.",
"   </p>",
"   <p>",
"    Another analysis evaluated cost-effectiveness of ICD therapy in the 1095 patients from the United States in the MADIT II trial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19657/abstract/29\">",
"     29",
"    </a>",
"    ]. Although the patient population was narrower than that in the above report, this study utilized actual cost and outcome data from the patients in the trial. ICD cost-effectiveness in this analysis was less attractive, with the cost per year-of-life saved being estimated at $235,000.",
"   </p>",
"   <p>",
"    However, because significant ICD costs are incurred at the time of implantation, and survival benefit may become more substantial over time, overall cost-effectiveness may improve with longer follow-up. Using three alternative projections out to 12 years, estimated cost-effectiveness ranged from $78,600 to $114,000 per year-of-life saved. This study did not attempt to adjust for quality of life, but QALYs are usually lower than actual years-of-life saved; thus, the cost-effectiveness is less attractive in QALY terms.",
"   </p>",
"   <p>",
"    The cost-effectiveness of an ICD for secondary prevention has also been studied, with very wide ranges reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H10#H10\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Cost-effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topic (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden cardiac arrhythmic death (SCD) is a common problem that usually results from ventricular fibrillation (VF), which is sometimes preceded by monomorphic or polymorphic ventricular tachycardia (VT). The implantable cardioverter-defibrillator (ICD) has become the primary therapeutic modality for the secondary prevention of SCD and, in some groups of patients, for primary prevention. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A role for the ICD for primary prevention of sudden death is limited to specific risk groups, including patients with ischemic cardiomyopathy, nonischemic cardiomyopathy, and certain patients with selected genetic disorders who are at increased risk of SCD (eg, Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Multicenter Automatic Defibrillator Implantation Trial (MADIT, now called MADIT-I) demonstrated a mortality reduction after ICD placement in high-risk asymptomatic patients defined as those with a prior myocardial infarction (MI), nonsustained VT (NSVT) on monitoring, left ventricular ejection fraction (LVEF) &lt;35 percent, and inducible sustained monomorphic VT that remained inducible after administration of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'MADIT I trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MADIT II demonstrated that ICD implantation resulted in a significant reduction in all-cause mortality for patients with a prior MI and an LVEF &le;30 percent. The mortality reduction appeared to be entirely due to a reduction in SCD. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'MADIT II trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) reported that ICD therapy reduced all cause mortality in heart failure patients with ischemic or nonischemic cardiomyopathy and LVEF &le;35 percent. In contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      was not beneficial in these patients. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'SCD-HeFT trial'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'SCD-HeFT and nonischemic cardiomyopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial demonstrated a trend toward a reduction in mortality in patients with nonischemic cardiomyopathy, LVEF &le;35 percent, and ventricular premature beats or NSVT who were treated with an ICD. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'DEFINITE trial'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While ICD therapy is beneficial for some groups of patients, others may derive little or no benefit from an ICD. Patients with NYHA class IV heart failure have a very high mortality from progressive heart failure unless they are candidates for either cardiac transplantation or cardiac resynchronization therapy. Therefore, such patients are not usually considered appropriate candidates for ICD therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cost-effectiveness of ICD implantation for primary prevention in high-risk populations is difficult to determine, with estimates that can vary widely. However, most published reports estimate the cost-effectiveness to be well within a range that is generally considered acceptable in developed countries. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Cost-effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for the use of an ICD for primary prevention in patients with prior MI or nonischemic cardiomyopathy are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H29#H29\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'ICD therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H13#H13\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention of SCD'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/1\">",
"      Chan PS, Chow T, Kereiakes D, et al. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction. Arch Intern Med 2006; 166:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/2\">",
"      Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/3\">",
"      Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/4\">",
"      Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 1998; 97:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/5\">",
"      Moss AJ, Fadl Y, Zareba W, et al. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol 2001; 88:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/6\">",
"      Senges JC, Becker R, Schreiner KD, et al. Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial. Pacing Clin Electrophysiol 2002; 25:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/7\">",
"      Every NR, Hlatky MA, McDonald KM, et al. Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1998; 82:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/8\">",
"      Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/9\">",
"      Greenberg H, Case RB, Moss AJ, et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/10\">",
"      Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/11\">",
"      Bigger JT Jr, Whang W, Rottman JN, et al. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 1999; 99:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/12\">",
"      Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/13\">",
"      Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 2002; 106:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/14\">",
"      Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/15\">",
"      Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/16\">",
"      Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/17\">",
"      Orn S, Cleland JG, Romo M, et al. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med 2005; 118:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/18\">",
"      Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J Am Coll Cardiol 2003; 41:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/19\">",
"      B&auml;nsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/20\">",
"      Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/21\">",
"      Singh SN, Fisher SG, Carson PE, Fletcher RD. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. J Am Coll Cardiol 1998; 32:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/22\">",
"      Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation 2000; 101:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/23\">",
"      Zareba W, Piotrowicz K, McNitt S, et al. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Am J Cardiol 2005; 95:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/24\">",
"      Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/25\">",
"      K&uuml;hlkamp V, InSync 7272 ICD World Wide Investigators. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. J Am Coll Cardiol 2002; 39:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/26\">",
"      Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/27\">",
"      Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/28\">",
"      Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006; 114:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19657/abstract/29\">",
"      Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47:2310.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1030 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-C6403DFCA4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19657=[""].join("\n");
var outline_f19_12_19657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ISCHEMIC CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MADIT I trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MADIT II trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CABG Patch trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MUSTT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SCD-HeFT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Early post MI trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - DINAMIT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - IRIS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Possible explanations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NONISCHEMIC CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CAT and AMIOVIRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DEFINITE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SCD-HeFT and nonischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHER CATEGORIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NYHA class III HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ICD combined with CRT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - COMPANION trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COST-EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1030|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/48/39693\" title=\"figure 1\">",
"      ICD in NSVT in MADIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/35/20029\" title=\"figure 2\">",
"      ICD low EF post MI MADIT II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/1/23581\" title=\"figure 3\">",
"      ICD post CABG from CABG-Patch trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/34/1582\" title=\"figure 4\">",
"      ICD vs no ICD MUSTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/35/15925\" title=\"figure 5\">",
"      Cardiac resynchronization leads",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1030|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=related_link\">",
"      Management of nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_12_19658="General principles of infection control";
var content_f19_12_19658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of infection control",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19658/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19658/contributors\">",
"     N Deborah Friedman, MPH, MBBS, FRACP, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19658/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19658/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19658/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/12/19658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/12/19658/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/12/19658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection control is a discipline that applies epidemiologic and scientific principles and statistical analysis to the prevention or reduction in rates of nosocomial infections. Some experts in the field now prefer to use the phrase \"infection prevention and hospital epidemiology\" over the term infection control, as the words prevention and epidemiology more accurately define the discipline. Indeed, infection control is a key component of the broader discipline of hospital epidemiology. Effective infection control programs reduce rates of nosocomial infections and are cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recognition that infectious agents can be transmitted within hospitals to susceptible patients and health care workers began in the 1840s when Semmelweis noted that puerperal fever was associated with the lack of handwashing among clinicians performing autopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This discovery, in turn, led to the introduction of hand dips with chlorinated lime at Vienna General Hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/3\">",
"     3",
"    </a>",
"    ]. Eventually these ideas evolved into current guidelines about handwashing, although Semmelweis promoted hand cleansing and, paradoxically, was opposed to handwashing with soap and water [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection control programs became a requirement in the United States largely as a result of the mandates of the Joint Commission For Accreditation of Hospitals (JCAHO) and the leadership guidelines and definitions of the Centers for Disease Control and Prevention (CDC).",
"   </p>",
"   <p>",
"    In order to achieve the main goal of preventing or reducing the risk of hospital-acquired infections, a hospital epidemiology program should have the following oversight functions and responsibilities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surveillance, either hospital-wide or targeted",
"     </li>",
"     <li>",
"      Education about prevention of infections (eg, by hand disinfection)",
"     </li>",
"     <li>",
"      Outbreak investigations",
"     </li>",
"     <li>",
"      Cleaning, disinfection, and sterilization of equipment and disposal of infectious waste",
"     </li>",
"     <li>",
"      Hospital employee health, specifically after exposure to either bloodborne or respiratory pathogens",
"     </li>",
"     <li>",
"      Review of antibiotic utilization and its relationship to local antibiotic resistance patterns",
"     </li>",
"     <li>",
"      Prevention of infections due to intravascular devices",
"     </li>",
"     <li>",
"      Development of infection control policies and procedures",
"     </li>",
"     <li>",
"      Oversight on the use of new products that directly or indirectly relate to the risk of nosocomial infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospital infection control departments usually derive authority and communicate with other administrative components of hospitals via an infection control committee. This committee typically includes representatives from medical and surgical services, nursing, microbiology, hospital administration, and employee health.",
"   </p>",
"   <p>",
"    In order to be successful, infection control programs must have administrative support, resources, and an organizational commitment to a safety culture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/5\">",
"     5",
"    </a>",
"    ]. The authority of infection control personnel to direct policies and ensure compliance should be documented in writing and supported by the administrative leadership.",
"   </p>",
"   <p>",
"    Four major areas of infection control will be reviewed here:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Standard precautions, including hand hygiene",
"     </li>",
"     <li>",
"      Isolation precautions",
"     </li>",
"     <li>",
"      Environmental cleaning",
"     </li>",
"     <li>",
"      Surveillance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevention of specific infections, isolation policies, prophylaxis after exposure to blood-borne pathogens, and immunizations for healthcare workers are discussed in detail separately, as are infection control programs in other institutions such as long-term care facilities. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STANDARD PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various forms of isolation have been used in an attempt to reduce the spread of nosocomial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In 1996, the CDC and Hospital Infection Control Advisory Committee (HICPAC) issued a new system of isolation precautions (",
"    <a class=\"graphic graphic_table graphicRef50001 \" href=\"UTD.htm?24/18/24877\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/8\">",
"     8",
"    </a>",
"    ]. These guidelines were updated in 2007 as outlined in the following sections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard precautions are recommended in the care of all hospitalized patients. Standard precautions include the basic features of body substance isolation policies and universal precautions. When properly followed, they reduce the risk of transmission of infectious agents between patient and healthcare worker even when the presence of an infectious agent is unknown or not apparent.",
"   </p>",
"   <p>",
"    Standard precautions apply whenever contact with blood, other body fluids, nonintact skin, mucous membranes and secretions and excretions except sweat is likely or possible [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/8\">",
"     8",
"    </a>",
"    ]. They entail [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hand hygiene before and after every patient contact (including hand hygiene",
"      <strong>",
"       after",
"      </strong>",
"      gloves are removed)",
"     </li>",
"     <li>",
"      The use of gloves, gowns and eye protection in situations in which exposure to body secretions or blood is possible or likely",
"     </li>",
"     <li>",
"      The safe disposal of sharp instruments and needles in impervious containers",
"     </li>",
"     <li>",
"      The placement of soiled linens in impervious bags and bloody or contaminated materials such as feces or urine in sanitary toilets",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2007 CDC guidelines included several additional components [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Safe injection practices.",
"     </li>",
"     <li>",
"      Use of a mask when prolonged procedures involving puncture of the spinal canal are performed (such as myelography, epidural anesthesia, and injection of chemotherapeutic agents).",
"     </li>",
"     <li>",
"      Respiratory",
"      <span class=\"nowrap\">",
"       hygiene/cough",
"      </span>",
"      etiquette, which applies to all patients and accompanying family or friends who have signs of respiratory illness such as cough, congestion, rhinorrhea or increased volumes of respiratory secretions. Such individuals should cover their nose or mouth when coughing, promptly dispose used tissues and practice hand hygiene after contact with respiratory secretions. Use of a mask and spatial separation of such patients in waiting or patient care areas is also recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hand hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hand hygiene refers to either handwashing with soap and water or the use of alcohol-based gels or foams that do not require the use of water. Hand hygiene is the single most important measure to reduce transmission of microorganisms from one person to another or one site to another on the same patient (",
"    <a class=\"graphic graphic_table graphicRef77676 \" href=\"UTD.htm?14/28/14795\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/10\">",
"     10",
"    </a>",
"    ]. The primary problem with hand hygiene is laxity of practice, not a paucity of good products [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for the efficacy of hand hygiene is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SAVE LIVES: Clean Your Hands annual initiative is part of a major global effort led by the World Health Organization (WHO). It includes the \"My Five Moments for Hand Hygiene\", which define the key moments when healthcare workers should perform hand hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/12\">",
"     12",
"    </a>",
"    ]. This evidence-based, field-tested approach is applicable in a wide range of settings. The WHO approach recommends HCWs clean their hands:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Before touching a patient",
"     </li>",
"     <li>",
"      Before",
"      <span class=\"nowrap\">",
"       clean/aseptic",
"      </span>",
"      procedures",
"     </li>",
"     <li>",
"      After body fluid",
"      <span class=\"nowrap\">",
"       exposure/risk",
"      </span>",
"     </li>",
"     <li>",
"      After touching a patient",
"     </li>",
"     <li>",
"      After touching patient surroundings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2010 National Patient Safety Goals developed by the Joint Commission require all US hospitals to develop formal programs to promote and monitor hand hygiene by healthcare workers. Compliance became a criterion for hospital accreditation in January 2010.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Soap and water",
"    </span>",
"    &nbsp;&mdash;&nbsp;CDC guidelines advise use of a plain (nonantimicrobial) soap with water for routine handwashing, with use of an antimicrobial agent for specific circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef77676 \" href=\"UTD.htm?14/28/14795\">",
"     table 2",
"    </a>",
"    ). There are limited data with respect to the choice of plain soap, antiseptic soap, or antiseptic handrub [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of problems with handwashing with soap and water:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the past, compliance with handwashing rarely exceeded 45 percent, even under study conditions and even in intensive care units [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/3,14-17\">",
"       3,14-17",
"      </a>",
"      ]. However, aggressive programs to improve compliance with hand hygiene, as outlined by the 2010 National Patient Safety Goals, have been highly successful in many institutions [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/18\">",
"       18",
"      </a>",
"      ]. Unfortunately proper technique is often not followed when handwashing is performed. In one report, for example, the mean observed washing time was usually less than 10 seconds, compared with the recommended 15 to 30 seconds [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/16\">",
"       16",
"      </a>",
"      ]. The importance of duration of handwashing was illustrated in a study in which vancomycin-resistant enterococci (VRE) were inoculated onto the hands of healthy volunteers [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/19\">",
"       19",
"      </a>",
"      ]. A 30-second wash with water plus soap was necessary to completely eradicate VRE hand carriage. In contrast, a 5-second wash with water alone produced virtually no change in VRE recovery",
"     </li>",
"     <li>",
"      The frequency of handwashing by HCWs is affected by the accessibility of sinks, and by the characteristics of the soap used (eg, its smell, consistency, color, and even the ease in which the soap induces lathering) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/11\">",
"       11",
"      </a>",
"      ]. In addition, the location and type of soap dispensers can affect compliance.",
"     </li>",
"     <li>",
"      Handwashing with plain soap does not consistently or reliably prevent microbial transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frequent handwashing may cause skin damage and irritation, with resultant changes in microbial flora, increased skin shedding, and risk of transmission of microorganisms [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Alcohol based hand disinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol-containing hand disinfection (AHD) is an effective and practical alternative to standard soap and water (",
"    <a class=\"graphic graphic_table graphicRef77676 \" href=\"UTD.htm?14/28/14795\">",
"     table 2",
"    </a>",
"    ). Alcohol-based hand hygiene products have rapid antimicrobial effects and are equally effective against gram-positive and gram-negative organisms (when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/15\">",
"     15",
"    </a>",
"    ]. Alcohol-based preparations also require less time than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    to affect a maximum reduction in bacteria counts and are at least as tolerable on skin as are antiseptic detergents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/15,20\">",
"     15,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AHD is easier to perform and faster than handwashing with soap and water. This was illustrated in a study that estimated the time required for handwashing and bedside AHD in a typical 14-bed intensive care unit (ICU) with 12 healthcare workers, using an ideal duration of handwashing of 40 to 80 seconds and 20 seconds for AHD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/15\">",
"     15",
"    </a>",
"    ]. If 100 percent compliance were achieved, handwashing would consume 16 hours of nursing time per day shift, compared with only three hours required for AHD.",
"   </p>",
"   <p>",
"    These benefits have led to improved compliance and reductions in nosocomial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In a report from a Swiss teaching hospital, introduction of a bedside alcohol-based hand disinfectant led to a significant improvement in hand hygiene compliance and decreased the rates of nosocomial infection (9.9 versus 16.9 percent) and transmission of methicillin-resistant Staphylococcus aureus (0.9 versus 2.2 episodes per 10,000 patient days) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although AHD improves hand hygiene adherence rates, it is only one component for prevention of infection. A crossover trial of alcohol-based hand gel demonstrated that improved hand hygiene adherence was not associated with detectable changes in the incidence of healthcare-associated infection, although the study was underpowered to detect a statistically significant effect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important limitation of AHD is that it does not reduce the incidence of Clostridium difficile colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/22\">",
"     22",
"    </a>",
"    ]. This reflects the lack of activity of alcohol-based hand rubs against spore-forming bacteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\", section on 'Hand hygiene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3992351\">",
"    <span class=\"h3\">",
"     Prohibiting artificial nails",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the resident microflora of hands is found in the periungual and subungual areas. When the fingernails are long and when artificial fingernails are worn, there is an increase in periungual colonization with a variety of pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/11,24,25\">",
"     11,24,25",
"    </a>",
"    ]. Thus care should be taken to specifically clean fingernails and the surrounding periungual areas during hand hygiene.",
"   </p>",
"   <p>",
"    Both artificial fingernails and inadequately cleaned native fingernails have been epidemiologically linked to outbreaks of infection in intensive care unit patients, neonates, and patients undergoing surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Freshly applied nail polish does not increase the number of bacteria recovered from periungual skin, but chipped nail polish has been associated with increased numbers of organisms on fingernails [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/11,29\">",
"     11,29",
"    </a>",
"    ]. These organisms are not routinely removed by careful handwashing or even by surgical scrubs.",
"   </p>",
"   <p>",
"    Guidelines from the CDC and Association of Operating Room Nurses (AORN) prohibit the use of artificial fingernails or extenders by health care workers with \"direct contact with patients at high risk\" (eg, those in intensive care units or operating rooms) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/11,30\">",
"     11,30",
"    </a>",
"    ]. However, we agree with the policies in many United States hospitals that prohibit the use of artificial nails in all health care workers with direct patient contact.",
"   </p>",
"   <p>",
"    There is no consensus on the need to prohibit the wearing of rings in healthcare settings, even though several studies have shown that skin beneath rings is more heavily colonized with bacteria than adjacent skin not covered by rings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243644849\">",
"    <span class=\"h3\">",
"     Monitoring compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of hand hygiene compliance by dedicated trained personnel is effective to some degree but is time consuming and expensive, and the results are subject to sampling biases. Monitoring use of hand hygiene products, such as soap or alcohol foam, appears to be less useful. Electronic methods have also been employed to monitor compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/31\">",
"     31",
"    </a>",
"    ]. One study of remote video auditing combined with feedback produced a significant and sustained improvement in hand hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitals should develop formal programs to promote and monitor compliance with hand hygiene. Full compliance by hospital personnel with handwashing at a sink is not always practical; waterless alcohol-based hand rubs should be available at the bedside and their use should be promoted over handwashing with soap and water. Because AHD is associated with a tendency to desiccate the skin, the additional use of an appropriate emollient or barrier cream to further protect the skin is important [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend use of alcohol-containing hand disinfection products throughout the hospital because AHD is more efficient than handwashing with soap and water. A detailed review of antimicrobial ingredients designed for handwashing is presented in the CDC guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because AHD is not effective against C. difficile spores, soap and water should be used prior to and after contact with a patient with known or suspected C. difficile colitis (",
"    <a class=\"graphic graphic_table graphicRef77676 \" href=\"UTD.htm?14/28/14795\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\", section on 'Hand hygiene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gloves",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to handwashing, gloves play an important role in reducing the risks of transmission of microorganisms. There are three important reasons why gloves should be worn by hospital personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To provide a protective barrier for the hands from contaminated material such as blood or body fluids, or other potentially infectious material (such as vomit or feces) or from contaminated equipment.",
"     </li>",
"     <li>",
"      To reduce the chance of skin acquisition (colonization) of healthcare workers with microorganisms from a patient who is colonized or infected with pathogenic organisms.",
"     </li>",
"     <li>",
"      To reduce the transmission of existing microorganisms on the hands of hospital staff to patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, wearing gloves does not replace the need for hand hygiene for several reasons: (1) gloves may have small defects or tears that are unapparent, and (2) hands routinely become contaminated during removal of gloves [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. This was illustrated in a report that examined 206 glove pairs after they were worn by surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/34\">",
"     34",
"    </a>",
"    ]. Unrecognized perforations were noted in 14 percent; the majority was on the thumb and index fingers of the gloves [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/34\">",
"     34",
"    </a>",
"    ]. Surgical experience, type of gloves, type of surgery, and double gloving did not affect rates and sites of perforation. Reinforcement of the thumb and index fingers of gloves may be a way to reduce perforation risk.",
"   </p>",
"   <p>",
"    A study of washing gloved hands inoculated with selected nosocomial pathogens demonstrated that organisms (especially Staphylococcus aureus) could still be recovered from hands after the removal of the gloves [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/36\">",
"     36",
"    </a>",
"    ]. These findings are the principle reason why good handwashing",
"    <strong>",
"     after",
"    </strong>",
"    glove removal is essential. Gloves should also be changed between patient contacts. In addition, it is sometimes necessary to change heavily contaminated gloves while caring for a single patient to prevent cross-contamination of body sites or if contamination of portable equipment is likely to occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Masks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Masks are used for three purposes in infection control:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To protect healthcare personnel from infectious material from patients (such as respiratory secretions and aerosols containing blood or body fluids).",
"     </li>",
"     <li>",
"      To protect patients undergoing sterile procedures from respiratory aerosols generated by healthcare personnel.",
"     </li>",
"     <li>",
"      To limit spread of infectious respiratory secretions from patients who are coughing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Masks should not be confused with particulate respirators that are used to prevent transmission by airborne droplet nuclei of infectious agents such as M. tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ISOLATION PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the standard precautions, there are three isolation categories that reflect the major modes of microorganism transmission in nosocomial settings: contact, droplet, and airborne spread [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/8\">",
"     8",
"    </a>",
"    ]. The rooms of patients requiring contact precautions should be clearly marked with signs containing instructions regarding the type of precautions that must be observed. Ample supplies should be readily available outside the patient room to facilitate adherence, and hospital policies should be enforced [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Contact precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microorganisms can be transmitted to patients via contact between the patient and a healthcare worker, or by contact between the patient and a contaminated object (such as toys, clothing, inadequately disinfected endoscopes or other medical equipment) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contact precautions are recommended for the care of patients with selected multidrug-resistant bacteria, and various enteric, parasitic, and viral pathogens (",
"    <a class=\"graphic graphic_table graphicRef50001 \" href=\"UTD.htm?24/18/24877\">",
"     table 1",
"    </a>",
"    ). Ideally, patients who require contact precautions should either be in a private room or cohorted with patients who have the same active infection or are colonized with the same pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthcare workers involved in the care of patients on contact precautions should wear nonsterile gloves for all patient contact. Gowns are required if there is likely to be substantial direct contact with the patient or any infective material. Gowns and gloves should be removed prior to exiting isolation rooms, and hand hygiene must be performed immediately after patient contact. Medical equipment should be dedicated to a single patient when possible, to avoid transfer of pathogens via fomites. Equipment that must be shared should be cleaned and disinfected before use for another patient [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many healthcare workers incorrectly believe that the use of gloves and handwashing are not required upon room entry for patients on contact precautions if no direct contact with patients is anticipated. In fact, the environment in the rooms of such patients are frequently heavily contaminated with pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and C. difficile, thus indirect contamination of hands or clothing is likely to occur if appropriate isolation equipment is not used and if hand hygiene is ignored.",
"   </p>",
"   <p>",
"    Evidence for the efficacy of contact precautions are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\", section on 'Precautions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\", section on 'Contact precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Droplet precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Droplets are particles of respiratory secretions larger than 5 micron. Because droplets remain suspended in the air for limited periods, exposure of less than 3 feet (1 meter) is usually required for human-to-human transmission of droplet-borne pathogens. However, investigations during the 2003 outbreak of severe acute respiratory syndrome (SARS) suggested that droplets can occasionally be transmitted up to 6 feet from the source patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Droplet precautions should be used in the care of patients with suspected or confirmed infections with Neisseria meningitidis, Bordetella pertussis, influenza, adenovirus, Haemophilus influenzae type b, Mycoplasma pneumoniae, rubella, and other pathogens spread by droplets (",
"    <a class=\"graphic graphic_table graphicRef50001 \" href=\"UTD.htm?24/18/24877\">",
"     table 1",
"    </a>",
"    ). A few organisms (eg, some respiratory viruses) can be transmitted by droplets and via direct patient contact. In this setting, both droplet and contact precautions should be implemented.",
"   </p>",
"   <p>",
"    Health care workers within six to ten feet of patients on droplet precautions should wear a facemask [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/5\">",
"     5",
"    </a>",
"    ]. Special air handling systems and use of higher level respirator masks are NOT required for the care of patients with diseases that are capable of droplet transmission. The doors of rooms used to house these patients may remain open, in contrast to airborne precautions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Airborne precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to larger droplets in the preceding section, airborne droplet nuclei are particles of respiratory secretions smaller than 5 micron. Droplet nuclei can remain suspended in the air for extended periods, and thus they can be a source of human inhalational exposure to susceptible individuals.",
"   </p>",
"   <p>",
"    Airborne precautions should be used in the care of patients with suspected or confirmed tuberculosis (TB), measles, varicella, smallpox and SARS. TB is principally transmitted in hospitals by droplet nuclei, and thus the hospital can be a place where TB is transmitted to other patients and healthcare staff [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Healthcare workers immune to measles or varicella need not wear respiratory protection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/41\">",
"     41",
"    </a>",
"    ]. Also, airborne precautions are not needed in the setting of herpes zoster infection.",
"   </p>",
"   <p>",
"    Although SARS is transmitted predominantly by droplet spread and direct contact, airborne transmission can also occur. As a result, the CDC recommends contact and airborne precautions for this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=see_link&amp;anchor=H23#H23\">",
"     \"Severe acute respiratory syndrome (SARS)\", section on 'Infection control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients placed on airborne isolation precautions should be placed in an airborne infection isolation room (AIIR) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/5\">",
"     5",
"    </a>",
"    ]. The AIIR should be a private room with negative air pressure and a minimum of 6 to 12 air changes per hour. Doors to the isolation rooms must remain closed, and all persons entering must wear a respirator with a filtering capacity of 95 percent that allows a tight seal over the nose and mouth.",
"   </p>",
"   <p>",
"    If patients in respiratory isolation require transport outside their isolation rooms for medical procedures, they should wear surgical masks that cover their mouths and noses during transport. Procedures for these patients should be scheduled at times when they can be performed rapidly and when waiting areas are less crowded [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special protective environments are used for patients undergoing hematopoietic cell transplantation to minimize their exposure to invasive fungal infections such as aspergillosis. Such protective environments include HEPA filtration of incoming air, positive room air pressure relative to corridors, directed room air flow, ventilation systems that provide at least 12 air changes per hour, dust control measures and the prohibition of flowers and potted plants in patient rooms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3992580\">",
"    <span class=\"h1\">",
"     PATIENT BATHING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of antiseptic agents for patient bathing has been demonstrated to reduce the rate of hospital-acquired bloodstream infections (due to coagulase-negative staphylococci and fungal pathogens) and the risk of colonization with drug-resistant organisms, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococcus (VRE) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. The greatest efficacy has been demonstrated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    , an antiseptic agent with broad-spectrum activity against many organisms. Among more than 7000 patients in intensive care and bone marrow transplant units randomized to bathing with either 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    -impregnated washcloths or nonantimicrobial washcloths for a six-month period (followed by crossover for the alternate product for the subsequent six months), chlorhexidine bathing was associated with reduction in the rate of hospital-acquired bloodstream infections by 28 percent (6.6 to 4.78 cases per 1000 patient-days) and reduction in the rate of colonization with drug-resistant organisms by 23 percent (from 6.6 to 5.1 cases per 1000 patient-days) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emergence of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    is an important consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/51,53\">",
"     51,53",
"    </a>",
"    ]. In a study including two 15-bed intensive care units over a four-year period, introduction of a chlorhexidine-based surface antiseptic protocol was associated with a 70 percent reduction in MRSA transmission, although transmission of strains carrying the plasmid-born",
"    <span class=\"nowrap\">",
"     qacA/B",
"    </span>",
"    gene (which codes for multidrug efflux pumps and can lead to chlorhexidine resistance) was not reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other issues related to prevention and control of infection due to drug-resistant organisms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=see_link\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL CLEANING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental cleaning, disinfection, and sterilization are basic and important measures used to prevent or reduce infections in the hospital environment. The oversight and monitoring of cleaning, sterilization, and disinfection practices are direct responsibilities of an infection control unit. The exact definition of each term is important, since protocols for each procedure are different and their use in hospital infection control has to be precisely determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cleaning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cleaning is the removal of all foreign material (eg, soil, organic material) from objects. It is normally accomplished with water, mechanical action, and detergents or enzymatic products. Meticulous physical cleaning must always precede disinfection and sterilization procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], and is adequate alone for cleaning items such as blood pressure cuffs.",
"   </p>",
"   <p>",
"    Enforcement of routine environmental cleaning measures, as illustrated in a nonrandomized hospital based intervention study, was remarkably effective in reducing vancomycin-resistant enterococcus (VRE) acquisition among patients in a medical intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of environmental decontamination of rooms previously occupied by patients with MRSA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    VRE in ICUs is illustrated by a retrospective cohort study of patients admitted to eight ICUs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients admitted to rooms previously occupied by patients colonized or infected with MRSA or VRE were significantly more likely to become MRSA or VRE colonized than patients admitted to rooms whose prior occupant was MRSA or VRE negative (adjusted odds ratio [AOR] 1.4 for either MRSA or VRE).",
"   </p>",
"   <p>",
"    Ultraviolet markers may be used to assess the adequacy of environmental cleaning. In one study in which investigators evaluated for persistence of fluorescent markers on environmental surfaces, the efficacy of routine cleaning improved from 49 to 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/58\">",
"     58",
"    </a>",
"    ]. Monitored environmental cleaning should be a fundamental component of all hospitals' commitment to basic hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Disinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disinfection describes a process that eliminates many or all pathogenic microorganisms from inanimate objects, except for bacterial spores. In healthcare settings, disinfection is usually accomplished by the use of liquid chemicals. The efficacy of disinfection is affected by several factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous physical cleaning of the object",
"     </li>",
"     <li>",
"      Organic load on the object",
"     </li>",
"     <li>",
"      Type and level of microbial contamination",
"     </li>",
"     <li>",
"      Concentration of and exposure time to the germicide",
"     </li>",
"     <li>",
"      Physical configuration of the object",
"     </li>",
"     <li>",
"      Temperature and pH of the disinfection process",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sterilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sterilization is the complete elimination of all forms of microbial life. Sterilization can be accomplished by either physical or chemical processes. Steam under pressure, dry heat, low temperature sterilization processes (ethylene oxide gas, plasma sterilization), and liquid chemicals are the main sterilizing agents used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Steam sterilization remains the most widely used technique. Other potential tools for sterilization include ultraviolet irradiation and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    vapor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/60\">",
"     60",
"    </a>",
"    ]; these techniques require further study.",
"   </p>",
"   <p>",
"    A rational approach to disinfection and sterilization of patient care items or equipment was devised in 1968 and is still widely used. Patient care items were divided into critical, semicritical, and noncritical categories according to the degree of risk of infection involved in their use (",
"    <a class=\"graphic graphic_table graphicRef72222 \" href=\"UTD.htm?42/5/43100\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Single-use medical devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reuse of devices labeled \"single-use only\" remains controversial. Many such devices are costly, but their reuse may include the risk of exposing patients to cross-infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/61\">",
"     61",
"    </a>",
"    ]. Reuse is only acceptable if several important criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The device can be adequately cleaned and sterilized",
"     </li>",
"     <li>",
"      The cleaning process does not adversely affect the quality of the device",
"     </li>",
"     <li>",
"      The device will remain safe and effective for its intended use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Commonly reused \"single-use\" devices include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diathermy pencils used in surgery",
"     </li>",
"     <li>",
"      Scissors and forceps used in laparoscopic surgery",
"     </li>",
"     <li>",
"      Sclerosing needles, snares, and cytology brushes used in endoscopy",
"     </li>",
"     <li>",
"      Cannulas, stone-removing baskets, and balloon dilators used in ERCP",
"     </li>",
"     <li>",
"      Angiography catheters used in both cardiology and radiologic imaging",
"     </li>",
"     <li>",
"      Cardiac catheters, pacing electrodes, and pacemakers used in cardiology",
"     </li>",
"     <li>",
"      Bone-marrow trephine sets",
"     </li>",
"     <li>",
"      Plasma membrane filters used in hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/63\">",
"       63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Stopcocks used in bronchoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/63\">",
"       63",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Satisfactory cleaning and sterilization of any device should theoretically prevent infection transmission and make \"single-use\" devices safe to reuse. However, the physical characteristics of some devices (especially those constructed with heat-sensitive materials) may not withstand the process of sterilization and disinfection. Devices with a hollow narrow lumen or tiny narrow crevices",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    devices that cannot be disassembled for cleaning may be difficult or impossible to reliably clean and sterilize via autoclaving or with ethylene oxide. Even when requirements for satisfactory cleaning are followed, organic material frequently remains on these devices [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Disease transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic transmission of Creutzfeldt-Jakob disease (CJD) has occurred in neurosurgical patients when contaminated neurosurgical instruments, such as an implantable electrode that had previously been used in a patient with known CJD, were reused [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/64\">",
"     64",
"    </a>",
"    ]. The electrode had been \"sterilized\" with 70 percent alcohol and formaldehyde vapor, yet two years later the electrode was retrieved and implanted into a chimpanzee in which the disease subsequently developed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/65\">",
"     65",
"    </a>",
"    ]. Contaminated neurosurgical instruments have been suspected as modes of transmission in other patients.",
"   </p>",
"   <p>",
"    The following agents cannot inactivate the CJD prion protein: alcohol, ethylene oxide, formaldehyde, glutaraldehyde,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , iodine, ionizing radiation, phenolics, quaternary ammonium compounds, steam sterilization at 121&ordm;C, and urea at concentrations of 6 to 8",
"    <span class=\"nowrap\">",
"     mol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for sterilization require:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precleaning, soaking in 1 to 2N sodium hydroxide for one hour, followed by steam sterilization at 121&ordm;C for 30 minutes",
"     </li>",
"     <li>",
"      Precleaning, and sterilization at 132&ordm;C for 30 minutes without soaking in sodium hydroxide [",
"      <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Instruments used in neurosurgery on known or suspected cases CJD should not be autoclaved and reused, but should be discarded [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pseudo-outbreaks of infection from reuse of single-use devices [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/63\">",
"     63",
"    </a>",
"    ] and cross-infection with serious bloodborne pathogens have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/61,69\">",
"     61,69",
"    </a>",
"    ]. An independent health research firm concluded that there is no clear evidence that reuse of single-use devices is either safe or unsafe for patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Food and Drug Administration (FDA) recommends that single-use devices must be reprocessed with the same quality assurance and safety criteria used by the original manufacturer. One group studied whether reprocessed single-use devices would meet regulatory standards for sterility [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/70\">",
"     70",
"    </a>",
"    ]. Shockingly, they found that none of the reprocessed single-use instruments were effectively cleaned, disinfected, or sterilized. Given the stringency of the FDA directives, and the above data, it is likely that hospitals cannot comply with the regulations on reuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance for nosocomial infections is the cornerstone of all successful hospital infection control programs. The collection of accurate and relevant surveillance data in real time allows infection control practitioners to identify and understand important nosocomial or non-nosocomial (eg, long-term care facilities) infections or pathogens and to detect epidemics or outbreaks.",
"   </p>",
"   <p>",
"    Detection of clusters of infection often leads to the identification of preexisting systematic problems within the institution, such as surgical practices associated with an increase in surgical site infections (SSI) or failure to change tubing or other equipment on an appropriate schedule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effective surveillance involves counting cases, calculating rates of various infections, and reporting the data in an appropriate way to personnel involved in patient care [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Infection control programs that include SSI surveillance coupled with feedback are effective in reducing the rate of SSI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surveillance is only a starting point for most infection prevention programs. Surveillance often provides an important benchmark for assessing the need for and the effectiveness of intervention strategies. Surveillance without clear plans to use the data that are collected for specific and designated purposes is generally unwise.",
"   </p>",
"   <p>",
"    Surveillance can also result in the recognition of problems with products or materials with consequences far beyond a single institution. As an example, three early deaths from septic shock in previously healthy individuals undergoing total knee replacement (two) or cartilage graft replacement (one) were reported to the Minnesota Department of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/74\">",
"     74",
"    </a>",
"    ]. One patient had Clostridium sordellii isolated from the blood. Subsequent culture of unimplanted tissue from the same donor source as the osteochondral graft also grew Clostridium.",
"   </p>",
"   <p>",
"    A subsequent investigation by personnel from the CDC identified 26 other allograft recipients with clostridial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/75\">",
"     75",
"    </a>",
"    ]. As a result of this investigation, the CDC issued an advisory to tissue processors outlining additional steps to enhance tissue transplant safety and alerted clinicians to consider clostridial sepsis in allograft recipients with evidence of infection following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although surveillance is predominantly a component of acute care hospital infection control programs, it is also important in long-term care facilities (LTCF). Researchers have demonstrated infection rates of 3.6 and 6.0 infections per 1000 resident-days respectively in a LTCF in Utah [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/77\">",
"     77",
"    </a>",
"    ], and a German nursing home [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/78\">",
"     78",
"    </a>",
"    ]. In these studies, respiratory tract infections, gastroenteritis, skin and soft tissue infections, and urinary tract infections represented the majority of nosocomial infections. Surveillance in LTCF, although more challenging than surveillance in acute care hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/79\">",
"     79",
"    </a>",
"    ], can allow meaningful comparisons between facilities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/489?source=see_link&amp;anchor=H9#H9\">",
"     \"Principles of infection control in long-term care facilities\", section on 'Surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nosocomial infection rates can also be used to perform comparisons among hospitals. A prevalence study performed over a one week period in 18 acute care hospitals in Switzerland highlighted a problem with this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/80\">",
"     80",
"    </a>",
"    ]. Unadjusted nosocomial infection rates showed a significantly lower prevalence rate in smaller compared with intermediate or large hospitals (6.1 versus 10 and 10.9 percent, respectively). However, when case mix was considered in a multivariate analysis, hospital size was no longer a significant factor.",
"   </p>",
"   <p>",
"    It is important to note that comparisons among hospitals are only valid when there is adjustment for the overall health of the patient and specific surgical factors, as in the CDC's National Nosocomial Infection Surveillance System (NNIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/81\">",
"     81",
"    </a>",
"    ]. For example, rates of surgical site infections for many common surgical procedures in small community hospitals (median bed size 220) were different (many were lower; although a few were higher) from rates for the same procedures reported by the National Nosocomial Infection Study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Targeted hospital surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC first proposed hospital-wide surveillance in 1972. However, such surveillance was extremely labor intensive and actually provided few practical data about preventable infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/9\">",
"     9",
"    </a>",
"    ]. In 1986, the CDC introduced and promoted the concept of targeted hospital surveillance, and since then, targeted surveillance has become an essential part of most hospital infection control programs.",
"   </p>",
"   <p>",
"    Targeted surveillance must be defined in each hospital. Ideally, such surveillance should include specific patient populations or units at high risk for infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    selected infections that represent the highest priority, most serious consequences, or are highly preventable. As an example, surveillance of rotavirus infections may be a priority in pediatric hospitals, whereas surveillance of urinary catheter-associated infections may be a focus of targeted surveillance in a hospital that includes a large rehabilitation unit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Components of surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective surveillance systems require clear and uniform definitions of nosocomial infections, such as those developed by the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/83\">",
"     83",
"    </a>",
"    ]. Uniform definitions allow for comparisons of infection rates both locally and internationally. Surveillance should also be active and include routine review of microbiologic, pathologic, clinical, and nursing records. Effective surveillance systems usually include most of the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Routine review of microbiologic records",
"     </li>",
"     <li>",
"      Daily, weekly or biweekly rounds on wards",
"     </li>",
"     <li>",
"      Review of selected discharge diagnoses, codes, or key words",
"     </li>",
"     <li>",
"      Review of patients who are readmitted following surgical procedures or of patients who undergo reoperation",
"     </li>",
"     <li>",
"      Review of autopsy, radiologic, and pathologic reports",
"     </li>",
"     <li>",
"      Reports from nursing, medical, or surgical staff members of known or suspected infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Effective surveillance systems have some degree of redundancy in order to reduce systematic errors (information bias). This redundancy is effective if most or many infections are reported by more than one method. The surveillance of SSI, for example, should rely upon microbiologic data, regular ward rounds by infection control practitioners, and solicitation of reports of known or possible infection from surgeons and nurses during and after hospital discharge.",
"   </p>",
"   <p>",
"    Automated statistical tools using downloads from hospital information systems have been used to detect nosocomial infections. Such systems have the potential to identify outbreaks that may be missed by routine detection methods [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/84\">",
"     84",
"    </a>",
"    ]. Such systems, available from several commercial vendors, are usually expensive and often require extensive support from information technology personnel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Surveillance cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential component of surveillance is active surveillance cultures. This has primarily been studied for the control of methicillin-resistant Staphylococcus aureus and vancomycin-resistance enterococci. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\", section on 'Surveillance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\", section on 'Surveillance cultures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ADDITIONAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Regulatory bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The JCAHO is a nongovernmental organization that devises standards of quality used to accredit hospitals. These standards are varied and range from the responsibilities of the administration to employee education, safety in the workplace, and ethics. The JCAHO mandated in 1970 that all hospitals have infection control committees as a requirement for accreditation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/16\">",
"     16",
"    </a>",
"    ]. Accreditation is voluntary, although most hospitals view it as mandatory [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Occupational Safety and Health Administration (OSHA), established in 1970, is part of the United States Department of Labor and operates in all states under federal jurisdiction. OSHA has enforcement activities in the area of preventing occupational risk of bloodborne pathogen infections, and released the final standard on these exposures, which came into effect in 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/86\">",
"     86",
"    </a>",
"    ]. The standard requires employers to provide hepatitis B vaccination, personal protective clothing and equipment, postexposure medical evaluation and follow-up, and specific education and training. OSHA conducts periodic inspections of healthcare facilities to check their compliance with several standards and other inspections in response to various hazards and employee complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Quality assessment, risk management and continuous quality improvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components of quality monitoring include data collection and analysis, interpretation, remedial action to correct poor quality, and verification that these actions actually improved quality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/85\">",
"     85",
"    </a>",
"    ]. Both quality assessment and risk-management programs were developed primarily by administrators in response to economic forces, particularly the rising costs of care and malpractice suits [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/88\">",
"     88",
"    </a>",
"    ]. Traditional quality improvement and risk-management programs rely upon empiric case analysis and the occurrence of sentinel events, rather than the rates of specific events in populations. However, this approach has some serious deficiencies. The most serious flaw is the absence of predetermined baseline rates, which impairs the analysis of the significance of an event and the effect of an intervention. This approach has also not been shown to be cost effective. Infection control practitioners should be involved in shaping the quality assessment movement based upon a solid epidemiologic foundation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuous quality improvement (CQI) is a management technique originally based upon principles used in industry, but subsequently adapted for assessing the quality of care in healthcare facilities. Studying the relationship between a practice and an outcome, such as the timing of antibiotic administration and rates of SSI, is an example of CQI applied to healthcare. Epidemiology should be the cornerstone of CQI, which requires a system of careful surveillance, analysis, feedback, and education to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SAFETY INITIATIVES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Protecting 5 Million Lives campaign",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Institute of Medicine initiated a Protecting 5 Million Lives Campaign that included measures to reduce certain nosocomial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/89\">",
"     89",
"    </a>",
"    ]. The plan included five components: active surveillance cultures, hand hygiene, decontamination of the environment and equipment, contact precautions for infected and colonized patients, and the use of device bundles (central line bundle and ventilator bundle).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     National Patient Safety Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Patient Safety Goals for hospitals were introduced in January 2010 by the Joint Commisssion. These require hospitals to develop specific programs to address the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hand hygiene compliance",
"     </li>",
"     <li>",
"      The prevention of infections due to multi-drug resistant organisms",
"     </li>",
"     <li>",
"      Central line-associated bloodstream infections",
"     </li>",
"     <li>",
"      Surgical site infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Public reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Public reporting of nosocomial infection rates in hospitals is a state government-based initiative aimed at reducing infection rates and improving patient safety. Thirty-nine states have introduced legislation and six states have passed laws requiring disclosure of hospital-acquired infections to the state and, in most cases, to the public [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/90\">",
"     90",
"    </a>",
"    ]. Such public reporting is focused on process and outcome measures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reporting of infection rates through the CDC's National Healthcare Safety Network focuses on three types of common infections associated with high morbidity and mortality and likely to be controllable. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infections associated with central venous catheters",
"     </li>",
"     <li>",
"      Surgical site infections",
"     </li>",
"     <li>",
"      Ventilator-associated pneumonia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further research is needed to identify the most meaningful measures to report, to determine the best way to report infections, and assess whether such reporting improves patient safety. There is insufficient evidence on the merits and limitations of an HAI public reporting system. Therefore, the Healthcare Infection Control Practices Advisory Committee (HICPAC) has not recommended for or against mandatory public reporting of HAI rates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/12/19658/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8404266\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection control programs aim to prevent and reduce rates of nosocomial infections. Major components include standard (universal) precautions, isolation precautions, environmental cleaning, and surveillance (",
"      <a class=\"graphic graphic_table graphicRef50001 \" href=\"UTD.htm?24/18/24877\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard precautions are recommended in the care of all hospitalized patients. They can reduce the risk of transmission of infection between patients and healthcare workers, even when the presence of an infectious agent is unknown or not apparent. The precautions include hand hygiene before and after every patient contact, use of gloves, gowns and eye protection (for situations in which exposure to body fluids is possible), and safe disposal of sharp instruments in impervious containers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Standard precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hand hygiene refers to handwashing with soap and water or the use of alcohol-based gels or foams that do not require the use of water. Hand hygiene is the single most important measure to reduce transmission of microorganisms from one person to another or one site to another on the same patient (",
"      <a class=\"graphic graphic_table graphicRef77676 \" href=\"UTD.htm?14/28/14795\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hand hygiene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three isolation categories that reflect the major modes of microorganism transmission in nosocomial settings: contact, droplet, and airborne spread (",
"      <a class=\"graphic graphic_table graphicRef50001 \" href=\"UTD.htm?24/18/24877\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Isolation precautions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Contact precautions: Healthcare workers involved in the care of patients on contact precautions should wear nonsterile gloves for all patient contact. Gowns are required if there is likely to be substantial direct contact with the patient or any infective material. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Contact precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Droplet precautions: Healthcare workers within six to ten feet of patients on droplet precautions should wear a facemask. Use of higher level respirator masks is not required. The doors of rooms used to house these patients may remain open. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Droplet precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Airborne precautions: Patients placed on airborne isolation precautions should be placed in an airborne infection isolation room, a private room with negative air pressure and a minimum of 6 to 12 air changes per hour. Doors to the isolation rooms must remain closed, and all persons entering must wear a respirator with a filtering capacity of 95 percent that allows a tight seal over the nose and mouth. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Airborne precautions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Environmental cleaning, disinfection, and sterilization are important measures used to prevent or reduce infections in the hospital environment. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Environmental cleaning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      bathing among intensive care unit patients to reduce hospital-acquired bloodstream infections and the risk of colonization acquisition with multi-drug resistant organisms (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3992580\">",
"       'Patient bathing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surveillance for nosocomial infections is the cornerstone of successful hospital infection control programs. The collection of accurate surveillance data in real time allows infection control practitioners to identify and understand important pathogens and to detect outbreaks. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/1\">",
"      Haley RW, Culver DH, White JW, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 1985; 121:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/2\">",
"      Hall CB. The spread of influenza and other respiratory viruses: complexities and conjectures. Clin Infect Dis 2007; 45:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/3\">",
"      Harbarth S. Handwashing-the Semmelweis lesson misunderstood? Clin Infect Dis 2000; 30:990.",
"     </a>",
"    </li>",
"    <li>",
"     Edmond MB, Wenzel RP. Organization for Infection Control. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia, PA 2005. p.3323.",
"    </li>",
"    <li>",
"     Siegel JD, Rhinehart E, Jackson M, et al. Healthcare Infection Control Practices Advisory Committee 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings, June 2007 file://www.cdc.gov/ncidod/dhqp/gl_isolation.html (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/6\">",
"      Garner JS, Simmons BP. Guideline for isolation precautions in hospitals. Infect Control 1983; 4:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/7\">",
"      Garner JS. Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996; 24:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/8\">",
"      Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/9\">",
"      Whitehouse JD, Sexton DJ, Kirkland KB. Infection control: past, present, and future issues. Compr Ther 1998; 24:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/10\">",
"      Pittet D, Allegranzi B, Sax H, et al. Evidence-based model for hand transmission during patient care and the role of improved practices. Lancet Infect Dis 2006; 6:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/11\">",
"      Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. SAVE LIVES: Clean Your Hands: WHO's global annual campaign file://www.who.int/gpsc/5may/en/ (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/13\">",
"      Gould DJ, Chudleigh JH, Moralejo D, Drey N. Interventions to improve hand hygiene compliance in patient care. Cochrane Database Syst Rev 2007; :CD005186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/14\">",
"      Pittet D, Mourouga P, Perneger TV. Compliance with handwashing in a teaching hospital. Infection Control Program. Ann Intern Med 1999; 130:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/15\">",
"      Voss A, Widmer AF. No time for handwashing!? Handwashing versus alcoholic rub: can we afford 100% compliance? Infect Control Hosp Epidemiol 1997; 18:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/16\">",
"      Quraishi ZA, McGuckin M, Blais FX. Duration of handwashing in intensive care units: a descriptive study. Am J Infect Control 1984; 12:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/17\">",
"      Eckmanns T, Bessert J, Behnke M, et al. Compliance with antiseptic hand rub use in intensive care units: the Hawthorne effect. Infect Control Hosp Epidemiol 2006; 27:931.",
"     </a>",
"    </li>",
"    <li>",
"     2011 National Patient Safety Goals file://www.jointcommission.org/patientsafety/nationalpatientsafetygoals/ (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/19\">",
"      Noskin GA, Stosor V, Cooper I, Peterson LR. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol 1995; 16:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/20\">",
"      Larson E. Skin hygiene and infection prevention: more of the same or different approaches? Clin Infect Dis 1999; 29:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/21\">",
"      Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000; 356:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/22\">",
"      Gordin FM, Schultz ME, Huber RA, Gill JA. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. Infect Control Hosp Epidemiol 2005; 26:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/23\">",
"      Rupp ME, Fitzgerald T, Puumala S, et al. Prospective, controlled, cross-over trial of alcohol-based hand gel in critical care units . Infect Control Hosp Epidemiol 2008; 29:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/24\">",
"      Pottinger J, Burns S, Manske C. Bacterial carriage by artificial versus natural nails. Am J Infect Control 1989; 17:340.",
"     </a>",
"    </li>",
"    <li>",
"     McNeil SA, Phelps A, Barnes AL, Kauffman CA. The effect of fingernail length on microbial colonization of the hands of healthcare workers [abstract]. 39th Annual IDSA, October 25-28, San Francisco, CA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/26\">",
"      Moolenaar RL, Crutcher JM, San Joaquin VH, et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? Infect Control Hosp Epidemiol 2000; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/27\">",
"      Parry MF, Grant B, Yukna M, et al. Candida osteomyelitis and diskitis after spinal surgery: an outbreak that implicates artificial nail use. Clin Infect Dis 2001; 32:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/28\">",
"      Passaro DJ, Waring L, Armstrong R, et al. Postoperative Serratia marcescens wound infections traced to an out-of-hospital source. J Infect Dis 1997; 175:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/29\">",
"      Wynd CA, Samstag DE, Lapp AM. Bacterial carriage on the fingernails of OR nurses. AORN J 1994; 60:796, 799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/30\">",
"      Rubin DM. Prosthetic fingernails in the OR. A research study. AORN J 1988; 47:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/31\">",
"      Boyce JM. Hand hygiene compliance monitoring: current perspectives from the USA. J Hosp Infect 2008; 70 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/32\">",
"      Armellino D, Hussain E, Schilling ME, et al. Using high-technology to enforce low-technology safety measures: the use of third-party remote video auditing and real-time feedback in healthcare. Clin Infect Dis 2012; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     Emergency Care Research Institute. Special Report: Reuse of single-use medical devices: Making informed decisions. Plymouth Meeting, PA: ECRI; 1997:1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/34\">",
"      Alrawi S, Houshan L, Satheesan R, et al. Glove reinforcement: an alternative to double gloving. Infect Control Hosp Epidemiol 2001; 22:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/35\">",
"      Fuller C, Savage J, Besser S, et al. \"The dirty hand in the latex glove\": a study of hand hygiene compliance when gloves are worn. Infect Control Hosp Epidemiol 2011; 32:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/36\">",
"      Doebbeling BN, Pfaller MA, Houston AK, Wenzel RP. Removal of nosocomial pathogens from the contaminated glove. Implications for glove reuse and handwashing. Ann Intern Med 1988; 109:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/37\">",
"      Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/38\">",
"      Cronmiller JR, Nelson DK, Jackson DK, Kim CH. Efficacy of conventional endoscopic disinfection and sterilization methods against Helicobacter pylori contamination. Helicobacter 1999; 4:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/39\">",
"      Rey JF. Endoscopic disinfection: a worldwide problem. J Clin Gastroenterol 1999; 28:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/40\">",
"      Esteban J, Gadea I, Fern&auml;ndez-Roblas R, et al. Pseudo-outbreak of Aeromonas hydrophila isolates related to endoscopy. J Hosp Infect 1999; 41:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/41\">",
"      Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. Centers for Disease Control and Prevention. MMWR Recomm Rep 1994; 43:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/42\">",
"      McDonald LC, Archibald LK, Rheanpumikankit S, et al. Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. Lancet 1999; 354:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/43\">",
"      Do AN, Limpakarnjarat K, Uthaivoravit W, et al. Increased risk of Mycobacterium tuberculosis infection related to the occupational exposures of health care workers in Chiang Rai, Thailand. Int J Tuberc Lung Dis 1999; 3:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/44\">",
"      Cookson ST, Jarvis WR. Prevention of nosocomial transmission of Mycobacterium tuberculosis. Infect Dis Clin North Am 1997; 11:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/45\">",
"      Wilder-Smith A, Low JG. Risk of respiratory infections in health care workers: lessons on infection control emerge from the SARS outbreak. Southeast Asian J Trop Med Public Health 2005; 36:481.",
"     </a>",
"    </li>",
"    <li>",
"     Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS) file://www.cdc.gov/ncidod/sars/guidance/I/index.htm (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/47\">",
"      Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/48\">",
"      Vernon MO, Hayden MK, Trick WE, et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006; 166:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/49\">",
"      Bleasdale SC, Trick WE, Gonzalez IM, et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007; 167:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/50\">",
"      Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009; 37:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/51\">",
"      Batra R, Cooper BS, Whiteley C, et al. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2010; 50:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/52\">",
"      Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: expanding the armamentarium for infection control and prevention. Clin Infect Dis 2008; 46:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/53\">",
"      Lee AS, Macedo-Vinas M, Fran&ccedil;ois P, et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis 2011; 52:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/54\">",
"      Rutala WA. APIC guideline for selection and use of disinfectants. 1994, 1995, and 1996 APIC Guidelines Committee. Association for Professionals in Infection Control and Epidemiology, Inc. Am J Infect Control 1996; 24:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/55\">",
"      Rutala WA, Weber DJ. Disinfection and sterilization in health care facilities: what clinicians need to know. Clin Infect Dis 2004; 39:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/56\">",
"      Hayden MK, Bonten MJ, Blom DW, et al. Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures. Clin Infect Dis 2006; 42:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/57\">",
"      Huang SS, Datta R, Platt R. Risk of acquiring antibiotic-resistant bacteria from prior room occupants. Arch Intern Med 2006; 166:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/58\">",
"      Carling PC, Parry MF, Bruno-Murtha LA, Dick B. Improving environmental hygiene in 27 intensive care units to decrease multidrug-resistant bacterial transmission. Crit Care Med 2010; 38:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/59\">",
"      Miller BA, Sexton DJ. Shedding light on new methods to improve hospital cleanliness: the use of ultraviolet monitors as surrogate markers for bacterial contamination. Crit Care Med 2010; 38:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/60\">",
"      Passaretti CL, Otter JA, Reich NG, et al. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. Clin Infect Dis 2013; 56:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/61\">",
"      Collignon PJ, Graham E, Dreimanis DE. Reuse in sterile sites of single-use medical devices: how common is this in Australia? Med J Aust 1996; 164:533.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration Compliance Policy Guide. Reuse of medical disposable devices, 7124.6, FDA, Washington, DC 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/63\">",
"      Wilson SJ, Everts RJ, Kirkland KB, Sexton DJ. A pseudo-outbreak of Aureobasidium species lower respiratory tract infections caused by reuse of single-use stopcocks during bronchoscopy. Infect Control Hosp Epidemiol 2000; 21:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/64\">",
"      Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1977; 1:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/65\">",
"      Masters CL, Harris JO, Gajdusek DC, et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979; 5:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/66\">",
"      Fishman M, Fort GG, Mikolich DJ. Prevention of Creutzfeldt-Jakob disease in health care workers: a case study. Am J Infect Control 1998; 26:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/67\">",
"      Taguchi F, Tamai Y, Uchida K, et al. Proposal for a procedure for complete inactivation of the Creutzfeldt-Jakob disease agent. Arch Virol 1991; 119:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/68\">",
"      Taylor DM. Creutzfeldt-Jakob disease. Lancet 1996; 347:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/69\">",
"      Macedo de Oliveira A, White KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med 2005; 142:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/70\">",
"      Heeg P, Roth K, Reichl R, et al. Decontaminated single-use devices: an oxymoron that may be placing patients at risk for cross-contamination. Infect Control Hosp Epidemiol 2001; 22:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/71\">",
"      Kirkland KB, Briggs JP, Trivette SL, et al. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999; 20:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/72\">",
"      Kaye KS, Engemann JJ, Fulmer EM, et al. Favorable impact of an infection control network on nosocomial infection rates in community hospitals. Infect Control Hosp Epidemiol 2006; 27:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/73\">",
"      Gaynes R, Richards C, Edwards J, et al. Feeding back surveillance data to prevent hospital-acquired infections. Emerg Infect Dis 2001; 7:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/74\">",
"      Centers for Disease Control and Prevention (CDC). Unexplained deaths following knee surgery--Minnesota, November 2001. MMWR Morb Mortal Wkly Rep 2001; 50:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/75\">",
"      Centers for Disease Control and Prevention (CDC). Update: allograft-associated bacterial infections--United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/76\">",
"      Centers for Disease Control and Prevention (CDC). Update: Unexplained deaths following knee surgery--Minnesota, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/77\">",
"      Stevenson KB, Moore J, Colwell H, Sleeper B. Standardized infection surveillance in long-term care: interfacility comparisons from a regional cohort of facilities. Infect Control Hosp Epidemiol 2005; 26:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/78\">",
"      Engelhart ST, Hanses-Derendorf L, Exner M, Kramer MH. Prospective surveillance for healthcare-associated infections in German nursing home residents. J Hosp Infect 2005; 60:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/79\">",
"      Bradley SE. Double, double, toil and trouble: infections still spreading in long-term-care facilities. Infect Control Hosp Epidemiol 2005; 26:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/80\">",
"      Sax H, Pittet D, Swiss-NOSO Network. Interhospital differences in nosocomial infection rates: importance of case-mix adjustment. Arch Intern Med 2002; 162:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/81\">",
"      Horan TC, Emori TG. Definitions of key terms used in the NNIS System. Am J Infect Control 1997; 25:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/82\">",
"      Anderson DJ, Sexton DJ, Kanafani ZA, et al. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/83\">",
"      Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/84\">",
"      Huang SS, Yokoe DS, Stelling J, et al. Automated detection of infectious disease outbreaks in hospitals: a retrospective cohort study. PLoS Med 2010; 7:e1000238.",
"     </a>",
"    </li>",
"    <li>",
"     Wenzel RP. Organization for infection control. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 5th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000. p.2988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/86\">",
"      Department of Labor, Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens: final rule. Fed Reg 1991; 56: 64175.",
"     </a>",
"    </li>",
"    <li>",
"     McDonald LL, Pugliese G. Regulatory, accreditation, and professional agencies influencing infection control programs. In: Prevention and control of nosocomial infections, 2nd ed, Wenzel RP (Ed), Williams &amp; Wilkins, Baltimore 1993. p.58.",
"    </li>",
"    <li>",
"     Herwaldt LA. National issues and future concerns. In: Prevention and control of nosocomial infections, 2nd ed, Wenzel RP (Ed), Williams &amp; Wilkins, Baltimore 1993. p.1001.",
"    </li>",
"    <li>",
"     Institute for Healthcare Improvement file://www.ihi.org/IHI/Programs/Campaign (Accessed on December 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/90\">",
"      Weinstein RA, Siegel JD, Brennan PJ. Infection-control report cards--securing patient safety. N Engl J Med 2005; 353:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/12/19658/abstract/91\">",
"      McKibben L, Horan T, Tokars JI, et al. Guidance on public reporting of healthcare-associated infections: recommendations of the Healthcare Infection Control Practices Advisory Committee. Am J Infect Control 2005; 33:217.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4042 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-ADE281C057-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19658=[""].join("\n");
var outline_f19_12_19658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8404266\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STANDARD PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hand hygiene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Soap and water",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Alcohol based hand disinfection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3992351\">",
"      - Prohibiting artificial nails",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H243644849\">",
"      - Monitoring compliance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gloves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Masks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ISOLATION PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Contact precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Droplet precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Airborne precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3992580\">",
"      PATIENT BATHING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ENVIRONMENTAL CLEANING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cleaning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Disinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sterilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Single-use medical devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Disease transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Targeted hospital surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Components of surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Surveillance cultures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ADDITIONAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Regulatory bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Quality assessment, risk management and continuous quality improvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SAFETY INITIATIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Protecting 5 Million Lives campaign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      National Patient Safety Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Public reporting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8404266\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/4042\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/4042|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/18/24877\" title=\"table 1\">",
"      Isolation precautions system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/28/14795\" title=\"table 2\">",
"      Hand hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/5/43100\" title=\"table 3\">",
"      Sterilization processes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=related_link\">",
"      Epidemiology, prevention and control of vancomycin-resistant enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=related_link\">",
"      Prevention and control of Clostridium difficile in hospital and institutional settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/489?source=related_link\">",
"      Principles of infection control in long-term care facilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=related_link\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_12_19659="Fractures and associated nerve injuries";
var content_f19_12_19659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fractures and their associated nerve injuries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fracture",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        <strong>",
"         Upper extremity",
"        </strong>",
"       </td>",
"       <td>",
"        Clavicle",
"       </td>",
"       <td>",
"        Brachial plexus (C5-T1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Humerus shaft",
"       </td>",
"       <td>",
"        Radial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supracondylar (humerus)",
"       </td>",
"       <td>",
"        Median, anterior interosseus, ulnar, radial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal radius/ulna",
"       </td>",
"       <td>",
"        <p>",
"         Median",
"        </p>",
"        <p>",
"         Ulnar",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scaphoid",
"       </td>",
"       <td>",
"        Median (acute carpal tunnel)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Lower extremity",
"        </strong>",
"       </td>",
"       <td>",
"        Pelvis",
"       </td>",
"       <td>",
"        Lumbosacral plexopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetabulum",
"       </td>",
"       <td>",
"        Sciatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibular head",
"       </td>",
"       <td>",
"        Peroneal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19659=[""].join("\n");
var outline_f19_12_19659=null;
var title_f19_12_19660="Tx of resistant depression";
var content_f19_12_19660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment-resistant depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Patients who do not respond to typical antidepressant monotherapy with which most primary care physicians are comfortable may require additional strategies, including switching to different antidepressants, using a combination of medications, or using various augmentation strategies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The following strategies have varying levels of evidence, but they are frequently used by consultants and experts in the pharmacologic treatment of depression:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Switch to another agent of the same class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Switch to an agent of a different class (eg, from an SSRI to an SNRI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Switch to or add another agent (eg, an SSRI plus bupropion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Switch to an MAOI (with an appropriate washout of the previous SSRI to avoid the serotonergic syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Combine an SSRI at full dose and a tricyclic antidepressant at a low dose (eg, 15 to 30 mg/day of most TCAs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Combine an SSRI at full dose and mirtazapine at medium to full dose (eg, 15 to 30 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Augment with lithium in addition to an antidepressant, titrated by blood level, with a goal of 0.6 to 1.0 mEq/l (typically a dose of 600 to 900 mg/day, often dosed at bedtime)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Add thyroid hormone supplementation in euthyroid patients (eg, 50 to 75 mcg/day of triiodothyronine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Add an atypical antipsychotic (eg, olanzapine 5 to 15 mg at bedtime, ziprasidone 40 to 160 mg/day, risperidone 1 to 4 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Add a stimulant medication (eg, methylphenidate 20 to 40 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Add anticonvulsant agents (eg, lamotrigine 100 to 200 mg/day)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SSRI: selective serotonin reuptake inhibitor; SNRI: serotonin norepinephrine reputake inhibitor; TCA: tricyclic antidepressant; MAOI: monoamine oxidase inhibitor.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        file://cme.med.umich.edu/pdf/guideline/depression04.pdf (Accessed 8/16/04).",
"       </li>",
"       <li>",
"        Rosenbaum, JF, Fava, M. The Patient With Depression. In: MGH Guide to Primary Care Psychiatry, Stern, TA, Herman, JB, Slavin, PL (Eds), McGraw-Hill, New York 2004. p.111.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19660=[""].join("\n");
var outline_f19_12_19660=null;
var title_f19_12_19661="Rapid overview emergency management severe upper GI bleeding";
var content_f19_12_19661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview: Emergency management of severe upper GI bleeding",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptic ulcer, esophagogastric varices, arteriovenous malformation, tumor, esophageal (Mallory-Weiss) tear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Use of: NSAIDs, aspirin, anticoagulants, antiplatelet agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcohol abuse; previous GI bleed; liver disease; coagulopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Symptoms and signs: Abdominal pain; hematemesis or \"coffee ground\" emesis; passing melena/tarry stool (stool may be frankly bloody or maroon with massive or brisk upper GI bleeding)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tachycardia, orthostatic blood pressure changes suggest moderate to severe blood loss; hypotension suggests life-threatening blood loss (hypotension may be late finding in healthy younger adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rectal examination is performed to assess stool color (melena vs hematochezia vs brown) and perform guaiac testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Significant abdominal tenderness accompanied by signs of peritoneal irritation (eg, involuntary guarding) suggests perforation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain type and screen (or type and crossmatch for hemodynamic instability, severe bleeding, or high-risk patient)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain hemoglobin concentration (normal measurement may be inaccurate with acute severe hemorrhage), platelet count, coagulation studies (prothrombin time with INR), liver enzymes (AST, ALT), albumin, BUN and creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasogastric lavage may be helpful if the source of bleeding is unclear (upper or lower GI tract) or to clean the stomach prior to endoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Closely monitor airway, clinical status, vital signs, cardiac rhythm, urine output, nasogastric output (if nasogastric tube in place)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do NOT give patient anything by mouth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish two large bore IV lines (16 gauge or larger)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide supplemental oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat hypotension initially with rapid, bolus infusions of isotonic crystalloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Transfuse for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemodynamic instability despite crystalloid resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemoglobin &lt;10 g/dL (100 g/L) in high-risk patients (eg, elderly, coronary artery disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemoglobin &lt;7 g/dL (70 g/L) in low-risk patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Avoid over-transfusion with possible variceal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give fresh frozen plasma for coagulopathy; give platelets for thrombocytopenia (platelets &lt;50,000) or platelet dysfunction (eg, chronic aspirin therapy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain immediate consultation with gastroenterologist; obtain surgical and interventional radiology consultation for any large-scale bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pharmacotherapy for all patients with suspected or known severe bleeding:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give a proton pump inhibitor (eg, Esomeprazole 80 mg IV bolus, followed by 8 mg/hour OR Pantoprazole 80 mg IV bolus, followed by 8 mg/hour infusion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pharmacotherapy for known or suspected esophagogastric variceal bleeding and/or cirrhosis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give somatostatin or an analogue (eg, Octreotide 50 mcg bolus, followed by 50 mcg/hour infusion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give an antibiotic (eg, Ceftriaxone, Amoxicillin-clavulanate, or Quinolone)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Balloon tamponade may be performed as a temporizing measure for patients with uncontrollable hemorrhage likely due to varices using any of several devices (eg, Sengstaken-Blakemore tube, Minnesota tube); tracheal intubation is necessary if such a device is to be placed; ensure proper device placement prior to inflation to avoid esophageal rupture",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19661=[""].join("\n");
var outline_f19_12_19661=null;
var title_f19_12_19662="WCT algorithm";
var content_f19_12_19662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brief summary of the new stepwise, decision-tree algorithm's use",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 534px; background-image: url(data:image/gif;base64,R0lGODlhkAEWAtUAAP///8DAwAAAAEBAQICAgIiIiBEREczMzERERO7u7n9/fzMzMyIiIlVVVT8/P7u7u6qqqt3d3WZmZnd3d5mZmb+/v+Dg4DAwMBAQENDQ0GBgYCAgIKCgoPDw8JCQkHBwcFBQUB8fH7CwsF9fXy8vLw8PDwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACQARYCAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2YHQGhoqOkpaanqKmqq6ytrq+wqx2etGwBGAO5uru8vb6/wMHCw8TFxsfIwRgBtc1oAQPOgQPM0tZh0Nd+1NrdXNneetzh5FXg5Xbj6OtO5+xy6u/yR+7zbvH2+fX5a/j88vv+ofEncF3AgmUIItwDAYEAAQgmJEjw8ICVBwIMLDnY5YCABQuFKAx5xyODCAAOIDhAUYBFKgYealTCcciEhw+MYGQgZOcR/48gF7jMIvRlkQICJgCgOPNOzAQAIjB4iABlkpEk6yBdAHVIzIcgKUyFGKGlw6Q/M26MtmSshCNTc95UagToGaR09zwFAKEAAKRvr1bLusfjQwENICytCAAjgr8QW0JIELeuWppsk0D4aMBAVyJ4AUw1mnJqTJANXCY4K6DA6sOuzzJQnCD1QwipDxh+WGC3gASdl8pWLNS23yGbF8R8nHwBSKS8UwqtqJJq2YwODRywjVbIXCVYCc85cPMwS8YSDstsaTH1cSIemyKpCcC9ewDTf0cQMBtikdF25XZTYAAMOERqkzHg2X1C5DZEfJDRFRyClHkm1AMYybdZAwCkV//AZmCFNlUEQlEwhIIJUCCABExBxuFewiG2RHji1SGUa+itSAR7ADj03oOXJVHTfuqBZIRDU5k4RIsBunTAWNo9KdMBewkFAYz1uRQBd7+FBkBwVQoAQVEtIicjXhs2qJ6YKoLl20ctpgmjRxzOOFiNdxQgAUqUDRVTTptpx1cD7EUQE2lCQIiZEkjVWVkRbconRGcJYITaUN7pmKkEFKLIYJbbtfZll5pOKGaFCZAZJF8y+pgmZAQSUaKCVi2mkZwC1OoEjXi2Qd5YCCgG2UcAUJAfjvxlpCQRXz2UlxE1TSWsgUbEFKsQIAp1aajWcVfVax/Rxh1uTp72VKoPAaf/EbgLEKfaqoE+9Narw1bU7FvVPUSoWmlCpxS9gvXKCI9X0NcJwHTwKrAfBFthMCcIz6Hwwpg8TLEUE19cicUaP5Fxx5JwDDITH4/8iMgmB5xyJyivbETJLivScsxDwEzzITPfbPPNheRM8848D3JLMkQXbfTRSCd9zDJBXwJKLFBHLbUoAkxt9dWszNL01lQIwPXX1ngN9ti0iE322ZqYjfbalajN9tuQuA333FpgfXXVdk+tNd0jC6D034ATzTTffTcDNOH5yL3J4YjPo7gmjDf+zuOZRC75OpRjYvnlnnBAwOegh/65AKKXTgAHOJsu+gYaqB465+UMMIICtNdu//vtuNM+QmaEEOBA7sAHnznstQxQwRUV8D4IAQpgMTzxnhiPvPKCMO889N5Ib0Xyh1h/xfPYL3789tQH4r0V4Idf+fhVcG/I+VWkr/4l2hdopEeIIuF+IfA3xh9UEnjMEuQ3v0rUjzJ+WcCzlLC/3jWPCDt5SwCZQMACTqJ+jTHABBiQABLJq0DmGUIDl/fAIWBERQ+Y4ANiYoBlDaGCFowEBjskgJw04C2G8oiwiDDC6pWwJ7lCAAMmaAC/UMAzRYBhDB8xQ4wIYSwPoUABpsIiEZYPEP3DSAQMU5VcCcGLRFDiEhvRRLHd8AgttGL3fug/lKTnMUX8CxLDOEZalP9RCB60F1g+00PzsVGLUfHPCpVlBDHWUREzlEIfscjGKRjykIhIZBQW+Yf+ORKSnJAkFCjpB0tK4ZGYLIQmn8DJPngyCqAM5SBG6YRS8uGUUEilKqdBAgfY8pa4zKUubUmCK1YyBLsMpjBlOcs/ZGAVeEtFBg5hgVVcwAOrKGbYDHcnaZaDmIfYnDUngU1DaHObkeimKKsJzm6IkxDfLOciOJALvw0AdZ1IpzoTkYE1kVNz95xnLTCgHjvmU5+eAMFhQOBPgF7DA4fxQEENKg0LHGaZ0fsnQzexAQFsoHgSnWgmNCAADWBUo87ggADgGVGQNqMDArDAR01aC4+ulKX/nlDpS2FqTXnSlAqBy2lOP5COjN70DMnMm1Dt5gFftsGmP0UlJXwWBqQm9QnntANTweDUpzYhqnWY6heqatUBLtWobOBqV5OAVTpo1QtiHesRyjqHs3YhrWpN4ld7Glc1sFUObuUCXOv6xS4UQIBpQMCPiJDXLeyVr4+jSE6euCb/GOGvPRrsGAQ7H7D2w6d85QLlzui/rtQwCZBVA2XpYVk1HLaulLsSAOsEgM8e5TCPoexYGGAR6PgHAdPB4XSUcsTo2IYrWYoOaemaWTNkzgCTMcBiW7vcRH0WsqN94gR0+JfYPkaLDeAQlR4QkSEUALgLKMAUURLdIhRWC6eN/2vmJtAAsYSxucXiSXUjm4D0yMu986XsfqSiJARQ4AFCWYl95SWBwJSXsKVNQ3rVmjmg/Mi1QGpPbAugIqgsQAL4q8+EA7kl7UL4ht/9zBQnwgDJCuG8WVjwWIcnFF1BeAj2XcCE8zhEGvJnw/vNo1Jk057DUABdBihxZYlbXDLcNQmcJQOKsaDirh65CGdZgK7EsOQrNNmqT35Dla1w5adm2Q1brkKXk/rlNoQZp5gt8vUmceYpjPmnZbZFggeSZjWjb651ePNN47yGNmOsznbuGp4TBuhAf3KoiMZaUYlsaLTq9NFJ42meC93otem50gu5NKYLoulN/6PTns4HqP9DPY9Rk/odpj41OSyQCwxcYACSVjXc+HmYWMuabRw9jAhuDTeRHobXcHPoQ+YM7JtVVAAKLTbbPvAQiCobbSIQAAaezTaUEpTaa7sASbFNNgLIlNtk2xu49XDMRJv73OhOt96eOoBXQ/rd8I63vI0xuJ+mGk/3Blu+xbNvrvU7K/9uWsBDMnCeFRwhB/8ZpTmX8Jg1/NML3+bD+THxlFXcHhfPREOoIpGGRQFc3VFZGYKjs4i7zCQoUcl5MCUFlZBXVCIvAndYuyO1hKZM1ZKPb9JYhqJEwSH9bY1tP5K/kf+GVfqKOdu28plRgSW+1jGLs0ArI6UT4SYmfu0C0aj/c2IpCg8qeoy6EhCaRq1hLx/KkguJkPFL+CYxixmKYyCDAMn0Cb54jEnWRfJPrLPKOXD6knbUo67gkkXw8CGWpUCjI4dgiFjNIlRMUBJkqFf9QC65CQJiQnOnV51SZi97yP++nL87pzYPmU2xvqKRfFWlOXDiTl6shIS2u708FeHRgNfDmE89aCocBE/fRbWZ2IoqOF4iuZr8ovyUFKnpKM+InmDO2AdgXUW9IVZ6XCig47OcCJXx0IXqdXlsychDIPoIgvbDwYzUCkUqkkDxe+T9rhzgRlaf2410rykh8MhHkDIldpIEfpcmfod83YF8UKQUzQcU8TFlN2IAATQi/yB0GBBgEptHdmvyLN2XQN+He2LiP8AnBHixFUXQL0nxKs2SLgPWAG/SLjJygEcHGXsHALZXCXrCJ6MxKoCSERaBG4VyKEQAIrRFMsPnFwZ4fBoBGJMyeEuIFg1ILCbIeBLYW4+BFI+BIPQnI3ZxBB2IHyyHhVkiLGNxHKHhELGSJq5SdamxdksxebRiJhwig1MmfHTzK1QhLNARFsfSEqaxdul3GE1XBAoxc0nIfOsyHYX3W1DYdUYiFLFCJBRAJH4BZLQHIi8hFrBBBF/oc/4nFAZAe8NiFTcXE8sSLzryKqg3JYcRR/mCGIc4LErhd/mnPh4nZiaHDhEDBzfoDf+3iGa9sotv0IsUQ4yxk4vFZIzkoIy9wozZg4yz5IzdII38Bo18Q42EgY3WoI0kwY3O4I2ZZo10A44I527zdo7omI46VW83VW7q9o6x8EzwOI+vIG7jdgfkeI99kI/6uAf82I958I8AiY/iOJAEV5AGiXAImZCF4I70SAry+JCmYI8MqWDmqI4YKQzsWJEKtpDo5JEcuSsgKQgCyVIlaYMjGZIDOFMqaQYneZLSFACuAzqsM5OfgwgyaZM1aZMtCQW+EzxAeTt85gU/GZRGOZSkBktQhQhK6QRIGWpNeVVM2Uif1JNPEJUUNJVrZpVMgJVetUZbyZVK4JVK8JRbQJb/ZCWWXVlCV6KDNUhHYAlB/9MhgJWWajmWP5Rd9rOUcWlC/CFBdYkEZrlp8AMcN9FjcNJb1NdaWimXKKRCLOSGg4lp/YN9fwFef7V1jNmXQBQBQkRERjRHL3SXeFlIObF7EgBgEEEak4kFWZQrXLRfXzRlrdlolvRcwCVzsVKbVvCabuQfcVQAotlXpIkEt7lY3EEBPAaX7/NHXrQf1xWZhVScxkmVSsWZgkadRoCWgtmYd6adRcCda+Wd8QOe4WmdsUSe2WmeQiCe04mdl8Se7QlMwlSfuMSbVUAA9Gmf9omfdtZMqhCRqYAIAJoKAooK8ukxKQkIMKlRL7mgpPmg/wmKXhC6DRWqlhI6oVWQAa32ara2OBdqlbT2EASwUBpKBQJ1GCEakCvakgj1ENNmoicqBfX0ENdWUjNKBceWbDiao1KQa84WTy3akiJ1USzpo06AUi4lo0j6BNpGTU0qBR9AkSAapVHwbUxqpezQoGyTkzb5pWAapmI6pqBDkCFJAANApmq6pmw6k/7Jd2daotxkphx5k3PKaAlpp5LwpigZp5TAp1y6NnoaTnRakYMaN4XKkIf6CIA6pHG1qI7QqH56p5M2qVrgRGoQWuOJpwYJqfjxHhKwgg9xBE6kqWVgqnLFqQPpqVPkf8glBAcml2uAqsxJaJZaBIq1ekMQq/8PAEXzNWAm0qu/NkVTAVxnUXf3l3TQUYS2FZi1KjGOqlaeWh879h6xGkelWpcSABIa5D9/cRLAIUUclCriZSQpISjs5RE5QaujqaoAOa1tCUaRVQSyma1ylHr16jWhxQAUUGAkuCepsQAU0Caph1/sSpyVWqdyigShWJfX6hdIUV37oRgb9CUQq68CxK8jhkDeRVuC4lwSZpcJa6gLewQ34UKx2iZCkV+pxxNtMhXzJRomcqwaGEX1IkFg4aztOrKKWrJ3IV9lIKkKiwbQoVxAlah56rOMirSdqrSRyrSr6rSNILQk+6dQ+65SywhU27NW6679OK2LsLVJ27U8m6f/jXW2aJu2aru2bNu2anu1WrqM0Rq33jS3dPuRd4tqdpu307C3fPsHgfq3RxC4gisEHDoArgZrhasNa5K1i8sJKdpsj2sNLyptk2sNNSoAN3q5zbCjnCsNuYaln9s5FjW6zuBQS2q6tPCkqlsLU9q6tSC6sDu7e+q2tnu7uJu7uru7vNu7vvu7pFNMfHo2YBtDw9ttjmu8SVW8FnS8Y8O8BeS8YAO98yO9X0O96mO9XIO94aO9W8O92OO9TQO+0CO+nohk3ycGSPEjtPgI5BsSGwcRHccYU+CZsFWHzwpjhxEYQ7cAFmG/EPGWV3C+SOAgp9oaLdK+S8AlSuEb/kt+/3U3BW/CLVMnFdaxncmLJyiXEivxi04AhFlyLakKZaIihqLHIT7XEGJAwF6YvmGwvle3mEqghQAihWeCFr73BF2oJooxGn0BKxicMkzHLIcRFsByHRAxdQUswyM8BOx3Irkiegy4IpIFe4IVHcl6eMUhJtpyG2BoHNJxwbkBLqpnv53xG0JYeUNQFBCieZxHg4iHdcmRAK6nKzTME3YBw6FhwP43HF8cgs5lrmMoGkALQlv3vgjxdrTBGHOHhXb3KJz4dGVpBPSCIENXJwTrWOZnfJPIH6LhGYuXH2OiJcFxIRnyyZVCLLnRKQtSf3NhmWvsJGohgwcAw8ExF6EIFf/w13+GtyJ0XCQmMnQrEckJYiEWCCSt2MtV9Bqd154ZrMEguHIWsXsZwSM5bBPl955E8MSMFQElSCwPskEQliYU4oPE0hLo8hI+9xSqMngggc65ESZX4ie/gYHDycazLCpFYcsagXv4siaCrIWA0YUjEhomQcQWxsXpu8ODzIR0YpzPvDD7lyOx8n9MbH6CrM1EAIAmjBZouBpK0mJyOIYtgiKhjClF4RPtjMqLt8qngiIOoRh7YRvXYiVtrM8uwc8g9F0CYCJxaAQCvSJ20SfejBY+gXnFnM5FwNBBLcJBbDI5uBQ7+CesIihAWBGG8oHHkRqaubNFMGD8ixbA0dP/ExBlO8QqHFLOrTcdVQGG6pwR/GERK53FbT3GZh3GynF0mHiCVJHPHljLSrjThmIAW8QaNMclhOIb/ArBpMEu7oIoTK0ehILWEJ0yeAgRevh0xgIbfkhIQ9gsb5k5jrcGLHypnswqOusNiJwyHlyVSSAlLjwGpW0F6ffA9HfW5bDaJtPa13lTui054hs0v904wc0zw404xX0zx004yU0zy803zR0zz0030e0y0z031b0y1w03QSWR3v3d4J1orZOMGVneyJC45p3ew7BtfEu4k+vejwvfiyvfhUvfgmvff4vf1OaQ3n2g4S27832R6p3erza6J+lnYnngxGalCm7g/36LVwsepQ0et17qOjs5k4nwpRqwAV/64Lb5O0YZlNn9QiEelA4Q0T3pnk1cCKmkACjekiqev4PQ4i+ukjHu1SyOBS6eoDeOsIZA4zyOnnx5CEAun+fTllItwD6e4yTsF/uBd0Ww40ael3OY0ZOMCHIjRLny5Esg5exZmBo0FL9Fx9NBcyO+5D0SQF2UEzQb5TV+pmxkmSH2qd+1qUR+JKnZGjW0seHl5kFumjYmL1vyES505pu50W9hGynEv9fi5eZ5nJc5iN8q44KQ5TiEExsrZETg6OAJ6YYnRT5G6YFg6UKQHmxOFYPI6drZ44f+4zr+5nUq5E6ZCEX+5bIulf9Y/up//j20rutTHpZMbgWqTp36yZ/8aegCYOz2GQKwXpEFigr+bQqJsAoecAGrAOA+OuGcq+2Xy+3v7eFwgOBc6e2Cy2qI66G0IO4tOaLB6wnqrpKRWzXpHuE+6mujOu+cK2yaWwvvrpKei++cC6T8Tu8+Gm0xCvCXq6TN0O8qyboIf7kfgO2ZwPAhSaWbQPG0GwcYb1XPHt7qdgcb/1QEsAEDLm98GvLL2+yAcPIEz2vbbQcsf6uIKlUtf2svXwcxP7SUalY1L2s3Twc5X7U731Y9r2o/PwdBz7VDD+EyfwWYmgYH2+pE3/RC0OelLqqKY693kdpSz/Q6/1jyBRz/whKrfjmrXJ/0Y3sEuXpEuypZwjqqkAWsjeGrxBp4NJvFHLKstQVbIsvzVN8g1dr21eIXWl/q3KoUpQquLcTn5fog6OqCz3X2IF/0pwavhC2vB5av8yWc+OpFWs+v/voXAEvomcyv8hX1aN+0StCwGy1ZwYmxE1sgPPH6Maux46rp30olRpFhDSD5NP/3mYKykqWyGLuFDOCyqVf8MruFdWdbwby/NiZjfT/1X0+0hTwGqR+1RCsTUA4G2Y+1ZOv31T/zWUX5Sanyf/D9X4v+fqD++nj0cuD+9wj/cSD/40b/cGD/4Ib/bwAEAsCQWDQekUnlMjBYPqFR6ZRatV6x/1ntlgsgbAZh8ZhcNp/RafW6LOy+iU34nF633/F5qCXQ9/8BAwUHCQsNDwf1sOQUGx0fISMlJykbGSsxMzU3OTs9ky4/RUdJS01P45xQV1lbXV+1QmFnaWttRWVvdXd5e+dyfYOFh4k/Bi4wwjKImZudZwkEpKWfq62vPTOmBUCwvb/BGzGmPcLNz9GzQKaX093f4Ys8pDfi7e/NLaQ18Pv9qzcI4PCPYEFfGgRYMLiQ4SwOFxpGlHiqw4eJFzF2UpiRY0ePH0E2YjOSZEmTA9qFVKlLACKXL2HCvBBgZU1bbnQNoGmT5yuct3T2FMrqp62gQ5GWKlrraFKnnpbSav/6lGqmqLOmVtUq6SqsrFvBNupKZcGCLREmMMjyNWzbO1clCCgwZIIACUkgCIBQhIIABEPymkWSIK0AA3OHPBDQYEgEBtIQREDC1m1ICAggT0iQQNqBLQU6L7kK+m4CA2qTLPhbRDHqBQI8H2lgeELsIa8XA55LevLOyjUPCGAg+QCCA5xha1EcWsnVvozr7kUC2nZjwwDyTkgy20BtI8EZF6mr/Qjl3x1BL0hQxMA0sxQe+42AHLMA8kUSMJidvHmS4GYNCC8C6YjQD4n2EkAAtSQIe+wwIsAjIsHcejsPuG0a2As5zxT7CzQEkIMgPwEeMAIB9ZhL4irODjNgPQD/JgiPLheReK0v6R5YgEAj0FowwiF+rNDClQ6oa5rjQotrGxdDmw2xIQowYL4UkejKgNOenIACCbvbTrjwEpitAcmgCBIK84b06LUCNgQgrrskDA2zJwHAbZvqjOgKM8EACO5JCRh48QjQaATAMQY0I2K/aQy47U7sKBQyzY8KkECyET1rr8S8DPAMggY2jKA9PIdosz8pQCuxT7moCBAPNCeNqMj4EJAONAHes5NNaRzccjAqjxjLiAYaHaKBBaNQjM07YI1VKFO3ELYIBla7QlQBfK2jWWd5glYLaSXkQlBtfePW3CfAXWXbc7lNF5V12Y3V3VPgjTfNeU2p114L//EtRd99f+uXlH8BdkvgUQguOKyWYmrYYYdnUnjfkyhGhuKTUpJY419U2djjVoD5WGRcOh7ZZJJPTvmTkFVuORKWXY5ZEZhlrtkOmm02V59teO7Z55+BDlrooYkueht+cm4I52+WThqeprGB2ul0pLam6qnNufoZrbFmuuR3uO66FwsIKNvss8vWYAO02Sag3GrCFnuXAEJQwO678c5b77sdICAYo4X2W+5hAnCACwUE7+XgIhAfnHDDt2jcl8WJkNxxXwo/PHFeKB/C8st5yTzyzXfpHIDPQddFdC1QZ0nz1HtZXVTpGpDxidZvWWpOQ0m8nXTYa1kdgAIChUBKKf9wv+kIBQWIIILel0ge+FeEBwABQHfj9bj6ivX899yXlwCByHqvD0QjpJ8eZMiJeP6vAzqFsQHFxvX+7/CVJZH4zRag8/Tv1eeK6llvLn2Zhlrq8qDKAbAWurvLfh4gAThVCn0MDOAqBoiAucCPVMEh0//uZ6K7PE9/gcqP/9J3wVNkEDG3ssty7MI4C87CgUOIS4nMV78UqrAUA7TCDn3yOh7CwodVAKIrTHfEIXqiiFRQIlGEuMT1RZFzVJQiKpo4hSeuIokzvCITS+AAMY6RjGU04xhD4EWfVICNbXTjG+HYxhGo8Yub6MAhPDATQ2ykF2uwmBoGUse5fc0dcRP/pAAJSbVEHlIYhiTcIhmJOUhmbZKRHOQ9HGlJUnCAAGorGx/PwUlPEgCUmtQFQrbxjmhso5SmtAUHtlHJawRgG/VwJS92Jo1yvGMc+7hlLy7ADnisQxqB/KUuPiANDMRjHtLowDF3IQJpdAMeO4MINHXRgWLaIyAWwWZOEmIPhLztm9CwZTxgWU5dZABp8eiALNWJiozBY57xtKf67vgwfe5zn618Aj8BGlCX1HOIAUjGxRCa0IutrQoCUOhDIepHeAIvk6coW0O3NlHYVdQUF6WC6bCo0dRxtBQenQJIVyhS0JGUFCaVAkpNwdKayVQULo0CTHuo0svR9BM2hQJO/0nBU5cJtRM+RVdGBUlUThhVNEito1I3wdRTNQOqJ2OpBicBvSNIVUV3UMwkClCtIVTVZCEz3otIyDP/DQGrWhWLqrZKRyIsxUh2SUD/iCCB9vAMCV8NKyT+WgSyjoxlBvBVAQTzVSVglStwNQJXq2QE4xFnAREgXqkMIB3G9hWoqBIrAAYrMpZNYDUMQIxihzWNuZAoreoBwKIKoJjXxO8B7TEsjI4UAdyM0E6OLQJkgyVZAziWMyWiQPc2S4QHxEcIf1UStgCw3GkMjwGPcW0OD4AbxtyKAZ5x4WdD+zGWBScBtX0RaolAPMm0Fa7Pg0CU1hvb8t3lQcflDIEaMP/CTjVgNW79rVyHsBTEGgYxDdDOZpM7hAf5VawSAJB2/Doc01Bgf3ctAGIhFL8YBadEgU1FUifZPwkqdykjJiAASFScaVDAxBpUrASfR6bmEc+uzMUWA3zlXyIAN09KgN9eJts8IiQ4xtFtrof2OhwhM3gIODZxpSIwmwVQwIC8gg+UwKtTx8GMeMMl8aBMaFoUR9AsnKFwmOVrQ/ruplAAMGx+i1C7Vfl2xwBGsREqtR74qcoAqilCgt2cveGRby9pCfTwjtzkM29GzFDqbvyAlBz+GiG8HoMZZ5CF3lLNVswkqq1wsHVXXqXZTXf5tGFNIw316HYaETiAdXU8BB7JF6EoOVItEeqSrRMbwYCvGbT1eKUWAz7m1wDAMbD9kgAXbsmFd1GSnwWr5cFVGgD50XUeZj3XTFw2D9TWWHin8Vls27mzqJKGl7stbbl5GxLZDrBTv8juR7j7zs6Qd8Hu3Qh6l3tl6hZbvhWxb3hfEeB6ELi9/d21go8bowgH8TMOTtWEY23heIg4Myp+LoNGlOMdFwNDP+pxkUP0AhOfWj4FmnKV+8GfTFj5ywVK0HvOnOY1t/nNcZ5zne+c5z33+c+BHnShvyEIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FB: fascicular block.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vereckei, A, Duray, G, Szenasi, G, et al. Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia. Eur Heart J 2007; 28:589. Copyright &copy; 2007 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19662=[""].join("\n");
var outline_f19_12_19662=null;
var title_f19_12_19663="Left adrenal metastasis CT";
var content_f19_12_19663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraabdominal metastases from lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of the upper abdomen shows a large low attenuation necrotic left adrenal metastasis (small arrow) and another low attenuation necrotic metastatic focus in the pancreas (large arrow). This is M1b disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_12_19663=[""].join("\n");
var outline_f19_12_19663=null;
